var title_f28_63_29680="Scleral plaques in NSF";
var content_f28_63_29680=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F54337&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F54337&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Picture showing scleral plaques in eyes of patient with nephrogenic system fibrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient with nephrogenic systemic fibrosis has yellowish scleral plaques (arrows). These plaques do not affect vision.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission from: Shawn E Cowper, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_63_29680=[""].join("\n");
var outline_f28_63_29680=null;
var title_f28_63_29681="Endoscopic image of a transampullary uncovered metal stent";
var content_f28_63_29681=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic image of a transampullary uncovered metal stent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic post-deployment image of an uncovered metal stent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas G. Adler, MD, FACG, FASGE.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_63_29681=[""].join("\n");
var outline_f28_63_29681=null;
var title_f28_63_29682="Shoulder internal rotation 90 90 with resistance";
var content_f28_63_29682=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1140px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/86078/Sh_int_rot_90_resist_video.mp4?title=Shoulder+internal+rotation+90+90+with+resistance\" style=\"width:496px;height:288px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Shoulder internal rotation 90 90 position with resistance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Active internal rotation against resistance, with the arm held in 90 degrees of elbow flexion and 90 degrees of shoulder abduction, is a relatively advanced exercise performed later during rehabiliation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_63_29682=[""].join("\n");
var outline_f28_63_29682=null;
var title_f28_63_29683="Photo birth 4";
var content_f28_63_29683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Delivery sequence from crowning through birth of the newborn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 318px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE+AbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxi08Najr16VjDnd3rtbP4K6oSjeZgnB55r2vwZ4dtrGCMpEPM4ycd69Bs7UA7mHNZqm3omDhKWszxfwh8CLWFo7rVrmWWRDlY1GFB9/Wu01Two8dp9ktH8qLGGKjmu6ur3yEwg6d6828bfES10iKVGdBKqk4JrVUklZbnPVhSjrI8a8c+FjZ6rHbCUt7A8/jXG61oumwyBtwBHUZ61Y8UfEBr66meyDPI55kYdPpXBXVzNdStJPIXZuvNZqmk7jipSVlojVu9RihYpaAY9ulZc9zLM2Xc/TNQVPa20lzJtjXIBG49MVSikWoxgrs6XwLaebJPOTwDs6dOM11ml2V1rfhK/wBNt5GBt2kuYQO8qtuXj1OMZ96f4H0r7Po5l2ZMxL/8B7EflW1opbSvAc95En+lTFzF/vMxVT+Gc/hXuYSklTSl1TPCxFZzquUe6t8jp/A2qrrPhu1uPMUMVGM9Q3cH8a3JQ8AaSQ5UDdlR+f8Aj7V5V8MLo6PfT6JevhkImhdukkbH0+ufzr1g4hDtHC7RnIOR14rqpzcoK+/X1MKkVGTS26enQ5C4m87U1kBCoHCqxOc+tdnIBPfacij5ordpSucjngfyJrl9O0q01HSQH3Jm5fOPvAZ4x70nh2e8sbeZ3l8zUGZ4Y5jgiOKM4DEdzxgfrWq2sjNs0JUt4dQjhint4rtlYw725kUnJQ59D/8AWqWKVxBmRSrKxVlbqp964fxVrmnQrPau0d1dk8kruZmGf4h0/wDr1n+EfG5jl+y6/FNbAnCXEmXXbngN3GP5V4uYxoylyppS/rf9D6DJsVVpu0k+R/h5r9fvPRd5IIXG0Cqc8zxjHG09SOKrXfiDRo4/l1Ozbd93a5OV9enH41HPdRTW3nJPA1ucZkLAD9a+frtte69T7GlythKx2csckZ46VWeUBgA2dw/Kq32tZI90ciSL90FWBqNN5Yuc4HXsK8ttnbGNx9xJuIXpjikjk2jAzk8Y9qpks8me5JwKlQgkDceOtQa8uhehkbI2sDjuB1rWWbdhH4IHIPFc/CWVsE564HSphNlgc8nqK2o1XTfkZVKfMbMsoB4P146U1Wypdc4xVdJPOXDE4PGB1onYoAmTs64HevTc1y3Rhy62Jppx5QAGFz2rPcktsj5K8kA4p8k25FDDB9M9BUMhCPgHLe4rzpvmd2dUI2HSnapAPXBqndYKdQSB1xUrbTtPzGT0PpUboG7YJ6D0rPc0tYz5oSQG5x3IFKZAEZf4c9dvJp80gGc7sd6qpbtLnJKqB+J9qpK2wpa6sIlNxI3mZ2r0BPNKYPnxhSuOatkeSvpjHaoM5yG46npW9JWZy1PeOE8TeHzGXu9PUmPPzxjt7iud06/u9NvYbzTrmW2uom3JJG2CD/h7V6rd5WMLk4HXFcD4n0+NHN1agKD99ff1FepTn0Z4eKwy1nD5nZR/GfxCbZUlgsnlIw8uGXcfXAOBU0Xxx1/YiT2lo7IQVlQsHX/Gk8Fr8NI9MiGt2d/cXR/1k0wYLn2C9q6fUdO+FbQwtpdhb3YJ/eBLiRXA9cfXiqk1Z/1+B5U7Rt7n4GRF8bPFM159o022tUlPJXcdsh9WQ8ZPfGK3dK8c+Mry9OpnWvC1tcqmDos8ZWOcem7s3uGFCeDvA1pcxDWNN1bTpAQQlrceYvI43cZ4qt4k0DwreNHF4d+17lP+vuXB3ewXrXLPExirqX+ZpTpub5XCx3Nh8Z9GhVU8RaHq+j3ana5tSLmH6g8HH5/jXpfhzxDpPiOzF14d1O21KDGW8p8Sp7PGfmU/UV86eHtQGgyLFrlk6Wn8NxBl1H1Wumg8IeCvFFwl7ZSvDdsM+ZYuYXHuQOh/Kt6GJ5ldNGNan7OVmmj3zJXrkE+tGATznNeP2vhjX9FwnhjxzqMajj7Nq0X2hD7BjyBWnD4s8Z6OQviHwzHqMC/eu9HlySPXyzzXYqy6qxztruemsSoBFNyAMkc1x+i/Ejwvqsq239ppYXxODaaiPs0gPp83BP0NdcrHYG25Q9GHIP0NaxkpK6BgAQc96Vm2g0K4AJpDgjOc0xDCdwOPzHSmK5ydoJapGXcCDwKHaOGGSaaRIYIxueRztVR6k0MVhqh2Pztx6CnzSQ2ls893NFb26D5pJXCqPxNeZeK/i1ZWRe38NxLezDg3UwIiH0Xq36CvIdd8Qat4jnMmq30t0wOQrHCJ/uqOBXDWxkIaR1Z2UsHOWr0R7L4q+L2ladug8P251W5wf3rExwqf5t+H514/4m8W634jn8zWL5nQHKW0fyQp9F/qcmspY9uAF+amCM7uck1wzrTn8TO+GGhDY+wLCyitolDdhVfWNfsNMhd7iZUVRkknFeQeO/jZpWnB4NOl+0zcgCPmvn/xj481jxRIwuZjFbE8RIev1NepzJaRPPVSUtj2L4lfHCNDLZeH18yUfKZOwr591PUrzU7uS4vZ3lkkOTk1T6UVLdylBLV7hRRRSKCvQPBehefbrJtG2QDc3615/jPHTPFe7fDezRdOiPBA/HAxXZgqSqSfMtjzsxm4wSXU6FdPSz03C8bV6AYxxx9KyZmJ0TRLbG0+UZ29O+P6muv1BJG06bagwo7npXG3RuZljZeEjgSLOMcgc170Ekzw2YOshrS6s9XiG5rFsybTgvCfvj3x94fQ16XLd3ViqSPi5s2AO5OcqR1B+lcjY6b58qi4TdHn5h1zx0xWl4Yvfst3PoMZMi22Xs/N53Q/3Oe6E7f90rUNJSv3LWqt2NbRFjiunt4ZUksrxzJaSHqsneI+/pXJ+Obr7HqV1plnOkysyyz8cwnH+qz69zXR3aw2NteXtvHFFsGZrOVtqu+cKyMOjbiK8w8SpJYXNzaSPJJeZP2l3Ks2/P7zkEggnIznkCvLzbGSoQVKm7OXXsv60O7A4aNWTnNaL8Wc5qU1xO7G3lSKEcZ25aQ+o9BW3ovgvV7qEzXlwlsWwwWcs0gX/dHAz781qeDdMjwuo3CElWItoyvy5H8Z9h0HvXYx3StF8j7pCcN6k+tfORlpY9SpWknaPQ5AeAvKYltUAyOsUPzH8zWh/wAIzo8WUmeSV4xvkU3GWA9lHP4VqX2orBB5jKOPlReu81x+oudTtmiuookUsZHdECuW6DmlKSWjCFSrN+9JpGxPoOhyziC2u/s0wxuWO6UsM/7JPWox4ZvIWLafqspiP3VmXn8SKl8JadpdmFe3twbsjmWYb2J9uwrrGjCjOw9OVHQH1FS1FmkalWMv3cnoctHY63buFuLWG6TP3oJAG+vNNku0icxXLPby+ky4yfr0rqXXY+CGyMZzjFOZI5om3xo49JVDCsZYeD20PTo5tiKek7S/MwVyYjsG5eu9SCKiD7QFBJ9SaZqvh50xceH5xa3GT+4Y4R/p6H26fSsY6zdWU4h1y0eGQcBgv646EfSsZYeUdj2sNmdGtvozqrDzFbK8gdSeoqad+4JK9RVGxmFza+dayJNGRjcPX09qllkJVQrY7e1XGTjHlOu3M7oSSVmlByAvr2qMucnP13e9QNcozgAZOfpQrJG5YE7yeRnisZam6Vty+rgRgggk85x1pssbEAjaCePpVfdgfISBz1/nUhYmMHoB+f1qoxJk+hV8sSIwfPNOcBcEDk9yaRmw3Bz2H19KZvIQbzgnr6VdrGbYy6YnJ6gdB0x7UxULoHXPX1/nTxHvKhjtwMkk1Xnk2ksDgHpgdq6MPC7uzkqzsVtRuUhDFmXCjPH8VcpL/pErSTgKg5C/561PqF19qujz+4Q8e/vVYHcxPXngVvOWuhjTpc+rJopugycA5A/pThAlwQDEjAnHmAYYmoypJYnkL0qzaKQo5bcT0z0rPn5UdSwyeiL9tb6jDIv2S+uI9v3g77wParsFzqMTeXPBBdEDcWiOGH17VSiDh8mRhg53Z4J+lai3swjxGIwBkliOTWEpUpfEjOph5LSJZ0XxA0t89reXaQRkkgXKYwOy+hrtfCmn2dhf2t1BNK0ytvaVefMU/wAOOmPSuLEguIxHc20c0HBYkH5zjuKkgnktZA1lN9mRSD5SE7T/AMBPSspQgnzU5WZxPAyaaep9Ex6tZXLACN0LEKN4BJJ+laixOcERqAO/evFtD+IP9nAvcaZa3G0ZaSKUo4/Bsj8jXd6R8SdBuwoufttgx6C4hOP++lyK9rCVG4/vJJt9tDw8RgqtN6QdvvKPiCJNfFvBrOh6fdsDI8kN1Ds8lAeAHb7zn1HAzVLRvA8v2y6u/DL3/he3wGtzDdedDI3dWiLMCB65H0rqdWbS/FKRDT9djE6Hg212Ecc+3OPbvXUqr4Aj5A4z1z713OMJK9jzYwlGTvoeeTXvjTQUD6zJa39qoy13BallA/21TDr9QDV6x8V6re2n2uy8OPqlsD80+k30VwoH+421wf8AZIzXaBblSCqjPrXjHxY1zw/purSppNn5fi+NgXvrGZoPIPB+coQJGx/Ccgd/SsKr9jHm5tDWnTlUlyx1Z1k/xY8OWtpKSuovqUR2tp0tq0Eqt6MWGAPcZ9q8i8YeNtW8VSn+0JlhslbdFZwkiJPc/wB4+5rnLu5uby5kub64luLmVi0ksrl3Y+5NSWlszgM44PAFeTWxU63u9D3sPgY0UpS1Y1IzLyxwuMVMEWM7erCpyNiEDGegz2pVi4HdiOTUJJHU4qxAFJJ6ZPBOacsYGMetOmGwEAjPf2pbUMeWxtz0oMba2PHSME0Up6mkr1jyQooooAKKKKALdjaNdR3JXGY4y4Hckc17j8P7sPotm6AN5ijJx0rxDS3aK7VgSBg5HqDxXffC/UwA+myswaNvlHqM9K9LASSkk+p5eYwlKPN2/X+ke2TgR6fM7v8AKUySOM/hXD6ZdxDT1Er5+duM9s9K7OeZU026cJtwh7j0rzLT1M2lb4UYCJzGzvwHbrx9K9dP3rHkW0udTaX0Yuot0gADc9ABjmqs1rMmt3sFtganFJ/aOm84WVgMSxfR14x9K5uaQyJskV1YnClRkk/h1rqNIuLfWLaOC+lxc25HlTqeVI6H1pSs9Bx01G+LdViv9A01bB8293MkvluORj+FvcNwR7V55HaPeapcwqy5ecwq46LGnU13msWX9m6wqyXaXsMu64VdgBidj83PfJGR6ZNcp4Imj+1XIuARLFI0Z4zjkkn9a+TzNueIl5WX4X/U9vCPkoq3m/vZ2CQQ29sotVULGgjjB52gf/rzRDZW9uGjhRw7jBfOWrN16+a1sEkt7hTIzFUXbne3p+H+FRGy1e+2veag1sgXISEc5I74ribS0Gou12yzeaOt45MksobGxAeRn1/pxXP6LaLeanHHcuBAJAhZBuwM8tjuQO1XodN1OwQNpmqu5jyfKnHDGn+CnnVbqO8idLkN+9JTOMknr6Goa12NFom07joJZxdlXR4nibCtjHU5yfwrqLdsRqGY+Z1qpe/6TE0Yl2uWyjKBuGB/n86p2uoOLy7inyIotu0t0II61D0Z3UkpU1ZHRLEHTLMuSc7s8HjpR5O5MqSFxjpiss6lGjRGTaVc/KAOi+ta9lcRXJxE29QMZAOcVPOuhqqLtcZHbnJwB06Ec1Bd6dDcwmK7iWaEjlHGfy9PwrcEeFIOOfaofvZ2gZHarTMpR7HlGsaJc+Grv7Xpbt9hdvmGeg/ut/Q1sxXEcsPnw/MkvRu4PofQ12F3CssbrIqsrqVdGHDA1wT20vh2+KojT6fL0Rjw6/3SezDsaU4qW524XHVKL7rt3/4JYgGJWODuzn2qQdSDwTzwOlOSOCOVWhdpLecbonxyfY/7Q71YhQGZMnk9celYcjTsz6SnWhVgqkHoyO8VrdgWBORgE96h80scqx4/i9TUl5N5rbwRkDjIqiJ1jUqQPlHJ9M+laWXQlPuPd2yWZmwF+7jmpYT94tg8cY61SklIAKtgDJ3d/pVq1HygjnPcikotuxNSSSuTRkyPk52HGMisHxbM8CLEp2yOdox2HrXTSkRw47r37k15xr18bzU5G6rH8ic+nU16EYckbI8vn9pKz2I1VcKoxgdSO31p6yI0rRoMMgAbHaqaMyxOwwfp1FTxApHGNr4fnc3f/JrJxPQpy1SLKkswQ9S2DV6F0WMYIZox8uOv/wBeqUJ+bYozj+dWLdhGmNo47/4VhNXO+MdC+VDkJuPJBJ64WtCGNQj5wSCAB2HesdZSJC2NzdMdBnvj8Kvuzl9kQJ4B56AccY9awlFmUk27Gh9oLDc7NgYyB/Wq9zOsWGYF0UgKO5J9aYqmOP5hnBwOcck/0qZYvNVDsdxz8+MA49ahK7NUlELVHmVJC4DJnAPYZ6Y710ltKxQNI2WxkAHHAHT8KwVm3FUyq7sDauAB6jP9KmxOkiDDRRIxWUbgOMdQPTkV0Um4nNVipbm0k0LbN8MLqerbdx6c4NTCBWKCHfGAMD94w/MZrItQiQmOIlTkKTu3fp0qDxHrZ0yP7JaOft7jk4H7lT3P+0e3pWym310MKkIRV2h/iLXDaE2mm3N2LjHzyJcyAReww3X+Vc5bR7RucbiSWwe59SarWcRYF8E85yTnJ9a2bO1805YZGeOK56k3N2OeFJX52h1rbmRtzfePPBrT2hOOSR7dKdGnlj5BnHbrmh4GBwGPmE5Y+taRXKh8t9WVlUzT4KkIOT6VNKPLUgL09PWrESCGNY4yzMe9AhMjbSuO5yaZjU1ZmmJs7mGe/pV+0Q/w8n6UtxHgnGaLBGZfQg+tBltoeGnqaSlPU0leseKFFFFABS0lbng/TTqmtJbbd2UbA9SRxVQg5yUV1IqTVOLm+g7w1bedvc4AzgZFX4reXSfEUE8B2scs2DV/wzCLS4eBtpkibHzAirb2v2/xRbxsNse4DA/WvVp0kqa7pnkVcQ3Vkulj1TW70W3gqe7eRUDxqcY7kdOeeazfB1nFdeDBGJG+1AiaRXbI2n7u3047CovHixXPhuWzgDYjICccMyjgZ9KqeHNSlsbPS7mJ8pHbiCdccFhyP54r0E/f1OC3uFHU7R7a5yrbXRsjnke4pfCly326SN03ZHSuy1Ozg1e282OIBzy2ME5PXFcLZwvpPiGIT74lduHzgZ/lVvclHS+JIybiKUIAXgYD2KnNed6Y5HjPUo4HUJcR+bz3OB09DzXp/iuOWDRIL6EiU206lgecxtw3T04rzjWY/sOox3UYCPaybT8uMxPwD+GQa+XzOny4mT/mSf6foevg53pW9V+po26/8TO3SUBhDHJIvPRiQM1o3EMgiE9vIY5sDIz8p/xqrbOspjkESCTHMin51GDkYx0z7/hTvtsysEyGA+8G7ivKas2dD1tYp6Tq2oS65cWV8q7Nm6ORExtx2P1rSmRHEUhBMtvIrZQkFlz0Pr6/hUZuwwUrGRg/Nimed5E6OFyGBBGcEj603sF9brQ1LibnA5ByOKp30sdzLaxHq0e4MOMVHJMrDKMT3X34rN1LUIrSKwmnDohBgLBclWPTNHLc6ITaSsWdrw3KxOwaNFBVs53c11nh64yhjjLHcw5AyRXF3zRobRkGHJZGJJOQK6fwtC1xiVXHyZUqCQce/tXHKHLUsj1Y1FKkpM7B3YRgRqCchTnqKYkhwS6lSCRgjBPvToY9oAYnbj1zVQ3Jt7gpM2+Mc7j1A7VttuY25loWHXIOeW7HsTWfdWkd1A8E6ho5OCMdD6j0NaRkC9O44IqvMu5CVIVsZ59q0j2OecTgyp0W9ktLslrKVf8AWIOVPZwPUVG948EzWVywFyo3LJH9y4jPR1P8x2rrNUsIr+1aKXjdyrEco3r/APWrhdctJUtE0+6jEctu+6C5U4MQPv3UnmlJdGdeDxUqM79Huv1XmXpJj9lO0YJ46/5xWeWZiOoQHjiqVpqpnBtL8rFdgbUZeElx3HvTyWUHGQuBn2/wrNqzPooTjUhzRZOhDyNuY4B6evtW3DuWI/KMEEqPSuctBvmEmPkJ+Y55q3qN6lvbs4YtGvAbOP1rooR15mc2JbfukHibWPIsSmcSMu1UPXJ6n8K4GWTYjEsxx0+tWdRvft14XCgBVIQe31qi5aZtuzAA4A43fWutK7uzy5z0tEIp5nLpER8zhsn19K29PjlEa+a7OeRnrjntWTboihV2EsBgE929fpWlG5FsxQgADAY9ves6uuiOvALlfNN3+ZowRZQux54Ap5Pz7WPTn2BqnDcA4HIQnC8fexxn+tS20jyXbFAmzAwTyc/T1rlcXq2e3GrBxUY9TVAPmgKyhO5arNs7Fs+WSxOeRjp3/rWQ86hVUMTtPXHX61ILkqFf7vHGe/UVi4MG9LGrI52MTJvPf/61Wlulk+UOu0AF9wOeB/OsWC+hETyNKpk3YUNxx3PTFSW980hRLWPaRnDlN+Qfap5GtyOZPRGhN9nIQzFRypLKACM+/U+5rQtf32yQo7KqlCqgAOM8HJPNZ1vBJJcJ5jRytgZ+T7v4VuS3MWn6XJeXRRY1I2oi4DEdFA+tEXd2Jm7FfVdRGh2W5VjN5MCsUZ5Pux9hXHWUMl1M7ySFyx3O79WPemyS3Gq6g9zcNmSXuP4B2H0rd0+0CoFTpxknvV1JqCt1MFF1HzPYns7YNIF6BRW7bwYiz3AxxS6faLGu8nhRwMVpBCY8457ippRsrkzd3YqW6dSoOB1J4qQKGY8Y644pc72EcYxjggdBV+O2Ajz6dSc1ruZy0KUVupfOPrmrccG4biB/9aphGFXgdKkGMgEZB4AxTsZ26mRqUJWPj9e9V5o3ihjCcDrmtySJJX2nov41Uu4wyqox17UGM43dz51PU0lKeppK9U8IKKKWgBK7f4ThV8RrK3GzBBrlbGxluk3LG3lbwnmbTt3Y+7npn2roPDE50zXYAQVJO0g/0rswsLTU3sceMfNSlBb2LPjrfoPxF1FY2P2eSTzQB02uM8fQ5rpfBbLc6y1wFB8uMkHPSqPxgtVun0vVYgQhj8iU7emO9Y3hO+az8Natco5E0KEIM8HI7/mK6+Z068ovbc4JRVXDxmt9v0NjxP4yQ6gbGEGYQnbJNGvy7s9APQdK1fBWrxrJNazKZrdxkqeeD1/EV5tpCqkZDArKw3ZPcHvWmt21g6XUYb92wZiehXoaVHESb5pFVcNFe5Df8z3LS4HtZ0MLM8GMJx2/vH+RpfGejme0+1W3zMg39OTVXwdqSzW6ZKtEw3DJ79q78QRS22xlxH9c9R/9evTUup5rRykEraj4YaBCI/Pi8ls84Hc4rzXxDEJLLzJY8PDusbsA8gfwv+HT8q9cjsbbThMHykCKS3PAA5JrxW7h1aC1m14Rm40rXEa4uOMfYh5mEY/htOa8vNqLnBTitV+X9WOvBSs2m9/z/q5X0O8kXygW3qvyMc9x1P8AX8a1ml3GRlX5h147Vxt1cXOmz/aIgpZpPLnt15AOMqy+xGenHatVNfhuIUkhYBkB8yM8Nj0r5yUOp6dna51drPbzfu41+9gEN2P19KjuUCxlWwQDxn1Fc1LfW6yrJDKqKeV5/TNQ3XiO1MhUzLuwD8vIz9aFG6ISd9DdWdUkAMgVm5XPQms67vEvLW7tYmX7Xbf6Qkf8Rx95cHuOtczJ4llME1vLbRyRtnHzfdPqKxri/uLho3mfMyfdlAw351rGk2tTeEJ3PY/D8VlqWi2LSgyIq7kAYqSe5967Gx8mGMx24SMZ4CLx071598P5BNoFgxiVjEHXd6c13NqwUDPIHTjHesKi1ZvRbtymskjPhdowOu054qjrB/0YS253tCcuFOSF9ce1SrO6gFQMnrkU20WONgIUClSQB35OT9aysup10nyu7KVrcai0ihIRMjg7Xc7drdj9K1AxCK0ihXx8wHOG7809ixJ5Ud+tMYsr4A4H3s0loEpKfSxE6feGDnOQM9aytZ01dRsCq4FzECYieh9UPsf51sEe2W7etQPkBu4HGKvdamDTTujyXVdMhkt3Vi6yK2QGHQ919jnkfjWPFfTwDy7ws0fRZT/UV6f4s05DGl/GPvEJMD+jf0/KvP8AVrIpO7BRsY5BA45qIys+WR6GGrSXvRJoZdsXmoF29snINc/ruoNNKtvG+VHOQeBn26U+SOWBHjgcohGSh5B96xpozDGVK5Zj98dK66KjbQ3xFZyjfYmQqrbSDsHy56DJqG4lMaMgYZfknuPamAPOSGI2pyxB69q6Ow07S9NK3OsRXk/7x4ZLNIlKlTHlWEuSN24jIAyByDWrtHc5HOU4vkMGzldo227Aq/eLHqPQeprTitbqaKacL5kUMIuZdgLhFLBQGwMLye9Xtc1fVdc0fTY4ILO20mzklS0tYmVpULnLF2PzNyPvNWfbWl9brKks8sdvOoWdIpTiQA5AYdCAeaiTXWyN8Oqs0uRNrv0LMT+cdjxKH/2W6/hS3k8VpbhUkJk3456ge3aml7O0gKwhgwPBIzyetZF3IzXAyCsa8jI5NZxjzvyPRrV/q9O105Ptrb8jVgkUDDE7ic89h70lxdRbMo7hi21iRnH0ql9pcx5jKx7uoAyTS2kIYZdmLbu3SnyJasz+sylaFM0V2sAAig8cN1atywspGYLNCUQsMhTj3xn0rP0+Pykf5l+bgdyD7V1WkhWiMgUPIRsGfWuOrPoj06cGleQ/S7aN5gjRHAYku2QFH94j6VzPiDUjql8Irbd9khJSJc8Oem78f5Vq+KtRW3iNnbOGlmGZGH8K+n1P8qy9HsyFWTA3ZG0elKFoR52RyupOxc06z8lFCruduuO1dPYWY+UcHPbuKh0y1XKZ6k5GK6O2tiuMDBAwfX86543qSuyqrUVZEfklI1UZzj/JpWEjssakD1q4YfmJyee3pU8cK7gqjIHFdnKjlvbYr20CqEAH14q6RmPGASOlKi4JUDAORnNLMpXaqnOe4qrGdrkQXOeR2prR+WOKn2hPm7kcn1qMqAnJxngn3oGVi4iYngHGarkmSRXAHufao72TEgj4wSO1WIgBsIGQaLdTO12fNp6mkpT1NJXpnzgoBJAAyTWvFo7O8QJIBQMTjvmq+i2pubxM4CKeSelei2EFhiWGa4hF0AoCMcEjn5hXbhaKnrI4MZinRdomJpemzQ2LuIpGtI5UDOAdokIOAe27APvwax9fDwzLKpOUbcCODXWCHy1lwzqWkX5M8Hrzj+tZ+s2X2q0KlQD2I6g12VKfu2Rw0sQvaqUup0ME58QeEZLbKPLs86PcM5YDofwzXD+GApmvNLniaFLuI7SwIJB6fhxmrXgbUmsbx7KVipUllPr6im+N4WsNbt9QtT+4cbo9v8POSv0yTis6klOEavbRmlOm6c5YfvqvzRV1WEQuWjUrNbsFZccjHBBqeKAXdpwNyyKenfNdVZ6ZB4q01Li0bZehMFwM5Ho3qK5e1WXRdW/s7Uomg3nMRzhTz2Pp/wDqNCjySUnswjUcotL4kdf8ObmS2VbWR2CkfKwPpx09a9asrp0i2rICP7rdRXiVvfJpmrrbzK0YfDwyn7rE9s9jXfeItQvf7JUaXIqSzgDz2TJQHjA967qclBcq1scFROUuZ6XF+IGtm4szolrcIt7qUiWgC9QHIB/TNbmpyDTvEtj4dt4UOlWlgYyjLu83hRz6jAx+NUPh38PNO0zULfXL83V9qcX7xJLiQFEb+8FHUjtmt3xqbbT7W58RXreX9ihfbk4MpIwF+pOBVwvrKpoKVtIw1/zPB/Efg6ZZZZ9LvIXibdLBaHcrxpuJCKxyDgHjmuJleVSiyqUdRxldrYr3K+sZNPsdOivQ6XAtkLAsPlYrkj8zXNfFCw8N+G7dLLTftD6zcRo8kTTGSOFWUHdz0JzwK8zEYKEVzrQ9HCYycn7OSv2PLixIAJJHuaSnBXYMURmCjcxUE4HqfSnyII5Gj3K5BxuQ5B+leYewkRU8LkLtOWPbFBUqM8dcde9KgJUlFYlRkkdqVyktbM9A8Es3/CNXlsQRJHKRgtjkkGvSLeTYxGCVGMV5R8N5juvbYKrA7XZSeoPFeqWLKioQD83ACjnIrir6NkU/jaRfUlWIf5VYbs5xz/hVtV+VZQ46Zz6/SqYw5X93IrYOFI5rRgW3thKyKbktj/WLhVPcVzXO9U9LiWzrgg85OOn60ySN/tvmE4VoihHXkHNOHzy5Py5547VLMSFTnJBxxU8xFiNRk5OSd2CRTmHB7dQSKjvCYXtnbODIFYE+tTHduO7PHXHFUpEOGlzO1e2M1hNb7TslBjwOuSDj9SK8os7meGPZcqXiYbSj9cd/5V6n4njv7a2OoabO2YgDNCQGVlB+8B6jv6ivOri7imvJGniWMTMWCj7vPpUTl5HdgoNwkrXT+9GRd26FRLEwZGBKnv7jHas2XyCB8m2MjDAjIrQvYPIctC/y7vlYHkVXeJ7lMkoHK5wON2K1g7K9zr9kkrrYwJAsCyLBltzDaPQDvS2IknuIiSyJGesfBJP9abcO8c7RFTvC7QTWho8eLc8DA9fX1rtlLljc5KFJVayh0XT0NZp9PWazhtrdreMjy33nPzf3ie9PvI9o2gAdvQVmX6FXXJ4IwRiriSwNo0XzzPe72V1KjZtwNuDnOc7s8dMVyyV7SR79Kry81KXTYx5pGSUyQsdwHZemKg05DK32h22lTkNjqfT0q1qJ8qz2k4x8vHrWbbhnXBYgDoDwPxrqjrHQ8Gv7tdJ69beZdRlSaRnCSu5/i5x6+1X7KKQuNhjGfug4rOsy2cRIgUjaW/hI/rW3bQCHahJDg5Ibgen4VlVdjtwUOZ8y/r/M09OjaREkB742gbiD9P61tTXiabpP2qSHLsSkZB+Vm9h/WqUflw2xkzGgAOXf0H93njn8+1c/qF9JqVyGfAjQYRAOg9fxrjjDnd3selUnZJLcS1ikvbvfIxLMdzE11+n2oMyJgbQPzNZmgWqmLcRlj3HPArsdLgyd6Ie3y9hmsK0nUnyI0ivZxLFvCsSkj19Oa2IomMamQHnkgcURxdATz05qyM4OB+VdMIKEbI45ychq4IIxg9aW3+7hgBzx2p7jA9AR3pXwEHHOK1RluD9iAAT6Gnldygc8cE4phIGcZP8ASnR/Oeo554pBYjIBXLcg1BKh6L07e1Wnbk7eO3TtVafgE4oE/MyrpAbgMeNowKA5DDByTUl0rAg49xUR4wMYGaDnnVUEfOp6mirVrZSXEgC/UjByBU+q6c1mkb4ODw2R0r1lTk1zHzjqRUuW+pp6DFtQOAFOCck1Q8USmXXZ2yfkCKvYgBRV3R2BgQqnIIHXpWPq0vnapcyA5y/X17VrUl7iijlpJuu5Pt/kWbLXb+zUIkvmxZyUlG79etblt4ptpQRdwvCxHJQ7lz/OuPoqYYipHqaVMJSqata+R0urxxNLHqOlyLIyHcwU9vcV3GmafH4n0BrURZlK7ojjo2On415JG7RtujYq3qK7XwN41TRbxV1KN2tiRmWIZZP9rb3rqoYiPO+fRP7jlxOFqKCcNXH7yfSRqngu4W+aF5tGeTZI2CfJb+64/hP8+1enalouk/ELw4zQOgnb5oJl5Mbe/t61pPAt/s8R+ELi0vluF8q7tWOYrtPdT/EO4IqlB4aitfM17wXbXOm38D7rvRDJuhmHcxg8g+35V6UKNlyrWD/r7jzZVueXO9Jr8f8AgnlEnh3xVGG0m4tYb63G6MGRxiM/UnIIo0Lxbq3hGQaZr1gbu0Q5WGc7XT3RuhFerazOuqWEWpWq+U87GOeN+Cjj19D/APWrDTw/PqbCO4AlTptkAI/Ck8HopU5tNd9fkUsYn7tSCafbT5jH+OFjHEWtdGvPO7B5lC59yK5yHXfF/wAR9dtpLTT4p7SxcTrbs223Vx0LsfvHPau6s/h3ohUGeztxMOQUHINWtb1/RfBGnDzp2nkC4gskwGZvXjoPc1EqVSSvXnouxUa1JO1Gn7z7u5558T7HxBpVvHe+IvENo+pXL7UsrRSRtHU7vSvOwPtcpldnzx5rM5Zj2zzV/VNR1Hxf4ka6vZA11cNgD+GJeyj2FQ38I0qeIIj+cu4EuAUlGSMj8c/lXjYmqqk/db+Z7+Cw7pU71ErdbJfh6fiXZ7q70O1uo9Gu5UsdQgNpdOItvnJkNsOc+gPGDWRDDuhKqjm58wIi47EHr79MVvJDox0vyZZJJLmSJJ90RL4cuBtBwMNtzkNkccGs6K9WG/mEeJI1yoaQZZwOmcd8Y/KueTaWh3wpwc1zuyfzM8WspkKFcbThjngVNdSrDG1vCNufv/4VejttNvG3xXUsUpJLJgAE+1NuNI8qKSWB0uAvJUt8wHsB1rP2kW9TdYOrGDlTs0+qaeny19Sz4DX/AIqS3kLsixKzNjuMY/KvZNCm+2KZYJd0LMQDjjGOMGvHPC8e3UWiO7dJEUIxg4yMjNe1aNElvZQrt2AcKqjuB0rnxUzjo0n7Wz3NhERR8uc46nvUqYEm4DAHB/xpluRJIqHI4zg+1I0iRMA+fn4x6Vx3PQdJp2LaIykgjvnmobhFLMiMQQN2BUkrqibnJwBhgOwqrexhoFuISXdBwByCKJGcYXZW1NzNawKcAkn5j0FXbKc3EAJOZFwrgfzrBF2FfDgggc4q1bCLzRLFMQ3QK3dfSoUrM3nQSjym27fMVA+U9iOD615T4t0uLT7p/s9wjx78eRzvjzz+X+NegTakEuJIIxl1GdpOBXJeIFN/cC4uE+cqIzsXHPY5/SrlUW7Ncuo1IVeZbHH3KlbFjkMAcY9qo+cqlNgwF6evvV64t2SV4ZAR+NZEoMTMD2ramk0enXpezk5W0ZBrssTTxz7SccNjvVvRyGtzIQQzHJGKx9RbcjfXOK2rTb9mQg8Ef0ronHlppHDgn/tMmtkv+AM1XkZBAOc//WqtZEiOV2xtXJqxqAymSetY00+2zMYJBcnPHbNFOPNGwYuqqVZzfYjvbn7TdFmBMfRQOPxq5Gi+XsJ3y4Bbeeg+lZ9vBJKGeNTtQZZ+y1sWVuIkV8bXPJDda2qNRVkedhIzrTc5depasklVWQHasgAZTjBweK0dPdWldV3EAZyFySe5rMkeaZtuQkAxvPTPtUjNsJSIkc/w+npXJJc257dOShpHoWtTvBeOFQgxr3C43Ef0qXSbEzXK8ZAGT9arWcBkkQAZ5rt9JsBDbZYN5jEknFc9eqqceWJ0UqfM7snsrdUUBE2pnaPauptLZYoo1T+HjPrWZokcksMck0TQv12Nzj0rchBONvXnANZYenb3mTXld2ROIwEyGJYeo6UwZB75JpdzbwOinmhgw6Yxk8116o57Eu0MQwJKkfrUchAZsfn60LIduzGMDvQ4DgYA60xWFAOcZ+U96Y8uyTavHtmhySAuRjvz0qFj856AAd6YNpbiyyDAIPfvUZckDPJ6fh60wkZAyPpTckkjH5U0jir10kJJ85I6n3PaoguecVYC8dOfXNJt2gZHt1qrHk1a3MzwYaykKhY1yoIyDz/n86sXniO1u7QwTWTsduAwYLiuZPU0ler9YmtLnmvC027tal0X8kUJhtlWNCME9W/OqZJJyTknvSUVk3c3UVHYKKKKRQUUUUAdD4J8X6r4N1Vb3SZflJBkgY/K/v7N7ivobwh438PeJbpZLC+S01MthoLkiNn7nGev1H5CvlikIDcMAa6sPi50NtUcmIwcK+uzPrjX9Oii1CSVVRjdupdVAOGHBP5VzvinxJpHgy0aOeQteOhaO3TBfPbjsK8E0jxTrukMp0/VbmLbyoZvMCnGOA2QKyrq4mu7qW5u5pJ7mVt0ksjbmY+pNdk8zvG0FqcUMrfN770O81b4oarcQNFYgQM+d0x5Iz2UdhXBXE0txM89zK8sznLO7ZJ/GmVr6Fp3nuLmdf3CMAB/eNeZVrznrNnrYXBxUuWkje8OWC6bpv2u4QCeVwSWx8i9QPqazfEyXE1/NLdWs8OYwsETI3KknDD2J3e2a6e8a3kFstwiS4JxnkDjmsXUPHXiKOwbRodRZ9JhYmKGaJZfLGexYEjBJI9Mn1rkhdyue3XhClRUXscy0v2a4SS1Z9i8pvA69/1p904WNXZf9LkIcsOAB9PeqhDFS55yeT70bcsoj+YnHA9a25Vuecq0rOPf8PRE9jgzxoB948nGa1IVkkndIm8pQQd44yR1rPYNaW4VkKytzuHp6Gr9lBPNPFbglUI3MxI+6OuAKynrqjuwz5Pcad/89kbXh9XXXY1EklwTGWQOOBk9elemeG47iW8Zb1mZ4xgAHhe/FcB4FlE/iC+kyZIY4kiBPAPPSvUrEG3SRm+V2JDc/wAq8/EfFY6aE06038r7+RPdyKkYaAgOQRx15PSqnmMAFx+9Y4zjPNRz3cUTFZHUMeQByKitdVs1k4djMoJOR09cVzX5nY66qcI8zRuyzfKQ435XB/xrnr6bUNLeR7EiaBgSqsf9XWLrXjmxtWWK2fz7hjjy16Ln+83QCuZm8R63fbmtLiyt2SR42QEvjb0IboQeenpXWqMpK55tOpaVkr+Ruy6xvdd6bWx8zdAD+FOtNd8udFchlz2P9a891GTWra4JvCm6T5zngEdc1Xj1aeLaZosAgEFaX1OT1ueisbhvhqRa+R7K99Bd4dJFWQchmHP0ourfzLeYIxMgTCkngn39K880nXAdpD7h9eldZputRFwk2JEPXNck4zpu0kd1KmmlOi7mZqKCWzEjoFmQ7CMYxXK6gmVJ/iFdtqSCGbzkYyQM21lPOM9K5/VbPB3R8g+taYaokdWKhz09Fo/6scfIdwYY4rT01m+zhOm3j2xTbOwa4vXiQneVyq+vPP6VduIorRJlVmISUojOpUuhyAcfUGvRnJNWR8/h4unPnk/IguyBEQxGcVgeXJczAIPvNtB7AetaN7Ju2xp948VagtWLxCBRuUgHnAPYCnF+zVwr0/rdSy2RBBZIj7lx5IOQX6N74qQTeeS7k7AflxgVadNpkFxwynCgHI9KzdSuCXFtbht38Z7/AEqU3NmtSMMNC60Xbu+hNbytLMrqD5S8D3I71o28RchgD8zfkfWq9lD5cKqAN3AIHv2ro9J08yzAhCE2jcDzzWFeoonVhqUmlzbs0PD+m+WRPMgHzYH0rrILTfLgDKj17VVhgHlAYO0cdemK3LKEIQcjnGD0rzYJ1Z3Z3zahGxO8KxoFGOcA/WpkAyQ2CB3pXIROfXGDzUcp5BHAr0FZKyOB6iZJLMO1DEkh8g47VHEcbsjBA9OtOjYkckBaq4mrEqHJZyOT1xSAHc3zY56YqF5AG2Z6jtTIGYnqQeg5600TOSiiadwDnJwKpvIS3OAtPd8PjqPU1EM7eQAOmOgq0jz62IsO4DEKDgVIoGcj+VMjUlh356VbjXIHAC5z1q0jyqtRyYxABnPBI69RSvGD1Ixnt2qcJhT0Wl2dQB170GFj5ZPU0lKeppK7RBRRRQAUUUUAFFFFABRRRQAUUUUAWrG1a5diB+7QZY11Ni37oRhQEArC0W8mtBPHGsZSddjh1z+VaFtNsUpuxnjiueo22etguWMdNzU3j93HkjBPQeorlpr2W21C5aDaFkQwurDIZSOc1s3Jmd0aFgvPXNYeq2kltPmRgfMJPBopWvqVmF5UrW0TLPhvRZddu0tknW2g8xUe4lB8uPOTz74BOO+K3fFGhaVp62y6FqVrqMbmVD5YeKdSjcNIrcKCD8u08gdjWKmralN4fg8P21xMNPS4N41sG4ebbjfx7DFXrGCaTUIbTWLr7NHmMy3CIs/kxk/ewpyT7ZHvitJvsY4WMHGzjr3+WxkTB4pGEvLhRhQd3Xtj1rQsYgg8ySF5xKpQBTs2t2BzSahNZSat9ohEsFpGQ0SnBcgDGWI/iLc+2azo5nmlnCgHz26MSe/b3rNptG1OcacrvW+y6+r39D0HwNpQPhiQsyrJdlnYk9wcKo/KvU5bD7Ppum2yKzSyLuaRhyx789wOlcj8N9IeWXT0kJ2R7WVegODkA57V0nijW5odVnETIrwgqsWPlUsc8DsK86U+bnmz1sLgZQiqcdXv+hyXiuWK01C4SJiVjATJ7nqa4W5mv7y2luYZ0gs5CYiQ+HcDkgeg9+9S+N9TZ5mjLMWdsysB78msEXU72qqttvhU5Dxjjj27VrhqNo+0a3IxuIhdYe70Wvm/8iO4aKykCxBvJlG7B7HuKu6bLp50+dfMnjvUdRGFAKFeclj1BHGMcdauNb2p0UXqtHJIWC3UDkLtRiQoHOSx2kngbfl5Oauazrum6siWJ02eLT4E2WZacSz2Sb2bykkwNyHcPvAkY4IBIrstdankzcoT/d6r7rGe+syzJFb3EgEqL+7ZeQDyOc9+awZLeSHbFIwwRwc8fhWjfW9o8dq1jJMJmDCVJEwEYHg7snORjsMEVAkNyyA3AIhHGQM4oVo7MqalWSUo6rZ+Xn/mRafP9gu1lWMO6OrqjLvVmU5Csp6qTjPtV2x1hhOVnURsW6KMKOemO1bVhoq3vhvV9VtyBPYeUpjVSQwIzvz2IxWdpWmRatqc08k9raW0VrJcyebIFDmNeUXJGWbHAGee1JuNRWaFR9thp81N27rodHa6iLmIq5+fHGD1rR8jz4eMle4Pb61k+I/C8/hV2uLbUbPU9M3IY7i2Yn5WGQcEdOx9DV3QL5JcKxGH615eIoun70dj6Whivb07dTE1fTzhnjBQr/EOxFc/cXF7JbAXD5jRRboCeiglh+pP516fd2qSgjB6Zx615zq0JS9lBBXDkYIx+ldGDr865WeZmFFP34lSyhkabcwJAGc1vW8YCBCWPfBPWq1moVMkDnrWl9nkMLYJQY+bnHHpV1p3ep14DDezhdaszL9ghRi23BLZHbHSs+wheW8KykeafnYEfz9K2202NI0kK4LDKsTzUGnxBr+UqMknGfU1UaiUXYxr4aUqsZz77fI1dMs/tUzKnQNz9PWuzsbJIIVUE4HPJ6kVS0Wz+xwxbk+91GcfnW5BGN/zLtwcZPevKqSdSVuh6cIqCuWrCNWwXQrn1rSRfmUFQfwpiAqCCOpwKsQ8FS3Ve+K7KVNQiclSd3cc2BG+cAgZOKiZj5QYJge/aluXDA8YwMGo+oAY5GfWtCYptEbNtAz9RT8ArwRnOOtRqw5K8DNTR4+ZSufX/CqitbmFWookLAuwDfmO9KIumzhRyST3qyyAkdTinrHhcjH4dq2UbHkVsRcpqnAAxyaUQn0JB6CrZQAehqNx0Iz9KdjhnNyGRrzk8cVZjTqM8cdaijXkep5/CrcUXIJ9MYFOxkC5IORg05YyMcDHWrCRAqMg1J5YyM4osUkfIZ6mkpT1NJXWZhXQaFoI1CMNIxBbpg4xWbpumXGoTBIUbaTy2K9U8PaMbW2RQpyoA+tZVJ9EcuIq20i9Tib7wZdJlrZww/ut1rEu9Fv7ViJIGIHda9rWxmkOCpqzDowkH7yLd25FJOSMI4ma31Pnt1ZDh1Kn3GKSvol/BtneLte2BJ9qg/4U/Y3JLBSma0Tk+hqsYuqPn2ivX/EvwduLC2aaykZv9k815fqOlXenzNFcxMpB9KfNbR6G8K8J7FCig/KSG4I9amitriWJpIoJXjXqyoSBTuatpblmLDRq+MbuDj1q1CcrjsfSquiyxi6Ec5HlSjbn0PY1cngMDkDK4OOTWEtHY6MPUs+Vl6CTMWw4FVteha4EDRAu5bHHfNJE4Oc8GnSoZrF09KhaO568rVaTj5GNHLNaSSLG3lyZKlh1HY4NSRXM0lzbbHSKUYi8wnAIzwW7cU2GK3NsvmyeVIZwjNjO1McnHeoNxV8qenQjj8a6LJ9DxVUnFJKX/A/4JNe7kmeNpIpQp4eI5U+4rQ8LwefqYJ52Dge9ZkrrNclwu1WIyB+ta1jdpBrzmBRHG3AA7Y71nVvyNLsduB5FiY1Ju6UkvzPonwTBJbaTNcyxJsRQCGPU5GB9a43X7qN7q9vTnO4k/wBKo6dr80lt5UkpAI6g4qj4guR/ZbhCQG/WvDevLTsfbun7JSqLr27FLS7CC5snvLsEmWbZnI5X6H3/AJVmvp4sb8SWKkKR88Sng4PUen0qfStI16G2iaUrFA2DG0yHbz05FS3azwyx+dOqsuQzLAxXj0I616EnJOy2POpVMPUpqU4vmXlqvuuR3VxC4/0i3kR5xiTMaMTgEAqeo7cZ96mfw34YHhyC7PiVBqs8U03lCByIXjU4gYf9NCV2ydOCMd6jii+3IR/aVgCvKrIroT+nFA0qxjt2ml1y0CSLtESo29mzyACOnTn3q4VGt0efioUKjtFv7rfoZcOkzXzJDIby11KSGOe1hktzieL5izg/3QBwe/NWbO6WLRZPMkjwkgdozw0gPDAevFdDB4Zu4NM1XUtM1pTqemwB/saqS7WrfLIyP0JG7lR0Ga5P7DNdWM/2Zw5C7incj1FVO0rGGHbUZyTud7pU8ulabqdl9rM2myWQnsZEUbGA3PjHuWYEHoQfSuW8ErcRa9aTabJGLyJ/tFu7KGAYcg4YEZ9jVDQdWuIdIuNLkI8px8hOdykHJH061c8MxrDeglisqfNEVOAfUVm7xvqdUEqjVWKtdWfqXRNe2q3dpfLlLqQuCwCoCxyyMo4UZJxjGPpXPRGbSb+aEhljVsbTyV9vp716RqQt5lLyFZWIwPlwM+9YzaNAXR1RfMBVgknQ4PKfQjj8aXP9mRusM1FVKe/9fgO03U0khEbE8gYOc9q5f7E17qQtkeCNnLMDPII14BPLHgfjWhfW0MerXpjC6eDNmKxDMyorbiNjnqo4HPPNZc67rx1Iz+HWsqdJUptrZg5KrHbUWzXcqYBOcV1EOnwfY3lvJpIQsb+XhDKsjAAhQV6HGevHTpWfDa2sosVs2uvM8vNy0qgASZPCY6jGOTzmvW7u60+0+Gc0drB9l1OHZCJjHvLbgN65H99TjJ7cU2lKWr6XOhylTjFQ3bSPG9Y1AJEwdDHGByWAzn2A6CpfCdssu2ZlyJFzhj796i1W3WJHPlqJMYPsa1dDTyI1UcEYB49uRWUpL2do9SpU5KteT2R1dtHmQgYYAenTn/PNaSx4TaQSoOM+lZ1pIpRtrEMT/wB9D0q6JGYBV5HeooQ1uKrLoaCOGfYcepI6GriNtUkgkE5yT1qjYx9C5GD0yOvtWioyMFB8vXB4rqOezKzBSdoGQeKgDBiQxwR0yatyKEztACmqZQid5G4zzj0pIpMCwjPXC9akVv4lA7Gq0jEuWHAGATUkBKjrnnj2reCPHxk2i/HyuTk1LxjHX8aiibIG3OKdk9BjHYeta2PIbuITlcdvQdKZgMe5OakwSc46HGKVFGMDpxUk2HQpyD6mrsMQwMqBTYIuPSr8UYBPB575ppAkIseQQeR6VIsXPX8anVBwc04IPbHamWj5u0j4bXtywa6LBT6DFdvpnwxsogpeIMcdTzXpNrYOuPlwK1obAgVsqTlueDKrOe7OIsPCNlbKAkYGOlb1vo0MZAVBxXRJp6BfX61YS2Re3NaqkkTZmGukxleEAz6VNHpCg5K810MUSqBgCpAoJ71oqaK5LmXb6akePlFadvbqnOPwpxkjiGXOMdqiN00mBbrx6mrSSKskTXEUboRJjFcjrvgnSdabDQKSf4wORXUrbs2XuHJA568UpuliUCKIkdNx6UpRUl7wmrnDwfCDwxAPMktBIRzlzWzBoGmRWxt4LWFbfpsVBXQ4M4zI5IPQDpU0UKIAPlpKlFbIHDmPnH4ufCgWVrNregRlET55oB3HqPSvMrCVdUtB/wA/MQww/vj1r7bu4Irm3eGVA8bqQwPpXyX8VfCVx4G8U/b7Nc6dcOWTA4Geq1z1qVtjroVGnyt+hyG1opcAdODmtOG026PLdEpndgLnk0Xduk8SXMLfupRkH09qziv7xmIbJ6Ang++K5Xqe3hq7kYshy7nvmm1LcgLMw4xTVhkaURBG8wnAUjBzXUnocUovnceoirlCSecjA9alUiGSMgfMr8n+lNVyjqCTtAHI6gf5NO88qjxY+QuG56jFJ3ZpFxjrs/6Z2GnTBk9f0rQ8TyrFokbMAGAzgHg1l2A8yIMhzkZqDWJpZYbeMOEi37WkflVJHT68GvL9nzVE+x9lXrOOFTvr0+Zt2Hi+e30qOFGaEYyyP80ecD1qBtUin055IdQWN1f95GhJ3A9G56emKy/MtIQBua4IGAeo/KrKBbqF4kjePOCieUPnb8+MduK0suxzRptJRTTfp+Zt6Rf399ZfZbW4RWRicpbgvJuIwrOOwxnnpzWncavqulwxjVbeGaFxtEksBAzz8pOOcYPSs7w54emW5Ey+TFIpBwzn5ifZTWtqN9f+dBDbpbTnYw2TOQdwJzsPbHoefrW8UrHLUqNz9m1/l/mUtD161ne+tNQntLWwaN5IyqscNtI2qQMjd/Tmub0tzHNBJAr5QZbHOf8A63tWldpb3jtvtRb3OCSjJsyfbHBrP0YvBdhgOVBGT2rGR2U6PI7rZ/mO0mxN1qc0771iIkkd0KoRhSTtDcHBI+XqRwOav6fBc6rrD3ltbwQtKxYJCnlxxnvtHYe1RW0bFnCDhm4GPWuy8LW7QSB8KUY55OMGo5ubQ7oYNU4cz+4l07Tr1A/nuZAMI2R2I9PaibTZlw0SSbY+enIX29a7WwtXuLC+v2RUs7YqrStyGcnhF9T7dqIBiPjkHPH9KbpkxruF7I848cadFJpcV0i72iGScYJH8QNcLGIpJA8TsVYAkMMbD/dHPOBjmvVvGUYg065ZRkspJHWvPNC0pprMO0iRIAXZnz3PGMClKSijGhQc6t1t/X+Za0sRgAgsrk5HYZ9K6O+v5Y9MitoFktbaRdzqWJEmOhP0OcVR02zjiRAI90ocsXzwVxjGO31pt4h8oAJIYFJzubr34HpXLOWl0eq6CUk5I53UUea5TGdzN0B445zWhpc7vMhU43t1HequnN52pOpDHEDgY4IZhgfrXR6RYR2yRebhsANwMCickkos45+/OTRu6VYtIu9wQM7TW7aW0cY+YYI4xVWxk2DBHIGQDVgMwfr8xOSTW0FZaHPJajxyTkBccCnK3JAzjv71HI6lSOQ2Pzp3CxqckOenPSrRL0Jc4AyAVxUVwEKg5GR0pySZUdO2RmotwMhLKMnOOKpIzk7IzmOXxuYk+/erEYOemD3+tNkj2uzIBzUsK5xg59ya3ieLindlqDcF5GfxqwO+B14+lRxKRjt71ZC4BwPqao86xEAM8kc96kiUgjKkemaeR15/GpEQZHXOO9CEWrcc/wBKvRAD+H9Kr2y55A496uoDj+lUIeF45z6UpUcHj/GnoOfT+lO24PIPFMdyZR0x+NWlGFBHTtVSBiSO1XQMr9K7jwEIJOKA3p3qGYiNSzHFVopZbiTbFkL3amFzU85Ix87fhUYnmn/1KEA9zUlvYRLhpMsx9avIiqPlxVWZaTZSj08Md0pLt+lSXckVhFufHsB3qa5uVhiYoQXAziubtobjWLrfLuESN1Pf6UpO2iE3bRbl62mn1GbLZjgHQDqa2VCeWIyny/Skt4FhUIqirKJ6c00jSMLblNrNovngyR3WkVgeGXDVprwKjngDnKYBNMrl7FUITk9K5/xr4btvFGhz6fdoG3j5T3U44NdEGKDa/bvT2GVyp4pNJqzFY+OBpN34f1G+8P6ihEkTF4WP8S+1Y93GIpN4B3Y9O9fRPxs8Nfb9Oi1i0j/0qybcxXqy9xXhOpQjzywHysAQBXl1YuE7M78HUvLU4+9BEgYjnvVtfLuNLE32hFvrZycEkO68Yx64x+tRaoh3A4P41n1vHWKN8QvfuhSckn1OaUtlQMDrnOOaQ5zk9+aGJYkt1NWZXNHT9Vls4yoG7AwvtVWOSaW580qJZP8AaGRUUrtI+5iScAU0EjoSKhQSu0tWdDxFSSjGUm1HY6CDXJYMKbFQemFFbVhYXGt2MkzXctpcpIuYI48BYycbi5OSfQAVz/hkA3m6QRsmRu35yB68dq928E+G5b4tcWAiZUQrgKcMCOfvDrXFVcac7JfM+kwk54jD89eq+XtbT5tHJwWV/wCH7Evb3sl/bIw86KeM7gp/iU9frUlzHNcqJJ7aURSNuEkJDrjHBr0vUUewlS3ljRroRH92hLbkI6EHuOtczPaWtrCscDPFM4yrpkKfYrSc9DpwmGTkpROXW3iuEZJCWRehPU+/safeaA1lqDhXiKsqnMUgccjPOO9brRRErlPLDlVlCAE9ece9dPLcaDdXt0IrBksks3+zea+xlmAG1yf4icY2+9Yp33Z69Skk0+VtdbHC22mlWy6jBGQT6e1aDSxxCNInC5wAXPA+vtTtee3s4YzbXDzM0CGfem0JKeWVfVQeM96j8EaSdT1Bp7jIt1Zd7HooNZ8zUrLc73Gn7Pmlokb1vJdR28mnR3Rms4pmcGJv3Ujd3HTI9CecVux2s6WyM8LGOQErLjCtjrj6VsWNhZWV5PFaTLeQKS0bhRgoBnNaUttFPCNhyv3hz29BV8z2bPExGLptrljp/XpqeXeM4D9iZODkdv1rE8J6fBPJDYyOYhL8isVBXcDkBySMLxyc123iiw897gRzQwGCJp2aSTYWCjJC+regrir+9ju7qSS2gFpBIQEhB3HgYyx7seST6mok7NNrQ7MKlOPub/l2/ryGu0cMUpXYZHdlGwfLnOPl/wBnHrWVqNzFEG3Luwo2sO/tUswYQKvDBcqRnGK5rUrp7iVLO2UtLI23CDOB3NYpc+nQ6MX+6V29S74Vj82a6vCEZDL5SA9yAST9M8V0lvyxzknHXpzVK3s7fT7e0t4QxxGN3174+mavW0o37cvIMZGeg57VlOXNUujz4RcYWlubMDY2A444z6mrYkDmQdGH61mWpwm4kZPP1qzDhisqH5OmSK7KbujmmrMuLvkk2noP4jSyBo1wnIx3PSgbgikEbcHNSIMOr/fyMfStbGbIQjb1yeg9KdnkMe2e1K2S25uAOfeqzzDBPIU8kntVpGVRu1yQsTliM5qzbgE88Cs1ZATkH8PrV+3fDcVojwcQ3c0oFxxzmrAGQSKrwnIPHQeverSZ244wO1UmcrAKc8fjT4ozwcY/SpAMnkVYhjzgnORVk2HwocdO3ariKNvGPypkUeB6D1qyqk89sU0CiKijtSgCnfXpTCeRn1zVDsNts8ZHNX0IIx2qhb48tTmrsf3c9vpXaj55CNYLev8AvXIQdgahOn3FgfMtJPMjHOw1asZDvcDNWp5Aibehp2W40k1cp2GrWt03lMxinXqrU681BYwyw/ePG49KpmwWe484INw/iq5eQRw2SiYcKetCbtqF5WIbdX8jZy0kh5Y1q21uIYFRBjA7Uy1RWIkXIXHGasDI68CqSsaQjbUdG287WwGqccHFVWGRUkMuCFk/A0zRFrOBk0xX5JP4U9lJAx0oCDGMUDIpdkvbBqB0eA527k9qsSL0wOKkjRiMHkUmxWuZV3DDe2csLcxyKVK/WvmPxXpIsNSntmRz5EjDn06ivqq7tI7SCS8up4be1QbnlmcIij1JPFfNPxW8WaHfeIpV8Pebexso8y6C7YiQcZTPL/XgVx4qzSZvhozdT3Uec6hAkqEEYbHAxWEmk307N9ns55FHOQvH516Xp1tZTQie1xIejbh8yn0I7VfSASI4icCViDszz+FcKxHs9EerKLqKzVrHi5BBIIII4II6Uldf4z0gC5kuYBmX/lqAOp/xrklOGXjOD09a7KVVVI8yOerRlSaUupp6FaWd/N9nuZTFK33GDBfw54roW8B3MM0T3Em20cgZLKh5OOvTvml8PeHX1jTCpslkk3ZRQdrqKhkjvLBLmwDXAiXrHK5IGPauSdZubUJH1GHy6nDDxeIpJ3V01dP0a/W5Z0yHUvDWsQSWbmDULRiB0JIxhlPYqyn8Qa9M0fXng2LpP2m1cnIRjjyz3QnuPfFcq2miWa3voCJMIpMfTzOB0q9Hc20UpZoWy42mJi3yHtiuOdbmtc+hoZWqV0lo/ua6Hr/i67g1Dw5a65LDKsojW3dA20o475/P864GO8NyxS4G8noRxt9xS2+rRTaHBZarcAhiTGc8rjqSP5ZqnavHNaXn2dXkmgG/zDgErnHTPFNSbSsRhcPHDKUJ9Hp5XNMW1hHHEReCS5Yg+UPmJ65Of4ccDB5o1Boim1wyTowYbcbcevvWAk4jj3vtTfzye3+NZD60003lQFkghySGOc59KUZc2ljqqxdL3nLXoaGqvJeXSoTkAfMOmT2r03Tmnh0HTtK8zggDy8Djkk8+mSa8y052WdHfcXJ3HPYeteteFrR5v+JjdZDMMRKey+v41TfK3Y48RUfs1Key29eh1to1naaf9ks7WLYy/vZplBkLd8egqpcG3smhhXekjqWcMflzngAduKuHUJHto4C6iKPkIFHX1J71i61Ik0DbyM5yG9DTtoeBTTc/f67nA/EW7BLKMZbHWuFM+1Sc84GM9KveNNTM+rR24cuEyxNc9dzhS3zdBnOPas56n0uFSpwSJ7vUY0tHZxl9xPHatzwnoAt4Pt94n+mXGTtH8C8YFYPgbS5Na1xLuRSNPt2yoJz5jj+gr0aFMRgtkMSSSpx3rnry5PcXz/yE6v1j33t0/wA/8jmNatPJuQ0UvVGdVA9x/OnRfLc7NmAR1z1PXir/AIhjwgaMIJIyBnPGO+ayHDJHuB/iJPOePWudPYTjfUv25DZUgq27lT0FbEQxEqADI/WseQeWAR1xkmtOynEsYGMkdR6V3Updziqx05kWoRzjdhSOPSpISGRtx5B4NQB2EW0AH0OKRG3ls/6xeOK6kc5PKcKRxuJwap3KuoKMRxz9asEBxlmOBzUc3+qIwpIHX0qkZzWlinG4GRtwQeh7VZt5cepIPWqUgIJ9AeO1NSU7sggg1VzxcVCx01qwOMYB9a0Ycn8qwLCXIH+cV0FmpJBP48VcThSLsSA//Xq9FFjoKjt4sDPY1cjUgdCPXmtVqPlFQY9KeKAcYFRu2BVjsOY8dqheTGeuKSWXA68VUllH/wCqhklvTJBLbIfatIOqIWY8YrB0HKW+GJ47VsSxh4iWOM11R2PmkVbS4dJpCiZGcA0QmW9ugGc4HJx2qdAqREKMKO1Loa7pnc9zRboJLWxuIgSMKBwKrakFazeOQ8dquEZ6VTvyrQSJJjgZFaPY3loh9pGRbIV7DpTvPMZxIpHak0199oh54FTyruBH86F5DS00GrMr/dNLtzj0qrJAUO6M7T6UGWYLkrmi/cd+5qQS7UINSC4jY43YNZQm3Rs0jhEUZZnO0KPUk9K4jxR8TdK0mKWHQY49V1BePNkJW2jPqWHLfhx71M6sYK7ZUby0R6XdTWtjZyX2o3MFpYxDMk88gRFH1NeNeNf2gNPtPMtfBFj/AGjP0+3XalIF91T7z/jgfWvH/Fl54g8a3v2zXNXjvVQ/u4I8rBCPREHH49ax49DuR0kh29M81xTxKex6eHwsN6rJ/EXiHXvFt0LjxJqlxfsGykLNtijP+zGPlH5VSVVgJCgDvUt1p01vGzGRDt4GQQD+NYZv25AU56Ywaws6h61Krh6atE6G2upIZVlgkMbr2HQj0rqdK1GHUWKEBZwATH/e9Sv+FebLczMSfKl2+u01NFdyI4dRKrIchgCCv41nKhc1lVpVVpoz0/UrJLpWkgI37cNHIOteW+ILB9M1UqEKnO5QRXVaVr0mqSmGedFn2jaGbaHI9Pf271Y1/Tbu+sJFeOKVowSu1sEH/PappXoz1WhyVJc0eST1Ww/wreSG2Mtm5SeUDPfb6ir0WlXt3qRuL0R+W67SN+Sa850nUbnRr4qVfAOJIuh+o969BstUvLtF8iKb5hj5lxiscRSlSk2tmfZZRmFLG0Ywek47rv5m2Bc2RRbcRbQB8zdqguJFJZpH8x88mm23hnxBqOxo42VXbC/NwT+NWrnwhfWasZNZszMpGY4cueffGPrXHKUH9o9mNflfJb8v8/zIUjdy7kYLAZHcCnCxnEhkjlAbHVWwcd6NX8PXNlYpcWOqLdSBQ0sRGxkJHQD+LnPI9qzvDmredcvDPuSWPkrjirj7yvF3IWIpXs1ual3FetpM1o1tYt5n3bhs+Yg/DgmsrTvB+sPLJNHEyRRAMWcevQ129hCt1sLEbBz1ziul+xTKqSxYZAOTnBP4V2Rhyw0POqThOpd/icbouhhJg1yWfDAsCeDXpMWoRxqETBB5I9KyBomoagxFjsij5/ev0z6Vki31eyuJopjC7xnDLyDj1FZ8rWrMq0qdd2T26HYyXqOR5bHI/CuR8W6oLaCR0d3mIICq3X8Kj1bV/wCzbJ5J8px1NeV6t4hvbu7lcII0cbVBPIHrTWq0MqUI03zPb7yjDcvNdyzy5LuTn2q9Jp73Wk/avtC+bPceRFAuCzADLFhnKgZGOOefSs+xheWVI4s7mPX0FeoaBocdnb2bkwl3YyPEUzIu37rE9RuJ6dwKipUUNUdVKHND3np+ZreGdJTTLG3t4lGI0wQoxlj1plxGbeYeZje7F8n7oGe/tWzEpWNnfJcEjA9agu4DPDjAYA7st6d686V3qwjUSnrsYuo2sZimBIxwxYjg59PxrkZy32Uwk4dlYsc4wAeMV2Fw8dyryLu8xPmYt2GcY/KuZuk3SsHRTGG3p1GR3x6imtrm8ovl13NO3gxYxKwJbYMnriiFXRw4X2JFWwUEXJwVwcYpjEJgjnnP0r0nHl2PKVV6okWRVPfbng57e1K1wqsmzq3fFRfK2M4x1BFD7Qq8/TFaRdzNonKgnAB55IBokz5e9eucEVXMrAkrkY4I96c8rcYwePm9qtMllWbGCQvQc55qmsmXKqOQfSrkqLs+XvzjPSs1hskJLDc3b1qzzMZHQ6HSWG4BvzrrNP8AmTpkkfpXCadMA4yOO5712Gl3IO0A5NUtDyI7nSRL8oyasDoCOtUoZl2jrj3qfzTz/Wt0aDpGwpyelVppwAOTmmy3A2nmsu7uNpJ5x7U7iJ57jAJzz+VUZ7rseT61RnueDzwfWs2e6+Y5PAqHIhncaViS2EiY3YrXj/1G3mvPPAWufaNNCyN+8UYI/rXoCHdArA8GuunNSV0fMLTQqXjmPC54Na2kRhEBrGvSQgz2Nbunk+UmOPXirW5UNzST6day9VA2uW4GK1IzmqesLmBjitHsaz2E0gD7HHtORirxGRg+lVNMiL20ZiUg45C1W1rxFo2gIzavqVtA4/5ZK2+U/RBk1PMorUqGyRov93FZ2t6naeHtLk1LVXKWy8BRy8jHoqDuT+neuD1j4uQ4ePw/pLSvyFnvW2DPYhBkn6EivObu8u9SuGudRupr65lBDPMeV9lHQD2HFctXFxXwam8KEpasn8X+M7/xRe/vsW+mI37u1U/Ivu395vc1mrbs4wE5/T6VSu7SN7eNfMYKHVioHoelWo7yYhwE+XPzV5zk5O8megqajG0CWDQzCjyQRRW6MckbuD9KQ6XPLKi4+Zjx/wDWpHkeWQAydscdjXXeC4V+075W35xyeufWlKaSuLknJ6sveHPAMbQrLeDezc/NyKdJoBtb8qsEEZUn/lkpJ54r02EL5C4HB7VXurZJW3uPmXuB2ryK2InN6M9bC04Q+JXOSt9LjNxG8kEQQ/KVCgA++K3hpNsXMD2sDKw4JjHI9KsG22yqpA46E1etwI1Kt+WelYqpN7nRVhDoc7f+C9AvlIutIs2PTcIwpH4isa4+GuhSPuijuYW7sk5GfY57V3zuADkjH8qwbzWUVmWAggcF6v20o9TShCc3aJyk/wAOtGt5DLmQD+IsQTn69asf2NZ2pcWiRx7QMMeSR35NOv8AUIi5ZpCx75NYc+vwCTAboOPrUe0lJnv0ZVYxs56fga11qj20bRQg4B3KQMflXHXupiNz5QCEkn1O7vmm654gi8phkk+n9a841fxHES6qxlbP3Y+n4tXVQw06z0QVcXDDRc5NRv36/wCZ0+q6t5wBM2Xz2Pb61x17qdzLemSylweAeB82KrRSvqh2xmWKLnKRAMS2OPwzjmtLS9Iaa7EEA8ycDDD+79a9OFGFBe9uedLEVsdywoX5b77N+nU77wBd/aIIvOmIcPyua9ssQogiMgBDLnHrXi1noX2WzH2SQreIQ+d3G4dsd69H8L+II7zT41uCqyxDaVPVWrKM7PQ9HG4afJG+6O0Rvs8AkRwETOMcCuBbUv7S1zWJImV47YLGNo4L9WA+mRVDxt4wj06B7aG6zMQcIOTk1zXg3UjDor2sZkFzKxkmkdeMnknPpW0pKxx0MNOF2lr+hgfES9a4ultzJkZywBrm7eMzzKifM7dKqapfSX/iK5ji/eDcQhHf3+ldz4f0gWdsJZAGmI5Pv6VlWn7GKvuzqwUVjKj5fhjo36F3wxo8MMoeQAgDcwPG70UfWu4s1kkzNN80s2Cx9AOAPwGKx9PgAIR+3Uj9a6GxUFzwAoFeW25y1PRxNoq0S9FECg4HHUmkKqAQOh/hp+RxjBP55pH+62MBl5Oa6OXoeQ229TGXSIi7NMruDnAboOf1qtfWccnPkqGTgYGePStlpP3rZ78/SonXerDC7cdx0ooN8yRvVqSkryZy0m9HC7Cq5wMnnFDjKn5hg9RVi9gXeGUqDnIPUEelQMAwJ6EdeK9CSONrqRKxcgIVHYDvxUm8AgNhRjrUUiF2yDj6U0yISiucFTxmpWhNySQF9qqPlB5Pc/8A1qnAUgHpn9ahkC7VPQ5/WlLkoNhHXp61aYtyORTuIRRtwetZN4DE/wB1gO1bMh+UdQc/rWHqDszEuoDDjg1omcWJV0EFyUfnFdFpuo4Uc89hXDtKUOD+dXbG8ZWBBIqkeG/dkepWl+GGAc+uaui6GMhuDxXAWd6ygN2rVh1E7c5xnn61onYrmudHcXQx6VkXdzken1PWqc9+MH5iTjpWPe6ge7cdKTkS5Fq7ucNw31rGuL/B6nJqjfaovIzgiuev9UVTw3+FZuRNztfDCfZb1lilgIbnYJVz9MZr1zQtRsri2VP7QshKONjXChvxGa8AWCG+tnkEaiSMgq6KEOex/wAahljWdALuNN4/i2gZ+tb026Wh89yXdz6Pv4GdoliMbAnqrgitH7Xp9lEq3epWFucdJblF/rXyv5RjXYkjgegc8iqpSLzNssasoPU9Qf8ACtPrFtbFxptan0nqvxJ8I6SxWTVxeSr1jsozKfz6frXEeIPjVJeRPB4f0ZIFOQLm+cO3/fteh+prypY1AG0Ko7bejU5LceaHjHPQ49PWs54ifoaRinudaPF3ifW9iz63cwxxgjyrXECn645P51kjThGWaIgOTzubJJ75J5pbN44yF2hge/f61oNllDIpljPocGuOdS+56FCn2M9bdmJyg8wDoOD+FWVLRw7pGYxkdccg1LIN8SlVZyhxx94f/XpYWdj5UoTJGVYd/wD69ZOZ1KkupBIoOWiZWLHNN+bZ+7QHP4VYjh2IxwMg8D37ipoogdrDGMZ/Os+Z3NlFWK0MPygSDBYgitrRLoWk6q55biqioOjYCk9feow43lGwrqc/59ardWM1o7ns3h/UFubRUY7SOOa1XI5GOa808JaqFIUnDAbSK7WXV7eJFaaeNR3JbGK4KlK0jsjK6ui+0mD068VC0wUY6YHOa57UPFtnGHW2je4bGcRrkfhXD63401GdnjggaAY5Zgc1UMNKXQbqG/4u8YXWkieyu7UKZs+Rcxt8jLnkH0OO1ee3viyYQ7kLLGP4j8o/+v8AhVPURf6qSLm4d14OOuazL3RLeOISXc11IAMAA5/AV1rBU95HbTx0YQ5YKzKOqeOZi5WFDJ/tHIFYM3ifUZHLI0ceewGav6lpVpGyAW1zEx5zK/X8Kgi060BBMe705rthTw9NaRMX9exD0nZfd+Ri3d/d3pP2ieSTP8OePyqS20u5nwQmxfVuK6OO1gto/MMaRL/eeqF5rNsmVgR5m/vMdq1qqrlpSiKeXU6P7zG1bv8AH9X+A2DTXtDvjmLEjDqOMj2r0j4ewWg0ZvJIMjvhiDy2O2exFeTXF9eXaHGVi7rEMCpvD+vX2hXDSWLq0b/6yGQZR/qPX3qamHnVjq9TfA5thsFWThB8nft5r9T6CaCzWMTR/aDs4OMcmsfUNPjnkkS2mmgkmX/Wr8rK38sVx0HxFtJY18+G6tZB1WPEiH6dDVPVPHUTo32Uzu7dyoX+tcLoVb8qifU/2tgJU3OdVPT5/duQ63F/wjl0zXdwt3cfwuGyc1zlxr+p3SG3huJY4nPMcZwW+pFUb28kvZmlkUepycn862PD8CAhkwXJxkjqPSu/kjSjzTV2fJPE1MfX9jh5OMPxZ0fgjQ/s0YurpcyPzjuPSvQrOMNKuR90ZI9+wrF0WEtbqXUKM5ODmt+NNseT95+TivBr1JVKjnI+6w2Hp4WhGlT2NGxUkFgOp/Sti2YCLHHPU+1Z1nxFjpt6ir1uo2dME9PrUU1rc48Q7t3LkeeqkYHAqxLtAC7eT97mqu/y1wB8w5pJbkYXeOo61vexwuLZSlm/0kKARx19asbd0CMpUqfTt7VnysfMdgAxwD+FTxgxwAL3Pr+mKeGk3UNK0EoohuYg+Qgx7D1rHuUKtnJDDg+9bbvmMlSB3xVG7i3Ke/H3eua9FnHYy5n+6y5K/wARxiopEXYdgLY7envViePy8svI746VCrKe3GOG/pSaIaAAquTkDGePaog8izBmGVPA+lSKSMnd1OOnSpAPlJkHye3OKELYSWQbW7P/ADrGvFJTdkYz1q/cSGP/AFZJJqhdIyRYZcDv71SMK0bowbobQQKS1mwfpTbtsMecep7VVEmxuPrWlz53EwcZHT2l0VGCfl96tG6CglWwO1c3FcccdO/NOe7IXr0ocjCNzWuNRGCM9OTmsS/1TZn5jx0rNv7s7TyQR0rmb69dicHjoeaIpzehrbS7NLUNXHOCSe9YVxeSTN944z0qs7FjzQASRgV1wpKJhKo3oj1qWL+zrwuVLQSnDKDgex9qL/GUkh3GJsgbsZHscd63nsZLi3+z3g/eSYG7Pf1rCulMavDLHieJijA+o7/1rqzKlqqsVvv6ng4SV1yvoZbxnOR2pk0C5Vxzn5SfSrsIDqVB69M8U1Ldmd0U4ryGdxHbWysoLAhH4IHY+tbVrYxAYUdu3NZ1qsib03dPmwelbdqJGhVtw9xjFRLY0gQrZeX1UDHOetX7FQoMZHB+63v7UMp2DJHPIxSxDoVILZyM96yepvCTi7kwgH+sXKv0PbP1quYVimBlA8iRsHn7jH+hrRt5EIDucZ65GealdIpleOVFZW4wahdmeg+6M+e0MTFlw+RgqeCw/wAfSqxTywr7/wDR5ejA42t6H/PWrkcxjT7NMcuo+R/7w7VSuNyebiMyIf8AXW+fmGf4l9aGhxYEFd+csvRh0I9wajkeMR7p8Mv8MoPH0J7Got2+JDA/nqCQQhxJH9R3qs+0k+VMd5+9s+Vv+BKeDVqHcLF8XMycKrlD0eNv85rUstRmAVJJYbtT/Bdx8j/gQrhbzV7TTnxO5Q56wPhvxQ8flVCXx0sXEUZuVH3WZdh/KtVSclohOShpc9cmjt5UBNktvjvFICtZ13eWduNoHmOO2eleWTfEG+KFYbaOMe7k4rEvPEuqXQ5ufLU/wxjH61cMLPqQ68Een6hqdug3SGGLHRmIGK5+58UabHlZLrzMHI8tS3PtXnTs8zEyO8h9WJNEkTRgFh8p6GuiNBLRsl4m3wo6zVfEtpeJHHbpMFDZJZRk1HYahA86xRK0jkHqMfrXKV03w/hW98UWUDnBbdkDvhSaVSjGMWzswWPqqagrIxLu4uL64IdiwDYVc8DmpTZfZgkkvzgH5l7YqzFEkU8uRh/MIJ9Oa0/LWVCHAOeDRKry2S2NqGC9tzTm7y8yrZFbO9imS3jmRJFk8mUFo5MHO1gCMg9CPSma9FBdmKXTLGS1t402sJHVyWzljlVX5ckYBBIHGTUsULRzqsZKP0DeldPpfgq61TSrq9S8s1+zMqmB5dsspPTYO9ZuuqerZ1PL5YiNuXb9TzeSGSMgOhGenvT47aeQZSJiPWu11Xw0mnSwxyyLLKQfMjUsrRt6MCODV3Tba3kttmwrIBtIx+v0pyxi5bxVxUOHZTm1UlZGL4Wuf7Cl+0xwWk9y6NHsurdZguf4gGBGffqKs6TAFd0jTysv1J4A9vaoxayG6KYx5Z2/jWzZRK1zGhywzjaBnJHr7Vy1qi1fc9vAYPkaVrcuh2VtGI7eJAeMY4FaEeCBuIxVS3U4G41ow4UsTzx+deK3ofQyfYvWQARTkZ9PWtBc7FBwozmqCA8Y+7jOalW4y20hg2Mit6b5dTzqqc3oS3ExU8sMdcetVZZ2ZckkdwRUUkhLcrkHk+1VWmOD0wOntUVZcxdOlYvwyebwSPXPc1aPyxhRnOO9Z8Cb1D46nirynEykEnuRnIP0rqwkbanJibXsiu4+8u7GTjp3qO4ZdpOTuz0qzOC5GByDUKAOct8pPY16BxmaAVYjC4bnpUbQgfNjOf4RWiwXcSFwRxiqsoAYE5x6Z7fSkxWuVMGIZVflx65I9jTVOEGcZ9KtyRluASDjoelUJQUc7A3/AAKglpMeUUOCR8+eOetUbtC27jBHPJq6r7mJPbpSMvmAhiCenNOxm0cXqcbbycEA96xJXeNznJruL+3yG+UEY/GucvbPplcD6UHl4qhcz4p/l6/hT3l9SenSq5jKNxg049z6/pSPM9lZlG9ZtvB61hTqSx69e9bt4m5c4/TpWVJEc59e+K6aTsXKneJQEZPPFW7W23sOB1pyxgEZHFadoqgL0+taTqWWhlGko7np3hXW7O6iRpIUE7nGQeo9q1fFdirr/aMCKZWTZOP76dmHuK8c0y6uNDv/ACpCTDuyrHtXsvh3VLfVLEK2GlZcFO30+lfSe7Xg6dRHyNSDw81KO3Q437P5TK7H5Tz17VMSI5SWJGOASOora1bTRZyBVI8mT7oxkqe4HtWPc/NCQRyBkZ9a+XxFCVCbpzPVpSVWPNEid1DDaV9RjmtTS5t8ary3UjIxWQgJG0ZzjNaOl4STjktyB3z3rlkbwNRiWGAoJIwAKrx7t7lick8D0qdM7yIsjJ781HdbUTIKjtgenrUNGqiSW8nysvcc1I85LbRwxyQcc8VTVyQ5UAZ61Q1bWbPTvLa5lCkcgD7x49KXLdndT+HU02dSwDjcuOhrP1jVLbTUCX821GPySJy6+xH9a4rV/F896WFgpt4+m/8Aib/CubDPcynzWZz6scmumFB294yniIp+7qzs5/EIn3GCAK/8NyDtcj3FVYvEDicyXsnmKvA+UAj8ayIwViIU8A1k3p+cAnNONFT0ZlKtNvVj9TkS4u5J487HbIzVI1PCpeN14+X5uaYUJ7GuyNoq3YyuR0vIqQQPnhTWjZ6ZNcELHE8hbsgyTRKaQnJEGmRh5QD34rejslUlJ4y8DdfUe9dN4b+GOtX0kcpiFpEeT5h6j6V6JZ/DFcxx3d7jB+batYSjKbujOVWK2Z4FqPh+7tWLRRPNbkbklQZBHofetL4Tyxw/EfQ3mGUWVgR/wE19FHwZbeGbQPaTvPYzMI545RkKT0cfjXOWvgzSLfVZ70Wnl6gpLxOp+VWwa1lGTg4vsb4fER9pFtdUeIPue9umZcMJpCQe/wAxq5bgPMiA/e4H1r0W++Gk91oVvqejuZppFLyxE4OcnJFcCbdra78m5jaCaNuVYbea5pxaWp7uAx0ZS5JOzRu22inyA0mVLZw2OARUSxPHIHglXfG24qfukjpXR6Zf7FxLD50EwycAA7gKpazpaxxG8s1lRXGSh6g+hHrXBNO59lRrQlFRa+4brniKXX7mKfVmCTxQCFZFQc7fu5/xrnYZ3Ny0hbLdSQOtT3NzpbbUt9QUzEgBGj+bPfPpWdOZQVZSFz/EvSrUW9+pm68LL2buo9h8EjI0wJYnduPPOc1u6EgOHI+dhlfYdzXMzxTW10DKBluSVOQR6iuvsDEUCxnBKg5ClQR/h+tFaHNGyIwtVqVn0N+yy0o+b5AM1s2zDylxgEmsPTRiJGzgHcD+BrWsgAqnJGQeD1ry5xadmerKV43LsYO8sC4U9yeOKc06mXeTwBx/jUQkIGDkDpjsRUTgE4PUcDHSnLRHKtXqPeQmYhRnP5U17Rp2AjHXkg9MU0PkkA8DjpV6GbMYJGOwx3qqEFVlyyFUqOCuh/lxxRHaNoB6VGCQeRtI6kc0eYA+G+YHrjpimsTtYAFl9DXrRSSsjzZtvck8wqctn0OaYzKeVJweuKjdjsJzzjhehqNf9WrYUgdqZHmxm3hypz3POTSAZRiCBjufelJB3HGcnAIHSkyu35R7CmJoj3rvVWIJ71E6ByQRz1z6VYcDIYEdPTpUTA42ocH1pCKRGGwgAUDk96FZSuBkjOAPep2jZm34Pp7Gq8q/NgHaw6EHFMlizRCSM7gSRz0rA1K3bHzDFbkbupORwOM5zUN6BIoOMjPHamY1IJnE3cGxiPT0rNlfYTnjJrotSjXcQuc/0rmb5CGJxihI82rQ10GyOCMGqUoBHv1qMylWwTkCkLk98YrVRsY2S0GtwfajzihXsBRjd/iKZPGQeh6Z5q1bZnLPRnW6lZpelmUD5Dk8VV0a9udGuRLGWaIGuivrN7CSWBjwx6gdqyp4VOc425wPevralPW63PiYVdOR7HocVxHr+g7ogpkdduehVhyM1xyytt2P/rFba4Pr6/St34WB0mvrZ8tHt3KvpTfE+nmLWGa3Cs0iM0gxjGPmB9umK8/MMN9Yppr4kdWEq+yk49GY4XazZCkj35qzA2wggYwc8VFEweYAdT1JqaJQszgnnbkk/wA6+Zas7M9uELmk7A8khSeQB3rM1G9htYneWRVGOprnte8VRwzG209hLIOHk6ha4jUb24vZi1zK785APStIUHLc1clHY6LV/GM8qeTpyiNRwZj1P0HauUlkeaQySu0kh6sxyaZSgZrshCMNjNyb3JowRG3H0q9YR5JPeoY1PlDnPetXT4MIMAZJrKpKyMU9R5i/cE9frWHegrJz1x65rsJIv9HAxjisGfTZ7q5jitondzxwM1lRnZ6icrPUyrPImUDPPBxXaaD4H1LVlEkKKkfZm6EVteHPhZe3EST3reSp5xnmvQPA7NHG2nlxvgbaa1k22uxjOsvsnK6X8KpGcNe3I255VRXoHhjw9p+ig+RbqZB/ERk11awJFADIOT0FZrK094qxDPPT3q/ZqGvUwc3J2ZrQsxGRj24qUqzgE/fTofUVoWNjGkalsk4qeS3jPCLtYdK05bo0jF2KC4uLWS3lG6ORdpzXOfZZYYJRId00IaNj6jHDflXUiHDHk8VQ1S1KlrlCSpQpIMdR2NZynZG9CNqkX5og8Gxt/wAI3ZoQdy7hjH+0ag8TeCdJ8QrnUIMTdpo+GH496veEJcaPED03NxnPeugMZkwoGSf0rSDU6a9DWcHCrK3dng+seBdZ8PmR7KMajp68lV4cD6f4VRt71Lm3cFZlXGGWSMhkPpnv9a+nLDSoUTfKN7nselTalZ2D2zrdwwGMDkMo6V5tenFfA/vPdwOb1KFozXMfJkdlCLoyy2sUnmLtZsA/iaivtFhd2MEhCgYAL/J+Fek+K/Bkc5nvdFnW3jLbhC3KkV5bqEd9AJmlKKEcLsB5OfQelcMZdD7WlOGJj7SKs1voc7eQSwMVnfcN3Gf4R6V0nh2eOSPyDGm9OUIPOCOT71hXhknOJFyTxjHNXIYxHZRyW29JoHIbjnGM4P61tJ+6u5FOFqjtt+J2MR8oQRngBn6HvU+nEiFmyeTxnoKz7S9juoIpgQV3Akeh71etmJV1UqGU5HPavPrq7udy0XKXkkYqSWwpOCaZdMTtA4QnDc4NRRkAKBnPfFSOuQMj71ZxTZhPQlgdSww3A4JPUVb+6oQcg9/Q1noSrAAZGMYNWSSgzkYb0rrw9o3fU56zbJi/JXAyBzT9+V65Oar+YMncOgHBp6EnG3GcV3KVzkkSFgoLHAHfFRyOQeBgdz/SmvhjtH0PvSFMjIBx2pohgGxGwOcdSAKTcMqPWkbIPI47Ec5pG29AenQ4p3E2Lzg/NwOgpmMn72COnvQxOe3frSEcjON3XHagl6iMzbwAM45+lMlRODg5znNOeRgu5M5XkjvUbOD15HbPemDZG+AD0wxzxUUkSSADcwI6d6lkO5S2OnPNVhIqFieX6D0pkNGTe23zkqCQc8Y71zGowkZOfzruJ8MpyR7Vz+qQZ6J+OakylA4i5hIb0qkxK9a3b2EKxwCT29KypY8cdq6ISvuediKPVDrUggMe9WJApHPpVVDt9h2p0jArQ1qedUjI9d8SxC6tUuAAoXn8O9clL8xUYwSeBXbXPzWLO+T/AA9f6VzVvZmTWY03DDHNfaVHofBx3Ou8AQfY9PmncHzCCSf5VbltFu5J7gqWlePYFYcbM5IH5cVPbwfZrRIiqMrHeRnGcdAfarMrBLdj82FOevtz/KuZvQ6I7nmurpHoqXN8+82YkwBj5lYjlfpmvP8AWvEl3qG6OHNvbngqp5b6mvUvi4ix+Fp/lHmSSIS3fAIGK8S2mvBr0Yqq5M97DzbppDoWMYO3ikdixyaXacHmm7TU26mg2nIMsOM0bT7VPaxFpQARQ3ZA3ZGjbRAqBjAFdd4Z8PX2qyKtpCSM/exwK3Ph54ITWHSe6mXy/wC6M5r6G0LRLPS7KOK1hRQAOQK54UnVd3scbq20R5vo/wALVaIPqMmeM7R61q6H4VsNGvJdkSs/Ykc16Ow+XA4rmNQby9QfgfdzXR7KMNjCpJvqRTFSoVV/AVydjHHp3jW4yoCTR7wPU118KAsSe9cn4ojEOoWFzk5Emwgdwampor9iIJs6oyNcuAvGe/apooBCy4Xn19aZp/zoMAAD9atX37uNFA781lzc2rOlRsaUc5CDHFD3BBB3Z9apQMW4yas+SNo6Zq1JvY2ii5GonwwIz/OnT2pNpMoGSUOAfXFV9PyhwDxmtZjiF/UKatJSV2aQ92SZyHhgr/ZKvyAJGGSMYHrXZabHkBiR9c1z2kwhrKPJ4k3I3vyeaj1BGFuqebIBnB2nGa4HXdKCj5I9WFBYqo3e2rNvXfEyWw+yaYVkuc4aQcqn/wBeuWuL+Z9sE9wzyzttY57d6rSFIVdYl2gd+9Y1q8lxqzOzfLCuQPc15s5yqS5pH02Dy+lTg+Vba36sk8QSfZl8kOzxjJ6/pXH6iI5/3ZiDyHqf7tdVfMLmR1KjavX3NconDse+40W0PpcvjaHmjOazSPl4lYDnIHIqrb2cKTblxtlYCRG71tXfFvketZN5GRbM6MVcDdkVk/dkrHoSip027amLcwyaFdtscvYSHhiMmI+/tU8d4yzLIrAKxHOeDWjqcvySbhkMmSOvauU0BTKLi3kOQH+X2Brfk502zyazVOUYx+1+H/A/I66O76s2Qf5D1q9Z3ZeJVXkdge1cXZ3jBjHIN209RWva35QcLkD1qVDk2MW+bU3pJhuI2kjGOtXYgAASS2R361h290Z+MEHtV2B2Zzk/N0zWlOKWrOao3si+c8hcH19qUOSRwAO/aoFc4ySTjnNH+s+h4rZaGG5OhVTk4BJqVCcBQBUPGcYwR+tK2VTk5z6cVSIY8jHyjrjvTHjUn/aH5UqtuGQOBzQWbHJ781V7iGkJ6/nSMMHC9jxzTyAR0B780vl4O0Y59aCSIsBguMA9aZKo8sYIIP8AeFTR9duBuHepGQFDkD3qrCMib7uG+UjoDVaQrjOSMc89q0LpA5JxyPU1mXUa8Zz8xxigTZAZGBB6gd/WqdxMrnDDn0x+tdnoPw31bWrbz4L2yhhP97ezflj+tdLpPwgtIm83XdRmvPSKEeWn4nqafJI462PoUtJPX0PB9Q8tiQMbvQc/hTbPwtrWqEGw0u6lU/xlNqj8TX1NZ+HdD0hMWGlWsRA4bywzfmeaiv3eTKbtq+ijFQ5qmeZUzRT0hH7z5zT4Y6wFDXtxaWmeMbixFMk8C2Nv/r9UmlcdVij617PqVtGNzFdx9WrlNVljs4mdY+F6YHNYvFy6HMpTqbs//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The cardinal movement of extension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wolters Kluwer. Copyright &copy;2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_63_29683=[""].join("\n");
var outline_f28_63_29683=null;
var title_f28_63_29684="Skin abrasion PI";
var content_f28_63_29684=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F71752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F71752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Minor cuts and scrapes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 671px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Picture A shows a scrape (also called an \"abrasion\"). The scrape doesn't go all the way through the skin, so it does not need stitches. Picture B shows a cut that does go all the way through the skin. This cut is deep, so it needs stitches.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_63_29684=[""].join("\n");
var outline_f28_63_29684=null;
var title_f28_63_29685="Pyogenic flexor tenosynovitis";
var content_f28_63_29685=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F51632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F51632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 568px\">",
"   <div class=\"ttl\">",
"    Pyogenic flexor tenosynovitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 548px; height: 366px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In patients with pyogenic flexor tenosynovitis, four classic signs are described (Kanavel signs) including fusiform swelling of the whole finger, partially flexed posture of the finger, tenderness limited to the course of the flexor tendon sheath, and disproportionate pain on passive extension of the finger. The photographs illustrate the fusiform swelling of the finger and the partially flexed posture of the finger.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_63_29685=[""].join("\n");
var outline_f28_63_29685=null;
var title_f28_63_29686="Closure outer myometrium";
var content_f28_63_29686=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Closure of the outer myometrium during myomectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_63_29686=[""].join("\n");
var outline_f28_63_29686=null;
var title_f28_63_29687="Schematic CGH for microarray setup";
var content_f28_63_29687=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 598px\">",
"   <div class=\"ttl\">",
"    Schematic CGH for microarray setup",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 578px; height: 498px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the array CGH technique for a focused analysis of copy number imbalances along a region of interest (eg, 8q21.1). A tiling path of genomic clones (eg, BACs, PACs, PIs, cosmids) is generated to cover the region. After extraction and purification, these genomic DNA targets are arrayed onto glass slides.",
"    <br>",
"     Array CGH is performed by hybridizing labeled normal (Cy3) and tumor (Cy5) genomic DNA into the microarray and detected using a microarray scanner.",
"     <br>",
"      Each array spot, realigned",
"      <em>",
"       in silico",
"      </em>",
"      as a single contiguous map to correspond with the tiling path, can be analyzed by fluorescence ratio to identify the regions of copy number changes. These results may be correlated with",
"      <em>",
"       in silico",
"      </em>",
"      techniques to identify candidate genes of interest.",
"      <div class=\"footnotes\">",
"       CGH: Comparative genomic hybridization; BAC: Bacterial artificial chromosome; PAC: P1 bacteriophage artificial chromosome; P1: P1 bacteriophage; Cy3: Cyanine dye with green fluorescence; Cy5: Cyanine dye with red fluorescence.",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced from: Beheshti B, Park PC, Braude I, Squire JA. Micorarray CGH. In: Molecular Cytogenetics: Protocols and Applications. Humana Press, 2002, with kind permission from Springer Science + Business Media B.V. Copyright &copy; 2002.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_63_29687=[""].join("\n");
var outline_f28_63_29687=null;
var title_f28_63_29688="Perioperative management of diabetes mellitus";
var content_f28_63_29688=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Perioperative management of diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/63/29688/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/63/29688/contributors\">",
"     Nadia A Khan, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/63/29688/contributors\">",
"     William A Ghali, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/63/29688/contributors\">",
"     Enrico Cagliero, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/63/29688/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/63/29688/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/63/29688/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/63/29688/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/63/29688/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes mellitus is a common chronic disorder, affecting approximately 8 percent of the US population [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with diabetes have an increased incidence of cardiovascular disease and this, combined with the frequent microvascular complications of the disease, often translate into more surgical interventions. It is estimated that a diabetic patient has a 50 percent chance of requiring surgery in his or her lifetime [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/2\">",
"     2",
"    </a>",
"    ], and the proportion of surgical patients who have diabetes is close to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Careful assessment of diabetic patients prior to surgery is required because of their complexity and high risk of coronary heart disease, which may be relatively asymptomatic compared to the nondiabetic population. Diabetes mellitus is also associated with increased risk of perioperative infection and postoperative cardiovascular morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One key aspect of the perioperative management is glycemic control; complex interplay of the operative procedure, anesthesia, and additional postoperative factors such as sepsis, disrupted meal schedules and altered nutritional intake, hyperalimentation, and emesis can lead to labile blood glucose levels. A rational approach to diabetes mellitus management allows the clinician to anticipate alterations in glucose and improve glycemic control perioperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This review will discuss the preoperative evaluation of patients with diabetes, effect of surgery on glucose control, general goals of glycemic control, and management of diabetes mellitus in the early and late perioperative phase. The special circumstances of glucocorticoid therapy and hyperalimentation are also reviewed. More details regarding glucose control in hospitalized patients in general are found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26233?source=see_link\">",
"     \"Management of diabetes mellitus in hospitalized patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=see_link\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preoperative evaluation of any patient, including those with diabetes mellitus, focuses on cardiopulmonary risk assessment and modification. Coronary heart disease is much more common in individuals with diabetes than in the general population, and in addition, patients with diabetes have an increased risk of silent ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=see_link\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\"",
"    </a>",
"    .) Therefore, assessment of cardiac risk is essential in patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/5\">",
"     5",
"    </a>",
"    ]. Other associated conditions, such as hypertension, obesity, chronic kidney disease, cerebrovascular disease, and autonomic neuropathy need to be assessed prior to surgery as these conditions may complicate anesthesia and postoperative care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Evaluation for diabetic complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients require a careful history and physical examination, with further evaluation required in certain individuals. Key elements of the initial assessment include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Determination of the type of diabetes, since type 1 diabetes patients are at much higher risk of diabetic ketoacidosis",
"     </li>",
"     <li>",
"      Long-term complications of diabetes mellitus, including retinopathy, nephropathy, neuropathy, autonomic neuropathy, coronary heart disease, peripheral vascular disease, hypertension",
"     </li>",
"     <li>",
"      Assessment of baseline glycemic control, including frequency of monitoring, average blood glucose levels, range of blood glucose levels, hemoglobin A1C levels",
"     </li>",
"     <li>",
"      Assessment of hypoglycemia, including frequency, timing, awareness, and severity",
"     </li>",
"     <li>",
"      Detailed history of diabetes therapy, including insulin type, dose, and timing",
"     </li>",
"     <li>",
"      Other pharmacologic therapy, including type of medication, dosing, and specific timing",
"     </li>",
"     <li>",
"      Characteristics of surgery, including when the patient must stop eating prior to surgery, type of surgery (major or minor), timing of the operative procedure, and duration of the procedure",
"     </li>",
"     <li>",
"      Type of anesthetic, including epidural versus general anesthesia (epidural anesthesia has minimal effects on glucose metabolism and insulin resistance) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Preoperative laboratory investigations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basic investigations should at least include a baseline electrocardiogram and assessment of renal function. ECG abnormalities, such as abnormal q waves suggestive of previous myocardial infarction, and chronic kidney disease are risk factors for major postoperative cardiac events.",
"   </p>",
"   <p>",
"    If not previously assessed within the last three months, hemoglobin A1C levels will permit the determination of chronic glycemic control, and this is an important element in determining adequacy of current glycemic management, especially insulin dose, in insulin-dependent patients. There is also some suggestion that elevated A1C levels may predict a higher rate of postoperative infections. A retrospective cohort study of 490 diabetic men who underwent major noncardiac surgery in a VA setting found that a preoperative A1C &gt;7 percent was associated with a small but significant increase in postoperative infections compared to those with A1C &lt;7 percent (adjusted odds ratio [OR] 2.13, 95% CI 1.23-3.70) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Baseline glucose levels can also help to stratify risk for postoperative wound infections. Elevated preoperative glucose levels (&gt;200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [&gt;11",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    were associated with deep wound infections in a case control study (OR: 10.2, 95% CI: 2.4-43) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further investigations including noninvasive cardiac testing should be considered on an individual basis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EFFECT OF SURGERY ON GLUCOSE CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery and general anesthesia cause a neuroendocrine stress response with release of counterregulatory hormones such as epinephrine, glucagon, cortisol, and growth hormone, and of inflammatory cytokines such as interleukin-6 and tumor necrosis factor-alpha. These neurohormonal changes result in metabolic abnormalities including insulin resistance, decreased peripheral glucose utilization, impaired insulin secretion, increased lipolysis and protein catabolism, leading to hyperglycemia and even ketosis in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/12-21\">",
"     12-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The magnitude of counterregulatory hormone release varies per individual and is influenced by the type of anesthesia (general anesthesia is associated with larger metabolic abnormalities as compared to epidural anesthesia), the extent of the surgery (cardiovascular bypass surgery resulting in significantly higher degree of insulin resistance), and additional postoperative factors such as sepsis, hyperalimentation, and steroid use. The hyperglycemic response to these factors may be attenuated by the lack of caloric intake during and immediately after surgery, making the final glycemic balance difficult to predict.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     GENERAL GOALS OF GLYCEMIC CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of perioperative diabetic management include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maintenance of fluid and electrolyte balance",
"     </li>",
"     <li>",
"      Prevention of ketoacidosis",
"     </li>",
"     <li>",
"      Avoidance of marked hyperglycemia",
"     </li>",
"     <li>",
"      Avoidance of hypoglycemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Uncontrolled diabetes can lead to volume depletion from osmotic diuresis, and life-threatening conditions such as diabetic ketoacidosis (DKA) or nonketotic hyperosmolar state (NKH). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=see_link\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with type 1 diabetes mellitus are insulin deficient and are prone to developing ketosis and acidosis. A common mistake is to manage these patients like type 2 diabetes patients who are not ketosis prone and, for example, hold long-acting insulin if the glucose level is not \"too elevated\" with the consequent risk of ketoacidosis. Type 2 diabetes patients are susceptible to developing NKH that may lead to severe volume depletion and neurologic complications, and they may develop ketoacidosis in the setting of extreme stress.",
"   </p>",
"   <p>",
"    It is a long-standing clinical observation that patients with diabetes are more susceptible to infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, observational studies show an association between hyperglycemia in the immediate postoperative period and an increased risk of postoperative infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/22\">",
"     22",
"    </a>",
"    ]. However, whether or not hyperglycemia imposes an independent risk for infection is an unresolved question. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32502?source=see_link&amp;anchor=H2#H2\">",
"     \"Susceptibility to infections in persons with diabetes mellitus\", section on 'Are diabetics more susceptible to infection?'",
"    </a>",
"    .) Nevertheless, hyperglycemia can cause volume and electrolyte disturbances mediated by osmotic diuresis and may also result in caloric and protein loss in under-insulinized patients. These are undesirable in postoperative patients and should be avoided.",
"   </p>",
"   <p>",
"    Hypoglycemia is another potentially life-threatening complication of poor perioperative metabolic control. Even a few minutes of severe hypoglycemia (ie, serum glucose concentration &lt;40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.2",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    can be harmful, possibly inducing arrhythmias, other cardiac events, or transient cognitive deficits. Hypoglycemia and subsequent neuroglucopenia can be difficult to detect in sedated patients postoperatively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Glycemic targets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond avoidance of marked hyperglycemia and hypoglycemia, it is less clear as to how \"tight\" glucose control needs to be perioperatively. There is a paucity of controlled trials on the benefits and risks of \"loose\" or \"tight\" glycemic control in these patients, with the exception of patients in the intensive care unit or who have had an acute MI. Some studies show that achieving normoglycemia (80 to 110",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [4.4 to 6.1",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    in cardiac surgery patients or those requiring postoperative surgical ICU settings may reduce mortality. However, subsequent trials in mixed surgical and medical ICU patients have failed to show a benefit of such intensive control. These trials are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=see_link\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the vast majority of the patients in these studies were not previously known to have diabetes, but developed postoperative hyperglycemia during the course of their ICU care. A subgroup analysis of two randomized trials assessing tight control in the ICU setting raised the possibility that the apparent benefits of tight control may not extend to patients with known diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/23\">",
"     23",
"    </a>",
"    ]. Thus, the current optimal target for glucose in postoperative patients remains unclear. These preliminary findings highlight the need for prospective studies to determine the optimal target glucose for patients with known diabetes and for patients undergoing ambulatory surgery or surgical procedures that do not require critical care [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lack of clear evidence on how tightly to control glucose levels perioperatively in patients with diabetes is reflected in the varying glucose targets recommended by different guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Despite some variability in proposed targets, these published guidelines collectively propose attempting to achieve \"reasonable\" normoglycemia in a majority of surgical patients with, if possible, a majority of glucose readings below 180 to 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&lt;10 to 11",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    The American Diabetes Association has endorsed fasting glucose goals of 140",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    for general hospitalized patients, with random glucose readings &lt;180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (10",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26233?source=see_link&amp;anchor=H5#H5\">",
"     \"Management of diabetes mellitus in hospitalized patients\", section on 'Glycemic targets'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=see_link\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These recommendations are indirectly supported by an observational study of 531 patients admitted to a surgical and medical ICU, 523 of whom underwent analysis of their glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/28\">",
"     28",
"    </a>",
"    ]. Regression models from that analysis suggest that there is an association between lower glucose levels (less than 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [&lt;11",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    among critical care patients and lower mortality.",
"   </p>",
"   <p>",
"    Glycemic targets must take into account the individual patient's situation and whether these goals can be safely achieved within each individual hospital system. The specific issue of glycemic control in diabetic patients undergoing coronary artery bypass graft surgery is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40360?source=see_link&amp;anchor=H11#H11\">",
"     \"Medical therapy to prevent complications after coronary artery bypass graft surgery\", section on 'Glycemic control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EARLY PERIOPERATIVE PHASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several strategies exist to maintain target range glucose levels perioperatively, but there is no consensus as to the optimal strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/24\">",
"     24",
"    </a>",
"    ]. Most protocols for insulin administration are formulated by expert opinion and personal experience. The strategies described below, while sensible, have not been proven to optimally reduce outcomes of morbidity, mortality, and hospital length of stay.",
"   </p>",
"   <p>",
"    Ideally, all patients with diabetes mellitus should have their surgery as early as possible in the morning to minimize the disruption of their management routine while being nil per os.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Type 2 diabetes treated with diet alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generally, patients with type 2 diabetes managed by diet alone do not require any therapy perioperatively. Supplemental short-acting insulin (eg, regular, lispro, aspart or glulisine) may be given as a subcutaneous sliding scale in patients whose glucose levels rise over the desired target (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Sliding scale development'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Blood glucose levels should be checked preoperatively and soon after the surgery. Intravenous solutions do not require dextrose if insulin is not given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Type 2 diabetes treated with oral hypoglycemic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with type 2 diabetes who take oral hypoglycemic drugs or noninsulin injectables (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14375?source=see_link\">",
"     exenatide",
"    </a>",
"    ) are advised to continue their usual routine of antidiabetic medications until the morning of surgery. On the morning of surgery, they should hold their oral hypoglycemic and noninsulin injectable drugs. Sulfonylureas increase the risk of hypoglycemia,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    is contraindicated in conditions that increase the risk of renal hypoperfusion, lactate accumulation and tissue hypoxia, and thiazolidinediones may worsen fluid retention and peripheral edema and could precipitate congestive heart failure. Newer agents like DPP-IV inhibitors and GLP-1 analogs could alter GI motility and worsen the postoperative state. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link&amp;anchor=H11#H11\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\", section on 'Medications for initial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with good metabolic control on oral or noninsulin injectable agents will not need insulin for short surgical procedures. For patients who develop hyperglycemia, supplemental short-acting insulin may be administered subcutaneously as a sliding scale, based on frequently measured glucose levels which are often obtained on capillary \"fingerstick\" samples (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Sliding scale development'",
"    </a>",
"    below). Most antidiabetic medications can be restarted after surgery when patients resume eating, with the exception of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , which should be delayed in patients with suspected renal hypoperfusion until documentation of adequate renal function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Type 1 or insulin treated type 2 diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generally patients who use insulin can continue with subcutaneous insulin perioperatively (rather than an insulin infusion) for procedures that are not long and complex [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/6,20,29-34\">",
"     6,20,29-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some clinicians switch their patients taking long-acting insulin (eg, glargine) to an intermediate-acting insulin one to two days prior to surgery because of a potential increased risk for hypoglycemia with the former. However, if the basal insulin is correctly calibrated, it is reasonable to continue the long-acting insulin while the patient is NPO and on intravenous dextrose. There are no available data to support one approach over the other.",
"   </p>",
"   <p>",
"    It may be prudent to reduce the night time (supper or HS) intermediate-acting insulin on the night prior to surgery to prevent hypoglycemia if the patient has borderline hypoglycemia or \"tight\" control of the fasting blood glucose.",
"   </p>",
"   <p>",
"    Basal metabolic needs utilize approximately one-half of an individual's insulin even in the absence of oral intake; thus, patients should continue with some insulin even when not eating [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/35\">",
"     35",
"    </a>",
"    ]. This is mandatory in type 1 diabetes to prevent ketoacidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Timing of procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;For minor, early morning procedures where breakfast is likely only delayed, patients may delay taking their usual morning insulin until after the surgery and before eating.",
"   </p>",
"   <p>",
"    For patients undergoing morning procedures where breakfast and possibly lunch are likely to be missed or for surgeries that take place later in the day:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Omit any short-acting insulin on the morning of surgery.",
"     </li>",
"     <li>",
"      For patients who take insulin only in the morning, give between one-half to two-thirds of their usual total morning insulin dose (both intermediate and short-acting insulin) as intermediate or long-acting insulin to provide basal insulin during the procedure and prevent ketosis.",
"     </li>",
"     <li>",
"      For patients who take insulin two or more times per day, give between one-third to one-half of the total morning dose (both intermediate and short-acting insulin) as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/7/10359?source=see_link\">",
"       intermediate acting insulin",
"      </a>",
"      only.",
"     </li>",
"     <li>",
"      Patients on continuous insulin infusion may continue with their usual basal infusion rate.",
"     </li>",
"     <li>",
"      Start dextrose containing intravenous solution (either dextrose with water or one-half isotonic saline) at a rate of 75 to 125",
"      <span class=\"nowrap\">",
"       cc/hour",
"      </span>",
"      to provide 3.75 to 6.25 g",
"      <span class=\"nowrap\">",
"       glucose/hour",
"      </span>",
"      to avoid the metabolic changes of starvation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/29-34\">",
"       29-34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Long and complex procedures for type 1 or insulin treated type 2 diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous insulin is usually required for long and complex procedures (eg, coronary artery bypass graft, renal transplant, or prolonged neurosurgical operations). Studies comparing subcutaneous insulin administration versus intravenous infusion have found a marked increase in variability of the glucose concentration when using the subcutaneous route [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. This variability in plasma insulin has been attributed to the varying degrees of tissue perfusion associated with long and complex procedures.",
"   </p>",
"   <p>",
"    The safety of intravenous insulin infusion in highly monitored settings has been demonstrated by many studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/29-39\">",
"     29-39",
"    </a>",
"    ]. In addition, insulin infusions are more readily titrated because the half-life of intravenous insulin is short (ie, 5 to 10 minutes), allowing for more precise glucose control.",
"   </p>",
"   <p>",
"    Intravenous insulin regimens require close monitoring of blood glucose and electrolytes as well as appropriate interpretation by well-trained staff. Generally insulin infusions should be started early in the morning prior to surgery to allow time to achieve glycemic control. There are numerous intravenous insulin infusion algorithms published in the literature, with insulin and glucose solutions being infused separately, or as a combined glucose insulin potassium (GIK) solution [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/29-39\">",
"     29-39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/22/13666?source=see_link\">",
"     \"Interactive diabetes case 12: Perioperative management of a 67-year-old man with type 2 diabetes who undergoes coronary artery bypass surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Glucose insulin potassium infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The glucose insulin potassium (GIK) drip is a single solution infusion that includes 500 mL of 10 percent dextrose, 10 mmol of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    , and 15 units of short-acting insulin. The solution is infused at an initial rate of 100",
"    <span class=\"nowrap\">",
"     mL/hour.",
"    </span>",
"    The solution can be altered depending on the blood glucose measured every two hours by adding or subtracting five units of insulin. Potassium is added to prevent hypokalemia and is monitored at six hour intervals.",
"   </p>",
"   <p>",
"    This regimen is safe because the insulin and glucose are given together, but may require frequent changes of intravenous solution. The blood glucose should be monitored frequently, at least every two hours. The problem with this approach is that if glucose levels run \"low,\" based upon the target levels, and the infusion is stopped, patients with type 1 diabetes can quickly become ketotic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Separate insulin and glucose intravenous solutions",
"    </span>",
"    &nbsp;&mdash;&nbsp;With this regimen, dextrose is administered at approximately 5 to 10 g of",
"    <span class=\"nowrap\">",
"     glucose/hour,",
"    </span>",
"    and a separate insulin infusion is given using short-acting insulin. Most type 1 diabetes patients require an infusion at a rate of 1 to 2",
"    <span class=\"nowrap\">",
"     units/hour,",
"    </span>",
"    while more insulin resistant type 2 diabetes patients can require higher insulin rates.",
"   </p>",
"   <p>",
"    A commonly followed algorithm calculates the initial rate by dividing the blood glucose level (in",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    by 100 and then rounding the result in",
"    <span class=\"nowrap\">",
"     U/hour",
"    </span>",
"    (eg, glucose of 210, 210 divided by 100 = 2.1",
"    <span class=\"nowrap\">",
"     U/hour)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/33\">",
"     33",
"    </a>",
"    ]. Capillary glucose levels should be checked every one to two hours and the insulin infusion adjusted (eg, glucose 120 to 160 increase by 0.5",
"    <span class=\"nowrap\">",
"     U/hour,",
"    </span>",
"    160 to 200 increase by 1.0",
"    <span class=\"nowrap\">",
"     U/hour,",
"    </span>",
"    &gt;200 increase by 2.0",
"    <span class=\"nowrap\">",
"     U/hour).",
"    </span>",
"    In case of hypoglycemia the insulin infusion can be decreased; however, the temptation to stop the insulin infusion should be avoided in type 1 diabetes patients to avoid ketosis. The insulin infusion can be decreased to 0.5",
"    <span class=\"nowrap\">",
"     U/hour",
"    </span>",
"    and the glucose infusion rate increased to maintain glucose targets.",
"   </p>",
"   <p>",
"    The rate of insulin infusion may be titrated depending on the procedure and the degree of insulin resistance. For coronary artery bypass procedures, the insulin requirements may increase up to 10-fold, especially after recovery from the hypothermic period, necessitating an increase in the initial insulin rate by three to five times [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This regimen is flexible and does not require changes of entire solution bags like the GIK infusion. However, there is a concern that hypoglycemia will develop if the glucose infusion is inadvertently obstructed or held.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     LATE POSTOPERATIVE PHASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generally the preoperative diabetes treatment regimen (oral agents, oral agents plus insulin, or basal-bolus insulin) may be reinstated once the patient is eating well. However, there are a few caveats for certain oral hypoglycemic agents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       Metformin",
"      </a>",
"      should not be restarted in patients with renal insufficiency, significant hepatic impairment, or congestive heart failure.",
"     </li>",
"     <li>",
"      Sulfonylureas stimulate insulin secretion and may cause hypoglycemia; they should be started only after eating has been well established. A step-up approach can be used for patients on high dose sulfonylureas, starting at low doses and adjusting them until the usual dose is reached.",
"     </li>",
"     <li>",
"      Thiazolidinediones should not be used if patients develop congestive heart failure or problematic fluid retention, or if there are any liver function abnormalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If an insulin infusion has been used, it should be continued in patients who do not resume eating postoperatively. Once it seems likely that solid food will be tolerated, the patient can be switched to subcutaneous insulin, and then the insulin infusion can be discontinued. Because of the short half-life of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    , the first dose of subcutaneous insulin must be given before discontinuation of the intravenous insulin infusion. If intermediate or long-acting insulin is used, it should be given two to three hours prior to discontinuation, whereas short or rapid-acting insulin should be given one to two hours prior to stopping the infusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/22/13666?source=see_link\">",
"     \"Interactive diabetes case 12: Perioperative management of a 67-year-old man with type 2 diabetes who undergoes coronary artery bypass surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who were taking subcutaneous insulin in the early postoperative phase, before alimentation is restarted, should continue this treatment along with intravenous dextrose (5 to 10 g of",
"    <span class=\"nowrap\">",
"     glucose/hour",
"    </span>",
"    = 100 to 200",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    of dextrose in water or in one-half isotonic saline solution) to prevent hypoglycemia. Once the patient is able to tolerate food, outpatient or other insulin regimens can be titrated back.",
"   </p>",
"   <p>",
"    More details regarding the management of diabetes in hospitalized patients are found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26233?source=see_link\">",
"     \"Management of diabetes mellitus in hospitalized patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SLIDING SCALE DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frequent, small doses of short-acting insulin (sliding scales) are often used to correct elevated glucose levels. Sliding scales, especially when used as sole methods of insulin delivery, can be problematic, since they delay administration of insulin until hyperglycemia is present and frequently cause wide fluctuations in the serum glucose as they \"react\" to past glucose concentrations. Sliding scale should never be the sole insulin regimen in type 1 diabetes because ketosis can occur before significant hyperglycemia is present. In all patients with type 1 and in some insulin treated patients with type 2 diabetes, small doses of short-acting insulin should be given before meals (AC) and at bedtime (HS), or alternatively in patients who are NPO, every six hours, supplementing pre-scheduled basal and prandial insulin (basal-bolus insulin) to prevent hyperglycemia. In this setting, the additional insulin is referred to as correction insulin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26233?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of diabetes mellitus in hospitalized patients\", section on 'Correction insulin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This approach is supported by the results of a randomized trial of sliding scale",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    versus a basal-bolus insulin regimen (glargine once daily and glulisine before meals) in 211 patients with type 2 diabetes admitted to the hospital for general elective or emergency surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/41\">",
"     41",
"    </a>",
"    ]. Oral antidiabetic agents were discontinued on admission. Patients randomly assigned to sliding scale regular insulin alone had significantly higher mean glucose concentrations (172 versus 145",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [9.6 versus 8.0",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    and a significantly higher frequency of the composite outcome (24.3 versus 8.6 percent), which included wound infection, pneumonia, bacteremia, respiratory failure, and acute renal failure. Among the individual components of the composite outcome, higher frequency of wound infection (10.3 versus 2.9 percent) was the only outcome that reached borderline statistical significance (p = 0.05).",
"   </p>",
"   <p>",
"    Corrective insulin should be given when glucose levels are &gt;150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (8.3",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and the amounts depend upon the degree of insulin sensitivity of the patient and the glycemic target (",
"    <a class=\"graphic graphic_table graphicRef83834 \" href=\"UTD.htm?30/11/30908\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Glycemic targets'",
"    </a>",
"    above.) Elderly, lean type 1 diabetes patients or individuals with renal or liver failure are usually considered to be \"insulin sensitive,\" while obesity or treatment with glucocorticoids are usually associated with an insulin resistant state. Smaller doses of insulin are given at bedtime to avoid nocturnal hypoglycemia. Many different regimens have been used, with no studies demonstrating the superiority of one over the others (",
"    <a class=\"graphic graphic_table graphicRef83834 \" href=\"UTD.htm?30/11/30908\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SPECIAL CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Glucocorticoid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are used for the treatment of many disorders and are often given in \"stress\" doses perioperatively to prevent adrenal insufficiency. Glucocorticoids can worsen preexisting diabetes mellitus and may precipitate steroid-induced hyperglycemia in others. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17384?source=see_link\">",
"     \"The surgical patient taking glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link&amp;anchor=H22#H22\">",
"     \"Major side effects of systemic glucocorticoids\", section on 'Glucose metabolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment with glucocorticoids rarely leads to ketoacidosis. A variable rate insulin and glucose infusion may be appropriate in patients receiving high dose steroids, especially with variable dosing. Oral hypoglycemic medications should be used in patients with constant dose of steroids and minimal elevation in blood glucose; insulin is often necessary for those whose glucose levels are elevated (&gt;200",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    or 11",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/42\">",
"     42",
"    </a>",
"    ]. Twice daily intermediate-acting insulin with short-acting insulin given in a subcutaneous sliding scale may be needed to achieve glucose control. A two- to threefold increase in the total daily insulin dose is frequently needed in patients on high dose steroid therapy. Studies examining these treatment strategies are lacking and the recommendations presented are based primarily on simplicity of execution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hyperalimentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     Total parenteral nutrition",
"    </a>",
"    (TPN) and nasogastric enteral feeds are commonly used in patients who are malnourished or severely ill. TPN, especially in those with type 2 diabetes mellitus, will often increase the serum blood glucose and necessitate large doses of insulin to maintain glycemic control.",
"   </p>",
"   <p>",
"    Some investigators recommend using a variable rate insulin infusion when the patient is first started on TPN [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29688/abstract/42\">",
"     42",
"    </a>",
"    ]. Once the patient is on a stable infusion rate of TPN,",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    may have the daily requirement of insulin directly added to the TPN solution bag. As an example, if the patient requires 20 units of insulin per 24 hours, add 20 units of short-acting insulin in the TPN solution that is administered continuously over 24 hours. A subcutaneous insulin sliding scale using short-acting insulin may be used if insulin infusion is not feasible.",
"   </p>",
"   <p>",
"    For nasogastric feeds administered continuously over 24 hours, either a variable IV insulin infusion or twice daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/7/10359?source=see_link\">",
"     intermediate acting insulin",
"    </a>",
"    plus sliding scale every four to six hours may be administered. Changes in insulin regimen must precede any changes in nasogastric feeding regimens (ie, changes from 24 hour-infusion to TID bolus feeds). Thus, good communication between the surgeon, dietitian, and the person managing diabetes care is important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians are frequently asked to manage the patient with diabetes mellitus perioperatively when the evidence base to guide decision-making is of low to moderate quality. Many specific issues require further investigation including: optimal target range (although achieving normoglycemia appears to have no consistent mortality benefit), regimen of insulin administration, and the special circumstances of glucocorticoid use and hyperalimentation. Most protocols for insulin administration are formulated by expert opinion and personal experience.",
"   </p>",
"   <p>",
"    The strategies described in this topic review, while sensible, have not been proven to optimally reduce outcomes of morbidity, mortality, and hospital length of stay. The role of insulin infusions has not been clarified, but these strategies are often expensive, labor intensive, and even impossible at some hospitals. Ultimately, even well coordinated plans for diabetic management are dynamic, being influenced by predictable and sometimes unpredictable events. Decisions of which regimens to utilize and when will depend upon individual patients, hospital settings and resources, and the clinician's own judgment.",
"   </p>",
"   <p>",
"    Glucose control in critically ill patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=see_link\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. file://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf (Accessed on June 04, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/2\">",
"      Root HF. Preoperative medical care of the diabetic patient. Postgrad Med 1966; 40:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/3\">",
"      Clement S, Braithwaite SS, Magee MF, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004; 27:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/4\">",
"      Malone DL, Genuit T, Tracy JK, et al. Surgical site infections: reanalysis of risk factors. J Surg Res 2002; 103:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/5\">",
"      Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999; 100:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/6\">",
"      Jacober SJ, Sowers JR. An update on perioperative management of diabetes. Arch Intern Med 1999; 159:2405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/7\">",
"      Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/8\">",
"      Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979; 59:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/9\">",
"      Brandt M, Kehlet H, Binder C, et al. Effect of epidural analgesia on the glycoregulatory endocrine response to surgery. Clin Endocrinol (Oxf) 1976; 5:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/10\">",
"      Dronge AS, Perkal MF, Kancir S, et al. Long-term glycemic control and postoperative infectious complications. Arch Surg 2006; 141:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/11\">",
"      Trick WE, Scheckler WE, Tokars JI, et al. Modifiable risk factors associated with deep sternal site infection after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2000; 119:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/12\">",
"      Brandt, MR, Kehlet, H, Faber, O, Binder, C. C-peptide and insulin during blockade of the hyperglycemic response to surgery by epidural analgesia. Clin Endocrinol 1979; 6:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/13\">",
"      Clarke RS. The hyperglycaemic response to different types of surgery and anaesthesia. Br J Anaesth 1970; 42:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/14\">",
"      Clarke RS, Johnston H, Sheridan B. The influence of anaesthesia and surgery on plasma cortisol, insulin and free fatty acids. Br J Anaesth 1970; 42:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/15\">",
"      Russell RC, Walker CJ, Bloom SR. Hyperglucagonaemia in the surgical patient. Br Med J 1975; 1:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/16\">",
"      A&auml;rimaa M, Sl&auml;tis P, Haapaniemi L, Jeglinsky B. Glucose tolerance and insulin response during and after elective skeletal surgery. Ann Surg 1974; 179:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/17\">",
"      Wright PD, Henderson K, Johnston ID. Glucose utilization and insulin secretion during surgery in man. Br J Surg 1974; 61:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/18\">",
"      Lattermann R, Carli F, Wykes L, Schricker T. Perioperative glucose infusion and the catabolic response to surgery: the effect of epidural block. Anesth Analg 2003; 96:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/19\">",
"      Schricker T, Gougeon R, Eberhart L, et al. Type 2 diabetes mellitus and the catabolic response to surgery. Anesthesiology 2005; 102:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/20\">",
"      Gavin LA. Perioperative management of the diabetic patient. Endocrinol Metab Clin North Am 1992; 21:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/21\">",
"      Kennedy DJ, Butterworth JF 4th. Clinical review 57: Endocrine function during and after cardiopulmonary bypass: recent observations. J Clin Endocrinol Metab 1994; 78:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/22\">",
"      King JT Jr, Goulet JL, Perkal MF, Rosenthal RA. Glycemic control and infections in patients with diabetes undergoing noncardiac surgery. Ann Surg 2011; 253:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/23\">",
"      Van den Berghe G, Wilmer A, Milants I, et al. Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm. Diabetes 2006; 55:3151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/24\">",
"      Joshi GP, Chung F, Vann MA, et al. Society for Ambulatory Anesthesia consensus statement on perioperative blood glucose management in diabetic patients undergoing ambulatory surgery. Anesth Analg 2010; 111:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/25\">",
"      Canadian Diabetes Association 2008 Clinical Practice Guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32:S71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/26\">",
"      Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 2009; 32:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/27\">",
"      American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care 2013; 36 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/28\">",
"      Finney SJ, Zekveld C, Elia A, Evans TW. Glucose control and mortality in critically ill patients. JAMA 2003; 290:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/29\">",
"      Hirsch IB, McGill JB. Role of insulin in management of surgical patients with diabetes mellitus. Diabetes Care 1990; 13:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/30\">",
"      Peters A, Kerner W. Perioperative management of the diabetic patient. Exp Clin Endocrinol Diabetes 1995; 103:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/31\">",
"      Metchick LN, Petit WA Jr, Inzucchi SE, et al. Inpatient management of diabetes mellitus. Am J Med 2002; 113:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/32\">",
"      Marks JB. Perioperative management of diabetes. Am Fam Physician 2003; 67:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/33\">",
"      Smiley DD, Umpierrez GE. Perioperative glucose control in the diabetic or nondiabetic patient. South Med J 2006; 99:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/34\">",
"      Hoogwerf BJ. Perioperative management of diabetes mellitus: how should we act on the limited evidence? Cleve Clin J Med 2006; 73 Suppl 1:S95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/35\">",
"      Watts NB, Gebhart SS, Clark RV, Phillips LS. Postoperative management of diabetes mellitus: steady-state glucose control with bedside algorithm for insulin adjustment. Diabetes Care 1987; 10:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/36\">",
"      Pezzarossa A, Taddei F, Cimicchi MC, et al. Perioperative management of diabetic subjects. Subcutaneous versus intravenous insulin administration during glucose-potassium infusion. Diabetes Care 1988; 11:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/37\">",
"      van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/38\">",
"      Van den Berghe, G, Wilmer, A, Hermans, G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 54:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/39\">",
"      Goldberg NJ, Wingert TD, Levin SR, et al. Insulin therapy in the diabetic surgical patient: metabolic and hormone response to low dose insulin infusion. Diabetes Care 1981; 4:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/40\">",
"      Hoogwerf BJ. Perioperative management of diabetes mellitus: striving for metabolic balance. Cleve Clin J Med 1992; 59:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/41\">",
"      Umpierrez GE, Smiley D, Jacobs S, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care 2011; 34:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29688/abstract/42\">",
"      Hirsch IB, Paauw DS. Diabetes management in special situations. Endocrinol Metab Clin North Am 1997; 26:631.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1753 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-24348CF07F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_63_29688=[""].join("\n");
var outline_f28_63_29688=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREOPERATIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Preoperative laboratory investigations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EFFECT OF SURGERY ON GLUCOSE CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GENERAL GOALS OF GLYCEMIC CONTROL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Glycemic targets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EARLY PERIOPERATIVE PHASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Type 2 diabetes treated with diet alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Type 2 diabetes treated with oral hypoglycemic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Type 1 or insulin treated type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Timing of procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Long and complex procedures for type 1 or insulin treated type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Glucose insulin potassium infusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Separate insulin and glucose intravenous solutions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      LATE POSTOPERATIVE PHASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SLIDING SCALE DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SPECIAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hyperalimentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1753\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1753|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/11/30908\" title=\"table 1\">",
"      Subcutaneous sliding scale sample",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=related_link\">",
"      Glycemic control and intensive insulin therapy in critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/22/13666?source=related_link\">",
"      Interactive diabetes case 12: Perioperative management of a 67-year-old man with type 2 diabetes who undergoes coronary artery bypass surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26233?source=related_link\">",
"      Management of diabetes mellitus in hospitalized patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40360?source=related_link\">",
"      Medical therapy to prevent complications after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32502?source=related_link\">",
"      Susceptibility to infections in persons with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17384?source=related_link\">",
"      The surgical patient taking glucocorticoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_63_29689="Phenobarbital: Pediatric drug information";
var content_f28_63_29689=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Phenobarbital: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"    see \"Phenobarbital: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/59/8117?source=see_link\">",
"    see \"Phenobarbital: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F208959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PMS-Phenobarbital",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant, Barbiturate",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Barbiturate",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Hypnotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sedative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Anticonvulsant: Status epilepticus:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loading dose: I.V.: Initial: 15-20 mg/kg as a single dose; may repeat doses of 5-10 mg/kg every 15-20 minutes as needed (maximum total dose: 40 mg/kg) (Gilman, 1989; Lockman, 1979; Painter, 1978; Painter, 1981).",
"     <b>",
"      Note:",
"     </b>",
"     Additional respiratory support may be required, especially when maximizing loading dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance dose: Oral, I.V.: 3-4 mg/kg/day given once daily; maintenance dose usually starts 12 hours after loading dose; assess serum concentrations; increase to 5 mg/kg/day if needed (usually by second week of therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neonatal abstinence syndrome:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loading dose (optional):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 16 mg/kg in a single dose;  follow with maintenance dose 12-24 hours after loading dose",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 16 mg/kg divided into 2 doses and administered every 4-6 hours; follow with maintenance dose 12-24 hours after loading dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance dose: Oral, I.V.: Initial: 5 mg/kg/day divided every 12 hours; adjust dose according to abstinence scores and serum concentrations; usual required dose: 2-8 mg/kg/day. After patient is stabilized, decrease phenobarbital dose such that drug concentration decreases by 10% to 20% per day (AAP, 1998; Finnegan, 1979; Tran, 1999).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuroprotectant following anoxic injury (with or without cooling): I.V.: 40 mg/kg once; if introducing therapeutic hypothermia, administer prior to cooling (Hall, 1998; Meyn, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"      see \"Phenobarbital: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Anticonvulsant: Status epilepticus:",
"     <b>",
"      Loading dose:",
"     </b>",
"     I.V.: Infants and Children: Initial: 15-20 mg/kg (maximum: 1000 mg/dose); may repeat dose after 15 minutes as needed (maximum total dose: 40 mg/kg).",
"     <b>",
"      Note:",
"     </b>",
"     Additional respiratory support may be required, especially when maximizing loading dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Anticonvulsant",
"     <b>",
"      maintenance dose",
"     </b>",
"     : Oral, I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Maintenance dose usually starts 12 hours after loading dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 5-6 mg/kg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-5 years: 6-8 mg/kg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     5-12 years: 4-6 mg/kg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents &gt;12 years: 1-3 mg/kg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sedation: Oral: 2 mg/kg/dose 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hypnotic: I.M., I.V.: 3-5 mg/kg at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hyperbilirubinemia: &lt;12 years: Oral: 3-8 mg/kg/day in 2-3 divided doses; doses up to 12 mg/kg/day have been used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preoperative sedation: Oral, I.M., I.V.: 1-3 mg/kg 1-1.5 hours before procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anticonvulsant: Status epilepticus:",
"     <b>",
"      Loading dose:",
"     </b>",
"     I.V.: 10-20 mg/kg; may repeat dose in 20-minute intervals as needed (maximum total dose: 30 mg/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anticonvulsant",
"     <b>",
"      maintenance dose",
"     </b>",
"     : Oral, I.V.: 1-3 mg/kg/day in divided doses or 50-100 mg 2-3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sedation: Oral, I.M.: 30-120 mg/day in 2-3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hypnotic: Oral, I.M., I.V.: 100-320 mg at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hyperbilirubinemia: Oral: 90-180 mg/day in 2-3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preoperative sedation: I.M.: 100-200 mg 1-1.5 hours before procedure",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F208927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elixir, oral: 20 mg/5 mL (5 mL [DSC], 7.5 mL, 15 mL, 473 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium: 65 mg/mL (1 mL); 130 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 15 mg, 16.2 mg, 30 mg, 32.4 mg, 60 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F208910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F209007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer elixir with water, milk, or juice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Do not inject I.V. faster than 1 mg/kg/minute with a maximum of 30 mg/minute for infants and children and 60 mg/minute for adults &gt;60 kg. Neonatal studies that used a loading dose of 40 mg/kg for perinatal asphyxia infused the dose over 60 minutes (Hall, 1998). Do not administer intra-arterially (contraindicated); avoid extravasation; SubQ administration is not recommended. For I.M. administration, inject deep into muscle; do not exceed 5 mL per injection site (adults) due to potential for tissue irritation.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F209013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Caffeine citrate, doripenem, enalaprilat, fentanyl, fosphenytoin, levofloxacin, linezolid, meropenem, methadone, morphine, propofol, sufentanil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Doxapram, hydromorphone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Caffeine citrate, heparin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Hydromorphone, pantoprazole, ranitidine, sufentanil.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1054871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elixir: Protect from light",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Protect from light; not stable in aqueous solutions; use only clear solutions; do not add to acidic solutions, precipitation may occur",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of generalized tonic-clonic (grand mal) and partial seizures; neonatal seizures; febrile seizures in children; sedation; may also be used for prevention and treatment of neonatal hyperbilirubinemia and lowering of bilirubin in chronic cholestasis; management of sedative/hypnotic withdrawal; has been used for neonatal abstinence syndrome",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F209015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       PHENobarbital may be confused with PENTobarbital, Phenergan&reg;, phenytoin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F209012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, hypotension, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, ataxia, CNS excitation or depression, confusion, dizziness drowsiness, hallucinations, &ldquo;hangover&rdquo; effect, headache, hyperkinesia, impaired judgment, insomnia, lethargy, nervousness, nightmares, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Exfoliative dermatitis, rash, Stevens-Johnson syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, megaloblastic anemia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain at injection site, thrombophlebitis with I.V. use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Oliguria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea (especially with rapid I.V. use), hypoventilation, laryngospasm, respiratory depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Gangrene with inadvertent intra-arterial injection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to phenobarbital or any component; pre-existing CNS depression, severe uncontrolled pain, porphyria (manifest and latent), severe respiratory disease with dyspnea or obstruction; intra-arterial administration; use in nephritic patients (large doses)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal or hepatic impairment or respiratory diseases. Use with caution in patients with acute or chronic pain (paradoxical excitement may occur or important symptoms may be masked), hepatic dysfunction (decreased dosage may be needed; avoid use in patients with premonitory signs of hepatic coma), pregnancy (fetal abnormalities may occur; infants may experience withdrawal symptoms with chronic maternal use), or debilitated patients (paradoxical excitement, depression, or confusion may occur). Use with caution (if at all) in patients with depression or suicidal tendencies or in patients with a history of drug abuse (use in patients with a history of sedative/hypnotic addiction is not recommended).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Solution for injection is highly alkaline and extravasation may cause local tissue damage leading to necrosis; ensure patient has adequate intravenous access with I.V. use. Intra-arterial administration may cause reactions ranging from transient pain to gangrene and is contraindicated. Subcutaneous administration may cause tissue irritation (eg, redness, tenderness, necrosis) and is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tolerance and/or psychological and physical dependence may occur; abrupt discontinuation after prolonged use may result in withdrawal symptoms, seizures, or status epilepticus; withdraw gradually if used over extended periods of time. Rapid I.V. administration may cause respiratory depression, apnea, laryngospasm, or hypotension. Phenobarbital may cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Antiepileptic drugs (AEDs) increase the risk of suicidal behavior and ideation in patients receiving these medications for any indication. Pooled analyses of placebo-controlled trials involving 11 different AEDs (regardless of indication) showed a twofold increased risk of suicidal thoughts or behavior (estimated incidence rate: 0.43% in AED treated patients compared to 0.24% of patients receiving placebo); increased risk was observed as early as 1 week after initiation of AED and continued through duration of trials (most trials &le;24 weeks); risk did not vary significantly by age (age range: 5&ndash;100 years). Consider risks and benefits of AEDs before prescribing. Monitor all patients receiving an AED for emergence of suicidal thoughts or behavior, thoughts of self-harm, any unusual changes in behavior or mood, or the emergence or worsening of depressive symptoms; notify healthcare provider immediately if symptoms or concerning behavior occur.",
"     <b>",
"      Note:",
"     </b>",
"     The FDA requires a Medication Guide for all antiepileptic drugs informing patients of this risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Commercially available injection contains 10% alcohol and 67.8% propylene glycol. In neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; use dosage forms containing propylene glycol with caution in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F209000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major), CYP2C9 (minor), CYP2E1 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Induces",
"     </b>",
"     CYP1A2 (strong), CYP2A6 (strong), CYP2B6 (strong), CYP2C8 (strong), CYP2C9 (strong), CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F208919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Barbiturates may increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bendamustine: CYP1A2 Inducers (Strong) may decrease the serum concentration of Bendamustine. Concentrations of active metabolites may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Barbiturates may decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: PHENobarbital may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Barbiturates may increase the metabolism of Calcium Channel Blockers.  Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: PHENobarbital may decrease the serum concentration of Canagliflozin.  Management: Consider increasing canagliflozin dose to 300 mg/day in patients with estimated GFR &gt;60 mL/min/1.73 m2 who tolerate canagliflozin 100 mg/day and require greater glycemic control. Consider alternatives in patients with estimated GFR 45-60 mL/min/1.73 m2.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of Anticonvulsants (Barbiturate). Specifically, osteomalacia and rickets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: Barbiturates may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholestyramine Resin: May decrease the serum concentration of PHENobarbital. Management: Administer phenobarbital at least 1 hour before or 4-6 hours after administration of cholestyramine in order to minimize the risk for any significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: PHENobarbital may decrease the serum concentration of Cobicistat.  Management: Consider using an alternative antiepileptic when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Barbiturates may diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of a non-hormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Barbiturates may diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.  Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Barbiturates may decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cosyntropin: May enhance the hepatotoxic effect of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Barbiturates may increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inducers (Strong) may increase the metabolism of CYP1A2 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inducers (Strong) may increase the metabolism of CYP2B6 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inducers (Strong) may increase the metabolism of CYP2C8 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inducers (Strong) may increase the metabolism of CYP2C9 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: PHENobarbital may decrease the serum concentration of Darunavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: PHENobarbital may decrease the serum concentration of Deferasirox.  Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May increase the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inducers (Strong) may decrease the serum concentration of Diclofenac (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Barbiturates may increase the metabolism of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May decrease the metabolism of Barbiturates. Barbiturates may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxycycline: Barbiturates may decrease the serum concentration of Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: PHENobarbital may decrease the serum concentration of Elvitegravir.  Management: Consider using an alternative antiepileptic when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP2C8 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide: Barbiturates may decrease the serum concentration of Etoposide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide Phosphate: Barbiturates may decrease the serum concentration of Etoposide Phosphate. Barbiturates may increase the metabolism, via CYP isoenzymes, of etoposide phosphate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: PHENobarbital may decrease the serum concentration of Etravirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May increase the serum concentration of PHENobarbital. PHENobarbital may decrease the serum concentration of Felbamate. Management: In patients receiving phenobarbital, initiate felbamate at 1200 mg/day in divided doses 3-4 times daily and reduce phenobarbital dose by 20%. Monitor for increased phenobarbital concentrations/effects and decreased felbamate concentrations/effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Folic Acid: May decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Barbiturates may enhance the CNS depressant effect of Fosphenytoin. Barbiturates may decrease the serum concentration of Fosphenytoin. Fosphenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: Barbiturates may decrease the serum concentration of Griseofulvin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of Barbiturates. Management: Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine.  With concurrent use, monitor patients closely for excessive response to the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irinotecan: PHENobarbital may decrease the serum concentration of Irinotecan. Concentrations of the active metabolite SN-38 may also be reduced.  Management: Change to a non-enzyme inducing anticonvulsant, when clinically possible, at least 2 weeks prior to beginning irinotecan.  Dosage increases for irinotecan may be needed when used with phenobarbital, but specific dosing guidelines are not available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lacosamide: PHENobarbital may decrease the serum concentration of Lacosamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Barbiturates may decrease the serum concentration of LamoTRIgine.  Management: See lamotrigine prescribing information for specific age-dependent dosing guidelines regarding concurrent use with a barbiturate, as well as for adjusting lamotrigine dosing if concurrent barbiturate therapy is discontinued.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leucovorin Calcium-Levoleucovorin: May decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levomefolate: May decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: PHENobarbital may decrease the serum concentration of Lopinavir.  Management: Increased doses of lopinavir may be necessary when using these agents in combination.  Do not use a once daily lopinavir/ritonavir regimen together with phenobarbital. Increase monitoring of therapeutic response in all patients using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Barbiturates may enhance the CNS depressant effect of Meperidine. Barbiturates may increase serum concentrations of the active metabolite(s) of Meperidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Barbiturates may enhance the CNS depressant effect of Methadone. Barbiturates may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylfolate: May decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May increase the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Systemic): PHENobarbital may decrease the serum concentration of MetroNIDAZOLE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: PHENobarbital may decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced. OXcarbazepine may increase the serum concentration of PHENobarbital.  Management: Consider increasing the initial adult oxcarbazepine extended release tablet (Oxtellar XR) dose to 900 mg/day. No specific recommendations are available for other oxcarbazepine formulations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May enhance the CNS depressant effect of Barbiturates. Barbiturates may decrease the serum concentration of Phenytoin. Phenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inducers (Strong) may decrease the serum concentration of Pirfenidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP1A2 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May enhance the adverse/toxic effect of Barbiturates. Primidone is converted to phenobarbital, and thus becomes additive with existing barbiturate therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Barbiturates may decrease the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyridoxine: May increase the metabolism of Barbiturates. Apparent in high pyridoxine doses (eg, 200 mg/day)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Barbiturates may enhance the hepatotoxic effect of QuiNIDine. Barbiturates may decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: PHENobarbital may decrease the serum concentration of QuiNINE. QuiNINE may increase the serum concentration of PHENobarbital.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: PHENobarbital may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rufinamide: PHENobarbital may decrease the serum concentration of Rufinamide. Rufinamide may increase the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: PHENobarbital may decrease the serum concentration of Telaprevir. Telaprevir may decrease the serum concentration of PHENobarbital. Telaprevir may increase the serum concentration of PHENobarbital.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teniposide: Barbiturates may decrease the serum concentration of Teniposide.  Management: Consider alternatives to combined treatment with barbiturates and teniposide due to the potential for decreased teniposide concentrations.  If the combination cannot be avoided, monitor teniposide response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Barbiturates may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Barbiturates may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: PHENobarbital may decrease the serum concentration of Tipranavir. Tipranavir may decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: CYP2C8 Inducers (Strong) may decrease the serum concentration of Treprostinil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Barbiturates may increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May decrease the metabolism of Barbiturates. Barbiturates may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Barbiturates may increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Barbiturates may decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zonisamide: PHENobarbital may decrease the serum concentration of Zonisamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1054889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     High doses of pyridoxine may decrease drug effect; barbiturates may increase the metabolism of vitamins D and K; dietary requirements of vitamins D, K, C, B",
"     <sub>",
"      12",
"     </sub>",
"     , folate, and calcium may be increased with long-term use",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F208922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B/D (manufacturer dependent) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F208939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Barbiturates can be detected in the placenta, fetal liver, and fetal brain. Fetal and maternal blood concentrations may be similar following parenteral administration. An increased incidence of fetal abnormalities may occur following maternal use. The use of folic acid throughout pregnancy and vitamin K during the last month of pregnancy is recommended; epilepsy itself, number of medications, genetic factors, or a combination of these probably influence the teratogenicity of anticonvulsant therapy. When used during the third trimester of pregnancy, withdrawal symptoms may occur in the neonate, including seizures and hyperirritability; symptoms of withdrawal may be delayed in the neonate up to 14 days after birth. Use during labor does not impair uterine activity; however, respiratory depression may occur in the newborn; resuscitation equipment should be available, especially for premature infants.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CNS status, seizure activity, liver enzymes, CBC with differential, renal function, serum concentrations; signs and symptoms of suicidality (eg, anxiety, depression, behavior changes). With I.V. use: Respiratory rate, heart rate, blood pressure, I.V.  site (stop injection if patient complains of pain in the limb). For treatment of hyperbilirubinemia: Monitor bilirubin (total and direct)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1054880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic: 15-40 mcg/mL (SI: 65-172 micromoles/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Potentially toxic: &gt;40 mcg/mL (SI: &gt;172 micromoles/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Coma: &gt;50 mcg/mL (SI: &gt;215 micromoles/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Potentially lethal: &gt;80 mcg/mL (SI: &gt;344 micromoles/L)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Depresses CNS activity by binding to barbiturate site at GABA-receptor complex enhancing GABA activity; depresses reticular activating system; higher doses may be gabamimetic",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1054884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypnosis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Within 20-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Within 5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: I.V.: Within 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 6-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 4-10 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: 70% to 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: 0.8-1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 0.7-0.8 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 0.6-0.7 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 35% to 50%, decreased protein binding in neonates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver via hydroxylation and glucuronide conjugation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: 45-500 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 20-133 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 37-73 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 53-140 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Within 1-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 20% to 50% excreted unchanged in urine; clearance can be increased with alkalinization of urine or with oral multiple-dose activated charcoal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Moderately dialyzable (20% to 50%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1054873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/59/8117?source=see_link\">",
"      see \"Phenobarbital: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; limit caffeine. May be habit-forming; avoid abrupt discontinuation after prolonged use (withdrawal symptoms or an increase in seizure activity may occur). May cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. Antiepileptic agents may increase the risk of suicidal thoughts and behavior; notify physician if you feel more depressed or have thoughts of suicide or self-harm. Report worsening of seizure activity or loss of seizure control.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1054887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Allow adequate time to elapse between I.V. doses when treating active seizures; peak concentrations in the brain may require &ge;15 minutes to occur; repeating I.V. doses of phenobarbital until convulsions stop may cause the concentration in the brain to exceed the amount required to control seizure activity and result in severe barbiturate-induced CNS depression",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A retrospective study (Relling, 2000) demonstrated that enzyme-inducing antiepileptic drugs (AEDs) (carbamazepine, phenobarbital, and phenytoin) increased systemic clearance of antileukemic drugs (teniposide and methotrexate) and were associated with a worse event-free survival, CNS relapse, and hematologic relapse (ie, lower efficacy), in B-lineage ALL children receiving chemotherapy; the authors recommend using nonenzyme-inducing AEDs in patients receiving chemotherapy for ALL.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F5075239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An alcohol-free 10 mg/mL phenobarbital oral suspension may be made from tablets and one of two different vehicles (a 1:1 mixture of Ora-Plus&reg; and Ora-Sweet&reg; or a 1:1 mixture of Ora-Plus&reg; and Ora-Sweet&reg; SF). Crush ten phenobarbital 60 mg tablets in a glass mortar and reduce to a fine powder. Mix 30 mL of Ora-Plus&reg; and 30 mL of either Ora-Sweet&reg; or Ora-Sweet&reg; SF; stir vigorously. Add 15 mL of the vehicle to the powder and mix to a uniform paste. Transfer the mixture to a 2 ounce amber plastic prescription bottle. Rinse mortar and pestle with 15 mL of the vehicle; transfer to bottle. Repeat, then add quantity of vehicle sufficient to make 60 mL. Label \"shake well.\" May mix dose with chocolate syrup (1:1 volume) immediately before administration to mask the bitter aftertaste. Stable for 115 days when stored in amber plastic prescription bottles at room temperature.",
"    </p>",
"    <div class=\"reference\">",
"     Cober M and Johnson CE, &ldquo;Stability of an Extemporaneously Prepared Alcohol-Free Phenobarbital Suspension,&rdquo;",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 2007, 64(6):644-6.",
"     <span class=\"pubmed-id\">",
"      17353574",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Finnegan LP, Mitros TF, and Hopkins LE, \"Management of Neonatal Narcotic Abstinence Utilizing a Phenobarbital Loading Dose Method,\"",
"      <i>",
"       NIDA Res Monogr",
"      </i>",
"      , 1979, 27:247-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/63/29689/abstract-text/121340/pubmed\" id=\"121340\" target=\"_blank\">",
"        121340",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gilman JT, Gal P, Duchowny MS, et al, \"Rapid Sequential Phenobarbital Treatment of Neonatal Seizures,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1989, 83(5):674-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/63/29689/abstract-text/2717283/pubmed\" id=\"2717283\" target=\"_blank\">",
"        2717283",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hall RT, Hall FK, and Daily DK, \"High-Dose Phenobarbital Therapy in Term Newborn Infants With Severe Perinatal Asphyxia: A Randomized, Prospective Study With Three-Year Follow-Up,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1998, 132(2):345-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/63/29689/abstract-text/9506654/pubmed\" id=\"9506654\" target=\"_blank\">",
"        9506654",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, \"Preparing for Pediatric Emergencies: Drugs to Consider,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(2):433-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/63/29689/abstract-text/18245435/pubmed\" id=\"18245435\" target=\"_blank\">",
"        18245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kraus DM and Pham JT, \"Neonatal Therapy,\"",
"      <i>",
"       Applied Therapeutics: The Clinical Use of Drugs",
"      </i>",
"      , 9th ed, Koda-Kimble MA, Young LY, Kradjan WA, et al, eds, Baltimore, MD: Lippincott Williams &amp; Wilkins, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lockman LA, Kriel R, Zaske D, et al, \"Phenobarbital Dosage for Control of Neonatal Seizures,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 1979, 29(11):1445-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/63/29689/abstract-text/574197/pubmed\" id=\"574197\" target=\"_blank\">",
"        574197",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meyn DF Jr, Ness J, Ambalavanan N, et al, \"Prophylactic Phenobarbital and Whole-Body Cooling for Neonatal Hypoxic-Ischemic Encephalopathy,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2010, 157(2):334-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/63/29689/abstract-text/20553847/pubmed\" id=\"20553847\" target=\"_blank\">",
"        20553847",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"Neonatal Drug Withdrawal. American Academy of Pediatrics Committee on Drugs,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1998, 101(6):1079-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/63/29689/abstract-text/9614425/pubmed\" id=\"9614425\" target=\"_blank\">",
"        9614425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Painter MJ, Pippenger C, MacDonald H, et al, \"Phenobarbital and Diphenylhydantoin Levels in Neonates With Seizures,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1978, 92(2):315-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/63/29689/abstract-text/621616/pubmed\" id=\"621616\" target=\"_blank\">",
"        621616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Painter MJ, Pippenger C, Wasterlain C, et al, \"Phenobarbital and Phenytoin in Neonatal Seizures: Metabolism and Tissue Distribution,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 1981, 31(9):1107-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/63/29689/abstract-text/7196530/pubmed\" id=\"7196530\" target=\"_blank\">",
"        7196530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Relling MV, Pui CH, Sandlund JT, et al, &ldquo;Adverse Effect of Anticonvulsants on Efficacy of Chemotherapy for Acute Lymphoblastic Leukaemia,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2000, 356(9226):285-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/63/29689/abstract-text/11071183/pubmed\" id=\"11071183\" target=\"_blank\">",
"        11071183",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sabo-Graham T and Seay AR, \"Management of Status Epilepticus in Children,\"",
"      <i>",
"       Pediatr Rev",
"      </i>",
"      , 1998, 19(9):306-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/63/29689/abstract-text/9745313/pubmed\" id=\"9745313\" target=\"_blank\">",
"        9745313",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tran JH, \"Treatment of Neonatal Abstinence Syndrome,\"",
"      <i>",
"       J Pediatr Health Care",
"      </i>",
"      , 1999, 13(6 Pt 1):295-300.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/63/29689/abstract-text/10889678/pubmed\" id=\"10889678\" target=\"_blank\">",
"        10889678",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12698 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-115.66.252.144-FC8D04C3D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_63_29689=[""].join("\n");
var outline_f28_63_29689=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208959\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054876\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444744\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054868\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208927\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208910\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209007\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054882\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209013\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054871\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054881\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209015\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209012\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054886\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054867\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054866\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209000\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208919\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054889\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208922\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208939\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054875\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054880\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054865\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054884\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054885\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054873\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054887\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5075239\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12698\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12698|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=related_link\">",
"      Phenobarbital: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/59/8117?source=related_link\">",
"      Phenobarbital: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_63_29690="Drugs and the liver: Patterns of drug-induced liver injury";
var content_f28_63_29690=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Drugs and the liver: Patterns of drug-induced liver injury",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/63/29690/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/63/29690/contributors\">",
"     Anne M Larson, MD, FACP, AGAF",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/63/29690/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/63/29690/contributors\">",
"     Keith D Lindor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/63/29690/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/63/29690/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/63/29690/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver injury can develop following the use of many drugs, both prescription and over-the-counter, through a variety of mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. A high index of suspicion is often necessary to expeditiously establish the diagnosis.",
"   </p>",
"   <p>",
"    The different histologic types of drug-induced liver injury will be reviewed here. The metabolism of drugs by the liver and the mechanisms by which drugs might injure the liver and the use of medications in patients with liver disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13754?source=see_link\">",
"     \"Drugs and the liver: Metabolism and mechanisms of injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of the management of chronic hepatitis C virus infection\", section on 'Dose adjustments of medications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of the complications, prognosis, and management of cirrhosis\", section on 'Preventing superimposed insults'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced liver injury (also called DILI or drug-induced hepatotoxicity) is a well-recognized problem as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The annual incidence of DILI with approved prescription medications is estimated to be between one in 10,000 to 100,000 persons exposed; however, incidences as high as 14 per 100,000 population have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/3-9\">",
"       3-9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      DILI accounts for up to 10 percent of all adverse drug reactions [",
"      <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/4-6\">",
"       4-6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It is seen in up to 30 percent of patients who present with acute hepatitis and represents up to 10 percent of consultations by hepatologists, and about 1 percent of all general medical admissions [",
"      <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/4,10-13\">",
"       4,10-13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      DILI is the cause of acute jaundice in up to 50 percent of patients presenting with jaundice, depending upon the patient population and geographic location [",
"      <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/14-19\">",
"       14-19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It is the most common cause of acute liver failure in the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/20,21\">",
"       20,21",
"      </a>",
"      ], and it is the most frequently cited reason for withdrawal of medications from the marketplace [",
"      <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/20,22\">",
"       20,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Over 1000 medications and herbal products have been implicated in the development of DILI [",
"      <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H235295151\">",
"    <span class=\"h2\">",
"     Database of drugs, herbs, and supplements associated with hepatotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A",
"    <a class=\"external\" href=\"file://www.livertox.nih.gov/\">",
"     searchable database",
"    </a>",
"    of drugs, herbal medications, and dietary supplements has been developed by the National Institutes of Health [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SPECTRUM OF DRUG-INDUCED LIVER INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced liver injury (DILI) can be classified in several ways: its clinical presentation and laboratory features, the mechanism of hepatotoxicity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    its histological findings (",
"    <a class=\"graphic graphic_table graphicRef74021 graphicRef72121 \" href=\"UTD.htm?10/8/10381\">",
"     table 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/2\">",
"     2",
"    </a>",
"    ]. The clinical presentation varies widely and can mimic other forms of both acute and chronic liver disease. Acute presentations can range from mild asymptomatic biochemical abnormalities to an acute illness with jaundice that resembles viral hepatitis to acute liver failure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/2,3,10,11,25-29\">",
"     2,3,10,11,25-29",
"    </a>",
"    ]. The presence of jaundice (serum bilirubin &gt;2 times the upper limit of normal) in association with an elevation in serum aminotransferases (&gt;3 times the upper limit of normal) is associated with a worse prognosis than that seen in the setting of isolated aminotransferase abnormalities (an observation known as \"Hy's law\") [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/27,30\">",
"     27,30",
"    </a>",
"    ]. The mortality in this setting is approximately 9 to 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/31\">",
"     31",
"    </a>",
"    ]. Most new drugs are tested in fewer than 3000 people prior to drug-approval. As a result, cases of DILI, with an incidence of more than 1 in 10,000, may be missed. It has been suggested that for every 10 cases of ALT elevation (&gt;10 times the upper limit of normal) in a clinical trial, there will be one case of more severe liver injury that develops in the post-marketing setting following FDA-approval [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to an acute hepatitic presentation, some drugs are associated with chronic histologic inflammatory changes and a clinical syndrome resembling autoimmune hepatitis. Others can cause endothelial damage or thrombosis, leading to vascular complications such as sinusoidal obstruction syndrome (previously called veno-occlusive disease) or Budd-Chiari syndrome.",
"   </p>",
"   <p>",
"    Withdrawal of the offending drug usually leads to a reversal of the injury. However, some types of toxicity can be associated with a progressive course, possibly leading to fibrosis or cirrhosis, despite discontinuation of the drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Subclinical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many drugs can induce asymptomatic elevations in liver enzymes without producing overt clinical disease. Drug-induced liver injury (DILI) is generally considered subclinical or insignificant if the serum alanine aminotransferase (ALT) is &lt;3 times the upper limit of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/34\">",
"     34",
"    </a>",
"    ]. Subclinical liver disease has been described with certain antibiotics, antidepressants, lipid-lowering drugs, sulfonamides, salicylates, sulfonylureas, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    , generally in fewer than 5 to 10 percent of individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. A higher percentage of asymptomatic ALT elevations can be seen with other medications, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    (up to 20 percent) and tacrine (up to 50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most subclinical ALT elevations are benign and resolve once the offending agent has been discontinued. The time course of resolution can be variable but generally occurs over weeks to months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Acute liver injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute DILI is the most common form of liver injury caused by drugs, accounting for approximately 10 percent of all cases of acute hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/41\">",
"     41",
"    </a>",
"    ]. The patterns of acute injury may present as cholestasis, hepatocellular (cytotoxic) damage, a mixed pattern of cytotoxic and cholestatic injury, or, less commonly, steatosis (",
"    <a class=\"graphic graphic_table graphicRef70335 \" href=\"UTD.htm?40/48/41742\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/42\">",
"     42",
"    </a>",
"    ]. Discontinuation of the offending agent usually results in complete recovery, although the prognosis is generally worse in patients with hepatocellular injury presenting with jaundice [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/26,27,30\">",
"     26,27,30",
"    </a>",
"    ]. In the setting of cholestatic injury, jaundice can take months to resolve. DILI is probably the most common cause of cholestatic hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common drugs implicated in acute DILI in the United States are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    followed by antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/10,20,21\">",
"     10,20,21",
"    </a>",
"    ]. Worldwide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    is one of the most commonly reported antibiotics that cause DILI [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/2,26\">",
"     2,26",
"    </a>",
"    ]. Its classic pattern of hepatotoxicity is cholestatic. However, cytotoxic damage due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    -clavulanate has been observed more commonly in younger patients treated for a shorter duration compared with a",
"    <span class=\"nowrap\">",
"     cholestatic/mixed",
"    </span>",
"    type of reaction seen in older patients after prolonged treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Acute hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced acute hepatocellular injury is similar to that seen in viral hepatitis. Laboratory testing characteristically shows an elevation in serum aminotransferases. Histologically, portal and parenchymal hepatocellular injury leads to acute hepatocellular necrosis or apoptosis, steatosis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cellular degeneration.",
"   </p>",
"   <p>",
"    A hepatocyte that has become sensitized to the immune system dies by apoptosis triggered via death receptors at the cell surface [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Moderate degrees of oxidative stress also result in apoptosis at the intracellular level, while severe oxidative stress leads to necrotic cell lysis (necrosis).",
"   </p>",
"   <p>",
"    Hepatocellular injury can be spotty, affecting single hepatocytes, or it can be confluent, affecting groups of hepatocytes. Confluent necrosis can be zonal or nonzonal, depending upon the offending agent. If extensive enough, confluent necrosis results in acute liver failure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Zonal necrosis is characteristic of compounds with predictable, dose-dependent, intrinsic toxicity, such as halothane (zone 3), carbon tetrachloride (zone 3),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (zone 3), yellow phosphorus (zone 2), beryllium (zone 2), or iron sulfate (zone 1). Isolated necrosis in zones 1 and 2 is rare [",
"      <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/45\">",
"       45",
"      </a>",
"      ]. There may be little or no inflammatory response; however, damaged cells may accumulate fat (triglycerides).",
"     </li>",
"     <li>",
"      Nonzonal necrosis appears in a viral hepatitis-like pattern. It is more often seen with compounds that produce unpredictable idiosyncratic injury (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"       methyldopa",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      ). Certain medications, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , produce a nonspecific pattern of injury, which is completely reversible but rarely may be associated with progressive hepatic failure [",
"      <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cytotoxic hepatocellular injury is associated with a mortality rate of up to 10 percent overall and up to 80 percent or higher if acute liver failure develops [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/20,47-49\">",
"     20,47-49",
"    </a>",
"    ]. The best predictor of mortality in the setting of acute hepatocellular injury is a serum bilirubin level &gt;3 times the upper limit of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/27,30\">",
"     27,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Cholestatic injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cholestatic injury often resembles extrahepatic obstructive jaundice. Cholestatic injury is typically recognized by predominant elevations in alkaline phosphatase, &gamma;-glutamyl transferase, and bilirubin. Serum aminotransferases are only mildly elevated (usually less than eightfold). Patients rarely feel ill, with the most common symptoms being pruritus, jaundice,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dark urine. The overall prognosis for purely cholestatic injury is better than for hepatocellular injury, although fatalities have been reported.",
"   </p>",
"   <p>",
"    Compounds that have been associated with acute cholestatic injury include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    , estradiol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    estolate,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , troglitazone, and, rarely,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    . [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/45,50,51\">",
"     45,50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Four types of cholestasis can be seen on liver histology [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/47,48,50,52,53\">",
"     47,48,50,52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pure (canalicular, bland or noninflammatory) cholestasis is characterized by cholestasis with very little hepatocellular inflammation. Bile plugging is frequently seen, predominantly in zone 3 hepatocytes or canaliculi. Aminotransferases are generally normal or minimally elevated, with greater elevations in alkaline phosphatase and &gamma;-glutamyl transferase. This type of injury is often seen with the use of anabolic steroids or oral contraceptives. Drugs causing this type of injury interfere with hepatocyte secretion of bile constituents and other pigment and dye substances via the bile salt excretory protein (BSEP) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/50\">",
"       50",
"      </a>",
"      ]. The degree of cholestasis is characteristic for each drug.",
"     </li>",
"     <li>",
"      Cholestatic (hepatocanalicular, cholangiolitic, or inflammatory) cholestasis is characterized by portal inflammation, prominent cholestasis, and hepatocellular injury. Bile duct proliferation may be seen. Hepatocyte injury is usually localized to the zones of cholestasis. The laboratory pattern is mixed, with elevations in serum aminotransferases ranging from normal to eightfold, while serum alkaline phosphatase shows 3- to 10-fold elevations. Symptoms of hypersensitivity may be present, and this pattern has at times been referred to as \"hypersensitivity cholestasis\" [",
"      <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/54\">",
"       54",
"      </a>",
"      ]. Examples of drugs causing this pattern include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"       chlorpromazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/11/3253?source=see_link\">",
"       dicloxacillin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      estolate,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      , sulfonylureas, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"       terbinafine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/55,56\">",
"       55,56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ductopenic cholestasis is a chronic injury described below.",
"     </li>",
"     <li>",
"      Sclerosing cholangitis is also a chronic injury described below.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Mixed patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mixed patterns of injury are common and show elevations in both aminotransferases and alkaline phosphatase. An example of this pattern is seen in patients with hepatotoxicity due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    . Such patients may be at increased risk to develop chronic liver disease compared with other forms of hepatotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/57\">",
"     57",
"    </a>",
"    ]. Fluoroquinolones have also been associated with a mixed pattern, although in some cases cholestatic or hepatocellular patterns have predominated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Acute steatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced acute steatosis (fatty degeneration) is uncommon and occurs less often than chronic steatosis. Jaundice is usually mild, and serum aminotransferases are lower than that seen in cytotoxic injury. Although the biochemical features generally do not appear as severe as those seen in hepatocellular disease, the illness can be severe and the prognosis poor with high mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Its clinical features are similar to non-drug causes of steatosis, including Reye's syndrome,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency, or acute fatty liver of pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24166?source=see_link\">",
"     \"Acute fatty liver of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drugs that disrupt beta-oxidation of lipids and oxidative energy production lead to steatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/61\">",
"     61",
"    </a>",
"    ]. Histologically, acute steatosis tends to be microvesicular and predominantly triglyceride. This is especially true of steatohepatitis related to high-dose intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/49,62-66\">",
"     49,62-66",
"    </a>",
"    ]. Other drugs associated with microvesicular steatosis include camphor, cocaine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/25/9625?source=see_link\">",
"     piroxicam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33512?source=see_link\">",
"     tolmetin",
"    </a>",
"    , valproic acid,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    (AZT),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    (ddI) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/52,67,68\">",
"     52,67,68",
"    </a>",
"    ]. Herbal remedies, such as Jin bu huan (Lycopodium serratum), are increasingly identified as causes of steatosis and other forms of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25642?source=see_link\">",
"     \"Hepatotoxicity due to herbal medications and dietary supplements\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Extrahepatic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some drugs causing liver injury may be associated with clinical features dominated by extrahepatic manifestations. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drugs causing hypersensitivity reactions (eg, penicillin and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      ) may be associated with fever, rash, and peripheral eosinophilia.",
"     </li>",
"     <li>",
"      Some drugs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      , sulfonamides) may be associated with a mononucleosis-like illness (pseudomononucleosis) including lymph node enlargement, lymphocytosis, and atypical lymphocytes.",
"     </li>",
"     <li>",
"      Toxicity to multiple organs (eg, bone marrow, kidney, lung, skin, and vessels) may be seen with some drugs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"       chlorpromazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"       amoxicillin-clavulanate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/17/44312?source=see_link\">",
"       sulindac",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Serologic markers of autoimmunity may be seen in patients with toxicity related to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      , although their relationship to hepatic injury is unclear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Chronic hepatic injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs associated with chronic liver injury can resemble other causes of chronic liver disease such as autoimmune hepatitis or alcoholic liver disease (",
"    <a class=\"graphic graphic_table graphicRef70335 \" href=\"UTD.htm?40/48/41742\">",
"     table 2",
"    </a>",
"    ). Chronic injury generally resolves upon discontinuation of the offending drug, but this pattern of liver injury may progress to cirrhosis and liver failure. Chronic hepatic injury generally refers to the presence of persistently abnormal liver enzymes for over three to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. A progression to chronic disease is reported to occur in approximately 5 to 10 percent of adverse drug reactions and is more common among the",
"    <span class=\"nowrap\">",
"     cholestatic/mixed",
"    </span>",
"    types of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Chronic hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four types of chronic hepatitis have been associated with drug-induced hepatotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/47,48,52\">",
"     47,48,52",
"    </a>",
"    ]. As a general rule, these occur in patients taking the offending drug chronically.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autoimmune-like &mdash; This syndrome resembles type I (classic) autoimmune hepatitis and is serologically and morphologically indistinguishable [",
"      <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/45\">",
"       45",
"      </a>",
"      ]. There is a female preponderance, serologic markers of autoimmunity (ANA, smooth muscle antibody), hyperglobulinemia, and histological features consistent with autoimmune hepatitis (",
"      <a class=\"graphic graphic_table graphicRef65135 \" href=\"UTD.htm?8/0/8203\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/45,48\">",
"       45,48",
"      </a>",
"      ]. Extrahepatic manifestations, including rash, arthralgias, and peripheral eosinophilia, may be present. The clinical manifestations range from asymptomatic biochemical abnormalities to development of cirrhosis, although this is rare [",
"      <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/74\">",
"       74",
"      </a>",
"      ]. Drugs and herbs implicated include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"       methyldopa",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       minocycline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"       nitrofurantoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      , clometacin (an NSAID),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/23/17784?source=see_link\">",
"       fenofibrate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/2/37923?source=see_link\">",
"       papaverine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/9/5271?source=see_link\">",
"       propylthiouracil",
"      </a>",
"      , germander, statins, and ecstasy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/75,76\">",
"       75,76",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/32/27140?source=see_link\">",
"       \"Classification of autoimmune hepatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Viral hepatitis-like &mdash; This syndrome develops when drugs lead to either an acute or chronic hepatitis accompanied by autoimmune serologic markers differing from those seen with autoimmune-like disease. The antibodies resemble those seen in type 2 autoimmune hepatitis, a rare entity in the United States, and are directed against microsomal cellular components (",
"      <a class=\"graphic graphic_table graphicRef70335 \" href=\"UTD.htm?40/48/41742\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/77\">",
"       77",
"      </a>",
"      ]. Examples include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      , dihydralazine, and ticrynafen (withdrawn from the US market).",
"     </li>",
"     <li>",
"      Chronic hepatitis with negative autoimmune markers &mdash; A third rare type of injury leads to a syndrome with the histologic characteristics indistinguishable from chronic viral hepatitis, but without the presence of autoimmune serologic markers. This is a more nondescript type of injury and can progress to cirrhosis. Drugs associated with this type of injury include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"       lisinopril",
"      </a>",
"      , sulfonamides,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"       trazodone",
"      </a>",
"      , uracil, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Rarely, drugs may lead to chronic toxicity without active necroinflammatory disease. Examples include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/22/22887?source=see_link\">",
"       dantrolene",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Chronic steatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced chronic steatosis is predominantly macrovesicular in contrast to the microvesicular steatosis usually seen in acute drug injury. The clinical picture of bland macrovesicular steatosis tends to be less severe than that seen with acute microvesicular steatosis with the most common clinical manifestation being hepatomegaly. The challenge can be differentiating drug-induced steatosis from nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), which are not associated with medications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/60\">",
"     60",
"    </a>",
"    ]. Drug-induced steatohepatitis can also resemble alcoholic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/47,52\">",
"     47,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=see_link\">",
"     \"Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"    </a>",
"    .) Steatosis may remain asymptomatic or may evolve into steatohepatitis with progression to cirrhosis within weeks to months, followed by the development of chronic liver failure and subsequent hepatic insufficiency. Examples of implicated drugs include L-asparaginase,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    , perhexiline maleate, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/49,63-65,78\">",
"     49,63-65,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The distribution of fat within the hepatocyte may be in one of two forms: large droplet (at least half of the cytoplasm is occupied by a single lipid droplet) or small droplet (multiple lipid vacuoles are seen) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/45\">",
"     45",
"    </a>",
"    ]. Serum aminotransferases are typically moderately elevated. Drugs associated with these types of injury include chemotherapeutic agents (eg, 5-fluorouracil,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    ), chloroform, diethylstilbestrol, ethanol, glucocorticoids, gold,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/61/6102?source=see_link\">",
"     griseofulvin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , mercury,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    , NSAIDs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/17/44312?source=see_link\">",
"     sulindac",
"    </a>",
"    ), tamoxifen, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/45,79,80\">",
"     45,79,80",
"    </a>",
"    ]. These medications rarely cause steatohepatitis but may exacerbate or precipitate it in patients with risk factors for NASH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1147473876\">",
"    <span class=\"h3\">",
"     Steatohepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histologic features of steatohepatitis are characterized by the presence of variable steatosis, lobular inflammation (predominantly neutrophilic), and hepatocellular injury (ballooning) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/45\">",
"     45",
"    </a>",
"    ]. Acidophil bodies, Mallory hyaline, and pericellular fibrosis may also be present. Drugs that have been directly associated with the development of steatohepatitis include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , diethylaminoethoxyhexestrol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , and perhexiline maleate [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Fibrosis and cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive liver injury leads to scarring with subsequent cirrhosis. Clinical manifestations are typical of those seen with cirrhosis and portal hypertension from other causes. Drug-induced cirrhosis may result from steatosis (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ) or chronic hepatitis. Gradual progression to cirrhosis can be seen without any manifestation of clinical illness (as with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/82-85\">",
"     82-85",
"    </a>",
"    ]. Cirrhosis may also result from lesions of chronic intrahepatic cholestasis (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Chronic intrahepatic cholestasis'",
"    </a>",
"    below), chronic cholestasis (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/21/39253?source=see_link\">",
"     floxuridine",
"    </a>",
"    ), chronic congestive hepatopathy with sinusoidal obstruction syndrome (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    oral contraceptives) or hepatic vein thrombosis (oral contraceptives), and noncirrhotic portal hypertension (inorganic arsenic, copper sulfate, vinyl chloride, and vitamin A) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Phospholipidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phospholipidosis is rare. It may develop acutely but is more commonly seen after prolonged administration of the offending agent. This condition has been described in animal models and in patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    , perhexiline maleate,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/52/24390?source=see_link\">",
"     chlorpheniramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"     thioridazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/78,87\">",
"     78,87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lesions consist of lysosomes which are engorged with phospholipid, resulting in foamy hepatocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/65,78,88,89\">",
"     65,78,88,89",
"    </a>",
"    ]. It is believed that an interaction between the phospholipid and the offending drug leads to the formation of a complex, which prevents degradation of the phospholipid molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/52\">",
"     52",
"    </a>",
"    ]. These characteristic abnormal, lamellated lysosomes are visible on electron microscopy. There appears to be a high incidence of cirrhosis associated with this lesion, although the exact mechanism is not clear. Clinical manifestations consist of hepatomegaly with or without hepatic insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Chronic cholestasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several forms of chronic cholestasis are induced by drug-related liver injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Chronic intrahepatic cholestasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic cholestasis may evolve from acute drug-induced cholestasis. Most cases resolve with the withdrawal of the offending agent, but cholestasis can be prolonged, requiring several months (&gt;3 months) to resolve [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/34,90\">",
"     34,90",
"    </a>",
"    ]. Drugs causing chronic intrahepatic cholestasis can produce a syndrome histologically resembling primary biliary cirrhosis or biliary obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/45,47,52\">",
"     45,47,52",
"    </a>",
"    ]. However, unlike primary biliary cirrhosis, serum antimitochondrial antibodies are usually not seen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis\"",
"    </a>",
"    .) Drugs that have been reported to cause chronic intrahepatic cholestasis include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/25/19862?source=see_link\">",
"     cyproheptadine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    estolate,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    , organic arsenicals,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , thiabendazole,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/49/42774?source=see_link\">",
"     tolbutamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    , oral contraceptives, and anabolic steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/91-93\">",
"     91-93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2204312628\">",
"    <span class=\"h3\">",
"     Vanishing bile duct syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients develop a vanishing bile duct syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/90,94\">",
"     90,94",
"    </a>",
"    ]. In this setting, prolonged damage leads to the loss of bile ducts and overt ductopenia. In rare cases, a progression to cirrhosis and ultimately liver failure results. Drugs that have been implicated in the development of ductopenia include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/0/6151?source=see_link\">",
"     chlorpropamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , flucloxacillin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    , sulpiride, tenoxicam, thiabendazole, tricyclic antidepressants,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/2/10279?source=see_link\">",
"     zonisamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/95-97\">",
"     95-97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Biliary sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxicity predominantly involving the biliary tree is most commonly seen after intra-arterial infusion therapy of metastatic carcinoma with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/21/39253?source=see_link\">",
"     floxuridine",
"    </a>",
"    or 5-fluorodexoyuridine [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. The lesions resemble primary sclerosing cholangitis radiographically, cholangiographically, and histologically [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/52\">",
"     52",
"    </a>",
"    ]. Affected patients usually present with right upper abdominal pain, anorexia, weight loss, and jaundice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Vascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced hepatic vascular disease is uncommon but can have several presentations, each with distinctive features and drug associations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Hepatic vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic venous outflow obstruction (Budd-Chiari syndrome) may arise from drug-induced thrombosis of the hepatic veins or inferior vena cava. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31575?source=see_link\">",
"     \"Etiology of the Budd-Chiari syndrome\"",
"    </a>",
"    .) While often associated with myeloproliferative or coagulative disorders, the most prominent medications associated with this syndrome are the oral contraceptives [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/100\">",
"     100",
"    </a>",
"    ]. Without treatment, hepatic vein thrombosis will progress to portal hypertension, liver failure, and ultimately, death [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/101\">",
"     101",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3434?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Sinusoidal obstruction syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic sinusoidal obstruction syndrome (SOS, formerly known as veno-occlusive disease) clinically resembles the Budd-Chiari syndrome or congestive hepatopathy secondary to heart failure. However, the hepatic venous outflow obstruction in SOS is due to occlusion at the level of the terminal hepatic venules and hepatic sinusoids rather than the hepatic veins and inferior vena cava. Disease results secondary to endothelial cell injury, resulting in endothelial swelling and thrombosis. Obstruction then leads to sinusoidal dilation and congestion and hepatocellular necrosis, which can, in some cases, result in centrilobular fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/45\">",
"     45",
"    </a>",
"    ]. Drugs that have been associated with SOS include pyrrolizidine alkaloids (found in herbal remedies) (",
"    <a class=\"graphic graphic_table graphicRef61224 \" href=\"UTD.htm?36/16/37133\">",
"     table 4",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    , vitamin A, oral contraceptives,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    , and a number of chemotherapeutic agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/102-106\">",
"     102-106",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=see_link\">",
"     \"Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25642?source=see_link\">",
"     \"Hepatotoxicity due to herbal medications and dietary supplements\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Peliosis hepatis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peliosis hepatis is rare and characterized by multiple, small, dilated blood-filled cavities in the hepatic parenchyma. It is most commonly associated with hepatic tumors or with cholestatic jaundice but can be caused by several drugs including anabolic steroids, arsenic,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    , oral contraceptives,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    , diethylstilbestrol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , vitamin A, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/52,107-110\">",
"     52,107-110",
"    </a>",
"    ]. Lesions may resolve with discontinuation of the offending agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26887?source=see_link\">",
"     \"Peliosis hepatis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Granulomatous hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulomas in the liver are most commonly seen in the setting of infection, sarcoidosis, and primary biliary cirrhosis. In addition, noncaseating granulomas in the liver can be seen with a variety of drugs (",
"    <a class=\"graphic graphic_picture graphicRef64126 \" href=\"UTD.htm?18/3/18486\">",
"     picture 1",
"    </a>",
"    ). At least 60 drugs have been implicated, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    , gold, interferon,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    , penicillin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    , sulfonamides, and sulfonylureas [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/45,52,111-113\">",
"     45,52,111-113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The granulomas are usually located in the periportal and portal areas; however, they can be seen within the parenchyma as well. Drug-induced granulomas are not associated with the bile ducts. They can be associated with hepatocellular injury (granulomatous hepatitis) or cholestasis, but they are more often silent. Affected patients may develop low-grade fever and chronic fatigue; jaundice is rare. The injury is usually transient without significant sequelae. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40406?source=see_link\">",
"     \"Hepatic granulomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Neoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain medications have been associated with both benign and malignant neoplasms of the liver.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Hepatic adenoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic adenoma is a benign tumor of the liver, which may rarely rupture causing hemoperitoneum or may be associated with malignant transformation. The risk of hepatic adenoma is increased in women taking oral contraceptives (OCP) and in men taking anabolic steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/114\">",
"     114",
"    </a>",
"    ]. Adenomas have historically developed in women using high-dose OCPs or with use for greater than five years. Adenomas are now rarer as the level of estrogen in OCPs has fallen. Adenomas have also been reported in the setting of long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    use [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. Tumors related to steroid use usually regress once the offending drug has been discontinued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15352?source=see_link\">",
"     \"Hepatic adenoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Angiosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;This extremely rare tumor has been associated with use of thorotrast (a radiographic contrast agent used in the 1930s to 1950s), arsenic, potassium arsenite, radium, inorganic copper, polyvinyl chloride, and anabolic steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/52\">",
"     52",
"    </a>",
"    ]. The latent period between exposure and development of cancer can span decades. The prognosis is poor with a mean life expectancy of six months following diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Hepatocellular carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatocellular carcinoma has a wide incidence worldwide and many etiologies. The main chemical associations with the development of hepatocellular carcinoma include aflatoxin, oral contraceptives, and alcohol. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of DILI can be difficult. Obtaining a careful drug history is important but not always reliable. A review of pharmacy records can also be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/117\">",
"     117",
"    </a>",
"    ]. However, the relationship between exposure to the drug and hepatic toxicity is not always clear. Patients may be taking multiple medications, making identification of a single offending agent difficult, and they may have concomitant liver diseases (such as alcoholism or NASH), which can produce similar clinical and laboratory features. There is no gold standard and no specific serum biomarker or characteristic histologic feature that reliably identifies a drug as the cause of toxicity. Histologically, DILI can resemble autoimmune hepatitis. Certain histologic features (eg, portal inflammation, portal neutrophils and plasma cells, fibrosis and intracellular cholestasis) have been reported to be more common in DILI [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/118\">",
"     118",
"    </a>",
"    ]. However, in our experience, while portal neutrophils are unusual in autoimmune hepatitis, the other features are common in both disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35528?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and diagnosis of autoimmune hepatitis\", section on 'Histology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Council for International Organizations of Medical Sciences (CIOMS) developed a series of standard designations of drug-induced liver disorders and classification of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/72\">",
"     72",
"    </a>",
"    ]. The United States FDA Drug Hepatotoxicity Steering Committee proposed modifications to the CIOMS classification scheme for classifying hepatotoxicity in clinical trials (",
"    <a class=\"graphic graphic_table graphicRef76892 \" href=\"UTD.htm?3/32/3595\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/119,120\">",
"     119,120",
"    </a>",
"    ]. These guidelines are used as markers of hepatotoxicity in clinical trials.",
"   </p>",
"   <p>",
"    A number of scales have been developed that attempt to codify causality of drug toxicity into objective criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/121\">",
"     121",
"    </a>",
"    ]. Examples include the CIOMS Roussel-Uclaf Causality Assessment Method (RUCAM) scale, and the Maria &amp; Victorino (M &amp; V) clinical scale [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/72,122-124\">",
"     72,122-124",
"    </a>",
"    ]. However, they do not address all risk factors in all patients, and none of these scales are used routinely in clinical practice. The Drug-Induced Liver Injury Network (DILIN) developed the DILIN Causality Scoring System to adjudicate the causality of drug-induced injury for patients enrolled into its prospective clinical trial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/125\">",
"     125",
"    </a>",
"    ]. This model relies on structured expert opinion, and when compared to the RUCAM, it produces higher agreement rates and likelihood scores. However, intraobserver variability remains significant in both scales [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/125\">",
"     125",
"    </a>",
"    ]. Unfortunately, the DILIN scale is not a clinically viable option of determining causality since it relies on expert opinion.",
"   </p>",
"   <p>",
"    Features suggesting drug toxicity include a lack of illness prior to ingesting the drug, clinical illness or biochemical abnormalities developing after beginning the drug, and improvement after the drug is withdrawn. If an immunologic reaction is suspected, the illness will generally recur upon reintroduction of the offending substance. While it remains the gold standard for the diagnosis of drug induced liver injury, rechallenge is not advised. Nonspecific symptoms developing after introduction of a drug (such as nausea, anorexia, malaise, fatigue, right upper quadrant pain, or pruritus) may indicate drug toxicity and should prompt evaluation.",
"   </p>",
"   <p>",
"    Key elements for attributing liver injury to a drug include [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/126\">",
"     126",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Exposure must precede the onset of liver injury (although the latent period is highly variable)",
"     </li>",
"     <li>",
"      Underlying liver disease should be excluded",
"     </li>",
"     <li>",
"      Injury may improve when the drug is stopped (although in some cases injury may initially worsen for days or weeks, while in fulminant cases, declining liver biochemical tests may indicate deterioration rather than improvement)",
"     </li>",
"     <li>",
"      Liver injury may have recurred more rapidly and severely after repeated exposure",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main treatment for DILI is withdrawal of the offending drug. Early recognition of drug toxicity is important to permit assessment of severity and monitoring for acute liver failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=see_link\">",
"     \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .) Few specific therapies have been shown to be beneficial in clinical trials. Two exceptions are the use of N-acetylcysteine for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    toxicity and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    for cases of valproic acid overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/127,128\">",
"     127,128",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28264?source=see_link\">",
"     \"Valproic acid poisoning\"",
"    </a>",
"    .) Corticosteroids are of unproven benefit for most forms of drug hepatotoxicity, although they may have a role for treating patients with hypersensitivity reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/129\">",
"     129",
"    </a>",
"    ]. Our practice is to give corticosteroids to patients with hypersensitivity reactions who have progressive cholestasis despite drug withdrawal and who have biopsy features that resemble those seen in autoimmune hepatitis. In addition, we give corticosteroids to patients with extrahepatic manifestations of a hypersensitivity reaction that warrant steroid treatment (eg, severe pulmonary involvement in patients with DRESS [drug reaction with eosinophilia and systemic symptoms]). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35528?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and diagnosis of autoimmune hepatitis\", section on 'Histology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43929?source=see_link&amp;anchor=H97599699#H97599699\">",
"     \"Drug reaction with eosinophilia and systemic symptoms (DRESS)\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients should be followed by serial biochemical measurements. Hepatology consultation may be warranted in some cases. Recovery should be expected in the majority of patients after discontinuing the drug. However, acute liver failure caused by an idiosyncratic drug reaction has a mortality rate of over 80 percent without liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/20,82,130\">",
"     20,82,130",
"    </a>",
"    ]. As a result, these patients should be transferred to a transplant center early in the course of the illness [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/127\">",
"     127",
"    </a>",
"    ]. The development of jaundice (bilirubin greater than two times the upper limit of normal in the setting of an ALT greater than three times the upper limit of normal) following introduction of a drug potentially portends a poor prognosis and should also prompt immediate referral to a center with expertise in hepatology [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/27,30\">",
"     27,30",
"    </a>",
"    ]. Patients who recover from acute DILI with jaundice generally have a favorable prognosis, although some patients appear to develop progressive chronic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several risk factors for worse outcomes after liver transplantation for DILI were identified in an analysis of the United Network for Organ Sharing database [",
"    <a class=\"abstract\" href=\"UTD.htm?28/63/29690/abstract/132\">",
"     132",
"    </a>",
"    ]. The risk of death was increased in children who developed acute liver failure due to antiepileptics, those who developed acute liver failure due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    who required hemodialysis, those who required life support, and those with an elevated serum creatinine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=see_link\">",
"     \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the United States, the Food and Drug Administration records drug toxicity. Thus, cases of drug hepatotoxicity should be reported (1-800-332-1088 or",
"    <a class=\"external\" href=\"file://www.fda.gov/Safety/MedWatch/HowToReport/ucm085568.htm\">",
"     file://www.fda.gov/Safety/MedWatch/HowToReport/ucm085568.htm",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/6/23651?source=see_link\">",
"       \"Patient information: Toxic hepatitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H213375674\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liver injury can develop following the use of many drugs, both prescription and over-the-counter, through a variety of mechanisms. A high index of suspicion is often necessary to expeditiously establish the diagnosis. A",
"      <a class=\"external\" href=\"file://www.livertox.nih.gov/\">",
"       searchable database",
"      </a>",
"      of drugs, herbal medications, and dietary supplements has been developed by the National Institutes of Health.",
"     </li>",
"     <li>",
"      Drug-induced liver injury (DILI) can be classified in several ways: by its clinical presentation and laboratory features, the mechanism of hepatotoxicity,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      its histological findings (",
"      <a class=\"graphic graphic_table graphicRef74021 graphicRef72121 \" href=\"UTD.htm?10/8/10381\">",
"       table 1A-B",
"      </a>",
"      ). The clinical presentations vary widely and can mimic other forms of both acute and chronic liver disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Spectrum of drug-induced liver injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of DILI can be difficult. Obtaining a careful drug history is important but not always reliable. A review of pharmacy records can also be helpful. Features suggesting drug toxicity include lack of illness prior to ingesting the drug, clinical illness or biochemical abnormalities developing after beginning the drug, and improvement after the drug is withdrawn. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main treatment for DILI is withdrawal of the offending drug. Early recognition of drug toxicity is important to permit assessment of severity and monitoring for acute liver failure. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113577447\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's many contributions to our program, in particular, his work on this topic as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/1\">",
"      Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/2\">",
"      Chang CY, Schiano TD. Review article: drug hepatotoxicity. Aliment Pharmacol Ther 2007; 25:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/3\">",
"      Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/4\">",
"      Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis 2007; 11:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/5\">",
"      Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med 1992; 232:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/6\">",
"      Pillans PI. Drug associated hepatic reactions in New Zealand: 21 years experience. N Z Med J 1996; 109:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/7\">",
"      Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002; 22:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/8\">",
"      Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135:1924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/9\">",
"      Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis 2009; 29:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/10\">",
"      Galan MV, Potts JA, Silverman AL, Gordon SC. The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center [corrected]. J Clin Gastroenterol 2005; 39:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/11\">",
"      De Valle MB, Av Klinteberg V, Alem N, et al. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther 2006; 24:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/12\">",
"      D&oslash;ssing M, Andreasen PB. Drug-induced liver disease in Denmark. An analysis of 572 cases of hepatotoxicity reported to the Danish Board of Adverse Reactions to Drugs. Scand J Gastroenterol 1982; 17:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/13\">",
"      Meier Y, Cavallaro M, Roos M, et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005; 61:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/14\">",
"      Norris W, Paredes AH, Lewis JH. Drug-induced liver injury in 2007. Curr Opin Gastroenterol 2008; 24:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/15\">",
"      Vuppalanchi R, Liangpunsakul S, Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am J Gastroenterol 2007; 102:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/16\">",
"      Akhtar AJ, Shaheen M. Jaundice in African-American and Hispanic patients with AIDS. J Natl Med Assoc 2007; 99:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/17\">",
"      Hussaini SH, O'Brien CS, Despott EJ, Dalton HR. Antibiotic therapy: a major cause of drug-induced jaundice in southwest England. Eur J Gastroenterol Hepatol 2007; 19:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/18\">",
"      Jinjuvadia K, Kwan W, Fontana RJ. Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury. Am J Gastroenterol 2007; 102:2437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/19\">",
"      Wai CT, Tan BH, Chan CL, et al. Drug-induced liver injury at an Asian center: a prospective study. Liver Int 2007; 27:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/20\">",
"      Ostapowicz G, Fontana RJ, Schi&oslash;dt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/21\">",
"      Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005; 42:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/22\">",
"      Xu JJ, Diaz D, O'Brien PJ. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem Biol Interact 2004; 150:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/23\">",
"      Stirnimann G, Kessebohm K, Lauterburg B. Liver injury caused by drugs: an update. Swiss Med Wkly 2010; 140:w13080.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.livertox.nih.gov/ (Accessed on October 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/25\">",
"      Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 2002; 22:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/26\">",
"      Andrade RJ, Lucena MI, Fern&aacute;ndez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/27\">",
"      Bj&ouml;rnsson E. Drug-induced liver injury: Hy's rule revisited. Clin Pharmacol Ther 2006; 79:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/28\">",
"      de Abajo FJ, Montero D, Madurga M, Garc&iacute;a Rodr&iacute;guez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/29\">",
"      Russo MW, Galanko JA, Shrestha R, et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004; 10:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/30\">",
"      Reuben A. Hy's law. Hepatology 2004; 39:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/31\">",
"      Chalasani N, Bj&ouml;rnsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010; 138:2246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/32\">",
"      Maddur H, Chalasani N. Idiosyncratic drug-induced liver injury: a clinical update. Curr Gastroenterol Rep 2011; 13:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/33\">",
"      Lewis JH. 'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective. Pharmacoepidemiol Drug Saf 2006; 15:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/34\">",
"      Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 2006; 43:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/35\">",
"      Tolman KG. The liver and lovastatin. Am J Cardiol 2002; 89:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/36\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288:2998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/37\">",
"      Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615.",
"     </a>",
"    </li>",
"    <li>",
"     Lewis JH. Medication-related and other forms of toxic liver injury. In: Clinical Practice of Gastroenterology, Brandt LJ (Ed), Churchill Livingstone, Philadelphia 1998. p.855.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/39\">",
"      Monteith DK, Emmerling MR, Garvin J, Theiss JC. Cytotoxicity study of tacrine, structurally and pharmacologically related compounds using rat hepatocytes. Drug Chem Toxicol 1996; 19:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/40\">",
"      Maddrey WC. Isoniazid-induced liver disease. Semin Liver Dis 1981; 1:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/41\">",
"      Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis 2000; 4:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/42\">",
"      Batt AM, Ferrari L. Manifestations of chemically induced liver damage. Clin Chem 1995; 41:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/43\">",
"      Lucena MI, Andrade RJ, Fern&aacute;ndez MC, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology 2006; 44:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/44\">",
"      Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Saf 2007; 30:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/45\">",
"      Ramachandran R, Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol 2009; 62:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/46\">",
"      O'Connor N, Dargan PI, Jones AL. Hepatocellular damage from non-steroidal anti-inflammatory drugs. QJM 2003; 96:787.",
"     </a>",
"    </li>",
"    <li>",
"     Zimmerman HJ. Chapter 16: Drug-induced liver disease. In: Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver, 1st ed, Appleton-Century-Crofts, New York 1978. p.353.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/48\">",
"      Speeg KV, Bay MK. Prevention and treatment of drug-induced liver disease. Gastroenterol Clin North Am 1995; 24:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/49\">",
"      Agozzino F, Picca M, Pelosi G. Acute hepatitis complicating intravenous amiodarone treatment. Ital Heart J 2002; 3:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/50\">",
"      Stieger B, Fattinger K, Madon J, et al. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 2000; 118:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/51\">",
"      Chang CC, Petrelli M, Tomashefski JF Jr, McCullough AJ. Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug: a case report and review of the literature. Arch Pathol Lab Med 1999; 123:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/52\">",
"      Zimmerman HJ, Lewis JH. Chemical- and toxin-induced hepatotoxicity. Gastroenterol Clin North Am 1995; 24:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/53\">",
"      Larrey D. Drug-induced liver diseases. J Hepatol 2000; 32:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/54\">",
"      Ishak KG, Zimmerman HJ. Drug-induced and toxic granulomatous hepatitis. Baillieres Clin Gastroenterol 1988; 2:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/55\">",
"      Iverson SL, Uetrecht JP. Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity. Chem Res Toxicol 2001; 14:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/56\">",
"      Karthik SV, Casson D. Erythromycin-associated cholestatic hepatitis and liver dysfunction in children: the British experience. J Clin Gastroenterol 2005; 39:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/57\">",
"      Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology 2006; 44:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/58\">",
"      Orman ES, Conjeevaram HS, Vuppalanchi R, et al. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol 2011; 9:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/59\">",
"      Huang YL, Hong HS, Wang ZW, Kuo TT. Fatal sodium valproate-induced hypersensitivity syndrome with lichenoid dermatitis and fulminant hepatitis. J Am Acad Dermatol 2003; 49:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/60\">",
"      Farrell GC. Drugs and steatohepatitis. Semin Liver Dis 2002; 22:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/61\">",
"      Cullen JM. Mechanistic classification of liver injury. Toxicol Pathol 2005; 33:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/62\">",
"      Lee WM. Acute liver failure. N Engl J Med 1993; 329:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/63\">",
"      Rigas B. The evolving spectrum of amiodarone hepatotoxicity. Hepatology 1989; 10:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/64\">",
"      Gehenot M, Horsmans Y, Rahier J, Geubel AP. Subfulminant hepatitis requiring liver transplantation after benzarone administration. J Hepatol 1994; 20:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/65\">",
"      Lewis JH, Ranard RC, Caruso A, et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology 1989; 9:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/66\">",
"      R&auml;tz Bravo AE, Drewe J, Schlienger RG, et al. Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature. Crit Care Med 2005; 33:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/67\">",
"      Miller KD, Cameron M, Wood LV, et al. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 2000; 133:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/68\">",
"      Koch RO, Graziadei IW, Zangerle R, et al. Acute hepatic failure and lactate acidosis associated with antiretroviral treatment for HIV. Wien Klin Wochenschr 2003; 115:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/69\">",
"      Chitturi S, Farrell GC. Herbal hepatotoxicity: an expanding but poorly defined problem. J Gastroenterol Hepatol 2000; 15:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/70\">",
"      Stedman C. Herbal hepatotoxicity. Semin Liver Dis 2002; 22:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/71\">",
"      Woolf GM, Petrovic LM, Rojter SE, et al. Acute hepatitis associated with the Chinese herbal product jin bu huan. Ann Intern Med 1994; 121:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/72\">",
"      B&eacute;nichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/73\">",
"      Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/74\">",
"      Goldstein NS, Bayati N, Silverman AL, Gordon SC. Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis. Am J Clin Pathol 2000; 114:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/75\">",
"      Alla V, Abraham J, Siddiqui J, et al. Autoimmune hepatitis triggered by statins. J Clin Gastroenterol 2006; 40:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/76\">",
"      Pelli N, Setti M, Ceppa P, et al. Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol 2003; 15:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/77\">",
"      Mizutani T, Shinoda M, Tanaka Y, et al. Autoantibodies against CYP2D6 and other drug-metabolizing enzymes in autoimmune hepatitis type 2. Drug Metab Rev 2005; 37:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/78\">",
"      Poucell S, Ireton J, Valencia-Mayoral P, et al. Amiodarone-associated phospholipidosis and fibrosis of the liver. Light, immunohistochemical, and electron microscopic studies. Gastroenterology 1984; 86:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/79\">",
"      Paquot N, Delwaide J. Fatty liver in the intensive care unit. Curr Opin Clin Nutr Metab Care 2005; 8:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/80\">",
"      Zorzi D, Laurent A, Pawlik TM, et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007; 94:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/81\">",
"      Pawlik TM, Olino K, Gleisner AL, et al. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 2007; 11:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/82\">",
"      Lee WM. Drug-induced hepatotoxicity. N Engl J Med 1995; 333:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/83\">",
"      Newman M, Auerbach R, Feiner H, et al. The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment. Improvement in liver abnormalities after cessation of treatment. Arch Dermatol 1989; 125:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/84\">",
"      Lee WM, Denton WT. Chronic hepatitis and indolent cirrhosis due to methyldopa: the bottom of the iceberg? J S C Med Assoc 1989; 85:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/85\">",
"      Beyeler C, Reichen J, Thomann SR, et al. Quantitative liver function in patients with rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. Br J Rheumatol 1997; 36:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/86\">",
"      Geubel AP, De Galocsy C, Alves N, et al. Liver damage caused by therapeutic vitamin A administration: estimate of dose-related toxicity in 41 cases. Gastroenterology 1991; 100:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/87\">",
"      Letteron P, Fromenty B, Terris B, et al. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 1996; 24:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/88\">",
"      Somani P, Bandyopadhyay S, Klaunig JE, Gross SA. Amiodarone- and desethylamiodarone-induced myelinoid inclusion bodies and toxicity in cultured rat hepatocytes. Hepatology 1990; 11:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/89\">",
"      Lewis JH, Mullick F, Ishak KG, et al. Histopathologic analysis of suspected amiodarone hepatotoxicity. Hum Pathol 1990; 21:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/90\">",
"      Degott C, Feldmann G, Larrey D, et al. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology 1992; 15:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/91\">",
"      Ben-Yehuda A, Bloom A, Lijovetzky G, et al. Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis. Isr J Med Sci 1990; 26:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/92\">",
"      Larrey D, Erlinger S. Drug-induced cholestasis. Baillieres Clin Gastroenterol 1988; 2:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/93\">",
"      Zimmerman HJ, Lewis JH. Drug-induced cholestasis. Med Toxicol 1987; 2:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/94\">",
"      Moradpour D, Altorfer J, Flury R, et al. Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology 1994; 20:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/95\">",
"      Forbes GM, Jeffrey GP, Shilkin KB, Reed WD. Carbamazepine hepatotoxicity: another cause of the vanishing bile duct syndrome. Gastroenterology 1992; 102:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/96\">",
"      Vuppalanchi R, Chalasani N, Saxena R. Restoration of bile ducts in drug-induced vanishing bile duct syndrome due to zonisamide. Am J Surg Pathol 2006; 30:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/97\">",
"      Trak-Smayra V, Cazals-Hatem D, Asselah T, et al. Prolonged cholestasis and ductopenia associated with tenoxicam. J Hepatol 2003; 39:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/98\">",
"      Ludwig J, Kim CH, Wiesner RH, Krom RA. Floxuridine-induced sclerosing cholangitis: an ischemic cholangiopathy? Hepatology 1989; 9:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/99\">",
"      Alazmi WM, McHenry L, Watkins JL, et al. Chemotherapy-induced sclerosing cholangitis: long-term response to endoscopic therapy. J Clin Gastroenterol 2006; 40:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/100\">",
"      Lewis JH, Tice HL, Zimmerman HJ. Budd-Chiari syndrome associated with oral contraceptive steroids. Review of treatment of 47 cases. Dig Dis Sci 1983; 28:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/101\">",
"      Olzinski AT, Sanyal AJ. Treating Budd-Chiari Syndrome: making rational choices from a myriad of options. J Clin Gastroenterol 2000; 30:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/102\">",
"      Ridker PM, Ohkuma S, McDermott WV, et al. Hepatic venocclusive disease associated with the consumption of pyrrolizidine-containing dietary supplements. Gastroenterology 1985; 88:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/103\">",
"      McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/104\">",
"      Valla D, Le MG, Poynard T, et al. Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. A case-control study. Gastroenterology 1986; 90:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/105\">",
"      Zafrani ES, von Pinaudeau Y, Dhumeaux D. Drug-induced vascular lesions of the liver. Arch Intern Med 1983; 143:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/106\">",
"      Kandutsch S, Klinger M, Hacker S, et al. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. Eur J Surg Oncol 2008; 34:1231.",
"     </a>",
"    </li>",
"    <li>",
"     Ishak KG. Hepatic Histopathology. In: Diseases of the Liver, Schiff L, Schiff ER (Eds), JB Lippincott Company, 1993. p.175.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/108\">",
"      Cabasso A. Peliosis hepatis in a young adult bodybuilder. Med Sci Sports Exerc 1994; 26:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/109\">",
"      Tsirigotis P, Sella T, Shapira MY, et al. Peliosis hepatis following treatment with androgen-steroids in patients with bone marrow failure syndromes. Haematologica 2007; 92:e106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/110\">",
"      Perarnau JM, Bacq Y. Hepatic vascular involvement related to pregnancy, oral contraceptives, and estrogen replacement therapy. Semin Liver Dis 2008; 28:315.",
"     </a>",
"    </li>",
"    <li>",
"     Zimmerman HJ, Maddrey WC. Toxic and drug-induced hepatitis. In: Diseases of the liver, Schiff L, Schiff ER (Eds), JB Lippincott Company, Philadelphia 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/112\">",
"      Harrison RF, Elias E. Amiodarone-associated cirrhosis with hepatic and lymph node granulomas. Histopathology 1993; 22:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/113\">",
"      Gaya DR, Thorburn D, Oien KA, et al. Hepatic granulomas: a 10 year single centre experience. J Clin Pathol 2003; 56:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/114\">",
"      Mays ET, Christopherson W. Hepatic tumors induced by sex steroids. Semin Liver Dis 1984; 4:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/115\">",
"      Bork K, Pitton M, Harten P, Koch P. Hepatocellular adenomas in patients taking danazol for hereditary angio-oedema. Lancet 1999; 353:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/116\">",
"      Tazawa K, Yasuda M, Ohtani Y, et al. Multiple hepatocellular adenomas associated with long-term carbamazepine. Histopathology 1999; 35:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/117\">",
"      Barritt AS 4th, Lee J, Hayashi PH. Detective work in drug-induced liver injury: sometimes it is all about interviewing the right witness. Clin Gastroenterol Hepatol 2010; 8:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/118\">",
"      Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 2011; 54:931.",
"     </a>",
"    </li>",
"    <li>",
"     USFDA Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation file://www.fda.gov/cder/guidance/7507dft.htm (Accessed on August 21, 2008).",
"    </li>",
"    <li>",
"     Navaro, V. Hepatic adverse event nomenclature document file://www.fda.gov/cder/livertox/presentations2005/Vic_Navaro.ppt (Accessed on August 21, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/121\">",
"      Lucena MI, Camargo R, Andrade RJ, et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001; 33:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/122\">",
"      Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/123\">",
"      Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001; 33:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/124\">",
"      Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/125\">",
"      Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010; 51:2117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/126\">",
"      Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/127\">",
"      Polson J, Lee WM, American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure. Hepatology 2005; 41:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/128\">",
"      Bohan TP, Helton E, McDonald I, et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology 2001; 56:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/129\">",
"      Giannattasio A, D'Ambrosi M, Volpicelli M, Iorio R. Steroid therapy for a case of severe drug-induced cholestasis. Ann Pharmacother 2006; 40:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/130\">",
"      O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/131\">",
"      Bj&ouml;rnsson E, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol 2009; 50:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/63/29690/abstract/132\">",
"      Mindikoglu AL, Magder LS, Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. Liver Transpl 2009; 15:719.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3571 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-AF04787F30-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_63_29690=[""].join("\n");
var outline_f28_63_29690=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H213375674\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H235295151\">",
"      Database of drugs, herbs, and supplements associated with hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SPECTRUM OF DRUG-INDUCED LIVER INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Subclinical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Acute liver injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Acute hepatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Cholestatic injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Mixed patterns",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Acute steatosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Extrahepatic manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chronic hepatic injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Chronic hepatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Chronic steatosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1147473876\">",
"      - Steatohepatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Fibrosis and cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Phospholipidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Chronic cholestasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Chronic intrahepatic cholestasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2204312628\">",
"      - Vanishing bile duct syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Biliary sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Vascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Hepatic vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Sinusoidal obstruction syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Peliosis hepatis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Granulomatous hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Neoplasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Hepatic adenoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Angiosarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H213375674\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H113577447\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3571\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3571|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/3/18486\" title=\"picture 1\">",
"      Granulomatous hepatitis Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3571|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/31/25083\" title=\"table 1A\">",
"      Classification DILI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/41/20124\" title=\"table 1B\">",
"      Spectrum of hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/48/41742\" title=\"table 2\">",
"      Types of DILI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/0/8203\" title=\"table 3\">",
"      Classif autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/16/37133\" title=\"table 4\">",
"      Pyrrolizidine alkaloids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/32/3595\" title=\"table 5\">",
"      Classification of liver test abnormalities",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24166?source=related_link\">",
"      Acute fatty liver of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=related_link\">",
"      Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/32/27140?source=related_link\">",
"      Classification of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=related_link\">",
"      Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35528?source=related_link\">",
"      Clinical manifestations and diagnosis of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3434?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43929?source=related_link\">",
"      Drug reaction with eosinophilia and systemic symptoms (DRESS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13754?source=related_link\">",
"      Drugs and the liver: Metabolism and mechanisms of injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31575?source=related_link\">",
"      Etiology of the Budd-Chiari syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15352?source=related_link\">",
"      Hepatic adenoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40406?source=related_link\">",
"      Hepatic granulomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25642?source=related_link\">",
"      Hepatotoxicity due to herbal medications and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=related_link\">",
"      Overview of the complications, prognosis, and management of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=related_link\">",
"      Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/6/23651?source=related_link\">",
"      Patient information: Toxic hepatitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26887?source=related_link\">",
"      Peliosis hepatis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28264?source=related_link\">",
"      Valproic acid poisoning",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_63_29691="Colic management PI";
var content_f28_63_29691=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F69458&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F69458&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tips for reducing colic",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Change your baby's formula from cow's milk to soy-based or predigested",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If you breastfeed, try avoiding certain food groups, such as dairy (milk-based), eggs, nuts, and wheat. To do this, stop eating one of these types of foods for 1 week, and see if your baby's colic improves. If it does, keep that type of food out of your diet. If the colic does not improve, you can restart that food and try stopping another one.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Change your baby's bottle or nipple. Feed him or her in a sitting-up position and burp him or her often.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carry your baby more during the day in your arms, a sling, or a front carrier",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Put your baby in his or her car seat, and put the car seat in a safe place near a dishwasher, clothes dryer, or other source of \"white noise\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Take your baby for a ride in the car",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Give your baby a pacifier",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Put your baby in a baby swing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Massage your baby's belly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Swaddle your baby (see graphic \"How to swaddle PI\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Put a white noise or heartbeat machine near your baby",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Put a warm water bottle on your baby's belly (make sure the water is not too hot)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Give your baby a warm bath",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a list of different things that you can try to help reduce your baby's crying.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_63_29691=[""].join("\n");
var outline_f28_63_29691=null;
var title_f28_63_29692="Unfavorable prognostic factors early HL";
var content_f28_63_29692=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F55327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F55327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Unfavorable prognostic factors in early (stage I/II) Hodgkin lymphoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        European Organization for the Research and Treatment of Cancer (EORTC)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Large mediastinal adenopathy (&gt;1/3 maximum transverse thoracic diameter)",
"         </li>",
"         <li>",
"          Involvement of four or more lymph node regions",
"         </li>",
"         <li>",
"          Age &ge;50 years at diagnosis",
"         </li>",
"         <li>",
"          A defined combination of B symptoms* and elevated ESR: B symptoms and an ESR over 30 mm/hour or an ESR over 50 mm/hour without B symptoms",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        German Hodgkin's Study Group (GHSG)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Large mediastinal adenopathy (&gt;1/3 maximum transverse thoracic diameter)",
"         </li>",
"         <li>",
"          Three or more lymph node sites of involvement",
"         </li>",
"         <li>",
"          A defined combination of B symptoms and elevated ESR: B symptoms and an ESR over 30 mm/hour; an ESR over 50 mm/hour without B symptoms",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Groupe d'Etudes des Lymphomes de l'Adulte (GELA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Age 45 years or older",
"         </li>",
"         <li>",
"          Male gender",
"         </li>",
"         <li>",
"          Extranodal disease",
"         </li>",
"         <li>",
"          Hemoglobin 10.5 g/dL or less",
"         </li>",
"         <li>",
"          Absolute lymphocyte count of 600 mg/microL or less",
"         </li>",
"         <li>",
"          Elevated ESR",
"         </li>",
"         <li>",
"          B symptoms",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        National Cancer Institute of Canada (NCIC)/Eastern Cooperative Oncology Group (ECOG)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Large mediastinal adenopathy (&gt;1/3 maximum transverse thoracic diameter)",
"         </li>",
"         <li>",
"          Involvement of four or more sites",
"         </li>",
"         <li>",
"          Age &ge;40 years at diagnosis",
"         </li>",
"         <li>",
"          ESR &gt;50 mm/hour",
"         </li>",
"         <li>",
"          Mixed cellularity histology",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Once the diagnosis of Hodgkin lymphoma has been established, therapy and prognosis are based upon the stage of the disease. Among patients with stage I-II disease, there is subsequent stratification into favorable and unfavorable prognosis disease based upon the presence or absence of certain clinical features, such as age, B symptoms, and large mediastinal adenopathy. Stratification of patients with early stage disease into favorable and unfavorable subsets varies by region.",
"    <div class=\"footnotes\">",
"     ESR: erythrocyte sedimentation rate.",
"     <br>",
"      * B symptoms are systemic symptoms of significant unexplained fever, night sweats, or unexplained weight loss exceeding 10 percent of body weight during the six months prior to diagnosis.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_63_29692=[""].join("\n");
var outline_f28_63_29692=null;
var title_f28_63_29693="Studies of inhaled glucocorticoids and bone mineral density";
var content_f28_63_29693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of studies on the effect of inhaled glucocorticoids on bone mineral density",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Study",
"       </td>",
"       <td class=\"subtitle1\">",
"        Year",
"       </td>",
"       <td class=\"subtitle1\">",
"        Medications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Average dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lung disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Study type",
"        <br/>",
"        (number)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect on BMD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Decrease in BMD with inhaled glucocorticoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Wise",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"       <td>",
"        Triamcinolone",
"       </td>",
"       <td>",
"        1200 mcg/d",
"       </td>",
"       <td>",
"        COPD",
"       </td>",
"       <td>",
"        P (359)",
"       </td>",
"       <td>",
"        2 percent decrease in femoral neck BMD in inhaled GC group vs 0.22 percent decrease in placebo group over 3 yr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Marystone",
"       </td>",
"       <td>",
"        1995",
"       </td>",
"       <td>",
"        Not stated",
"       </td>",
"       <td>",
"        Not stated",
"       </td>",
"       <td>",
"        Asthma",
"       </td>",
"       <td>",
"        CS (34)",
"       </td>",
"       <td>",
"        4.2 percent lower spine BMD compared to never users (2.8 yr average duration of use)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Toogood",
"       </td>",
"       <td>",
"        1995",
"       </td>",
"       <td>",
"        Dexamethasone, budesonide, beclomethasone",
"       </td>",
"       <td>",
"        Not stated",
"       </td>",
"       <td>",
"        Asthma",
"       </td>",
"       <td>",
"        CS (69)",
"       </td>",
"       <td>",
"        0.5 SD decrease in spine BMD/yr for each 1000 microg/d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Wisniewski",
"       </td>",
"       <td>",
"        1997",
"       </td>",
"       <td>",
"        Beclomethasone, budesonide",
"       </td>",
"       <td>",
"        500 mcg/d",
"       </td>",
"       <td>",
"        Asthma",
"       </td>",
"       <td>",
"        CS (128)",
"       </td>",
"       <td>",
"        0.11 SD decrease in spine BMD/yr for each 1000 microg/d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ip",
"       </td>",
"       <td>",
"        1994",
"       </td>",
"       <td>",
"        Beclomethasone, budesonide",
"       </td>",
"       <td>",
"        1100 mcg/d",
"       </td>",
"       <td>",
"        Asthma",
"       </td>",
"       <td>",
"        CS (30)",
"       </td>",
"       <td>",
"        6.6 percent lower spine BMD compared to healthy control subjects (40 month average duration of use)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Packe",
"       </td>",
"       <td>",
"        1992",
"       </td>",
"       <td>",
"        Beclomethasone",
"       </td>",
"       <td>",
"        1000 to 2000 mcg/d",
"       </td>",
"       <td>",
"        Asthma",
"       </td>",
"       <td>",
"        CS (57)",
"       </td>",
"       <td>",
"        Spine BMD significantly lower than control asthmatics (3 yr average duration of use)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        No effect on BMD with inhaled glucocorticoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pauwels",
"       </td>",
"       <td>",
"        1999",
"       </td>",
"       <td>",
"        Budesonide",
"       </td>",
"       <td>",
"        400 mcg bid",
"       </td>",
"       <td>",
"        COPD",
"       </td>",
"       <td>",
"        P (286)",
"       </td>",
"       <td>",
"        No change in BMD after 3 yr in either treatment or placebo group",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hughes",
"       </td>",
"       <td>",
"        1999",
"       </td>",
"       <td>",
"        Fluticasone or budesonide",
"       </td>",
"       <td>",
"        500 mcg bid or 800 mcg bid",
"       </td>",
"       <td>",
"        Asthma",
"       </td>",
"       <td>",
"        P (59)",
"       </td>",
"       <td>",
"        No change in spine or hip BMD after 1 yr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Egan",
"       </td>",
"       <td>",
"        1999",
"       </td>",
"       <td>",
"        Fluticasone or beclomethasone",
"       </td>",
"       <td>",
"        500 mcg bid or 1000 mcg bid",
"       </td>",
"       <td>",
"        Asthma",
"       </td>",
"       <td>",
"        P (33)",
"       </td>",
"       <td>",
"        No change vs 3.9 percent decrease in spine BMD after 2 yr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Herrala",
"       </td>",
"       <td>",
"        1994",
"       </td>",
"       <td>",
"        Beclomethasone",
"       </td>",
"       <td>",
"        500 mcg bid",
"       </td>",
"       <td>",
"        Asthma",
"       </td>",
"       <td>",
"        P (38)",
"       </td>",
"       <td>",
"        No change in BMD after 1 year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Luengo",
"       </td>",
"       <td>",
"        1997",
"       </td>",
"       <td>",
"        Beclomethasone or budesonide",
"       </td>",
"       <td>",
"        662 mcg/d",
"       </td>",
"       <td>",
"        Asthma",
"       </td>",
"       <td>",
"        P (96)",
"       </td>",
"       <td>",
"        No difference in BMD between asthmatic and control groups. No difference in rate of bone loss over 2 yr between groups.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Boulet",
"       </td>",
"       <td>",
"        1994",
"       </td>",
"       <td>",
"        Beclomethasone or budesonide",
"       </td>",
"       <td>",
"        1140 mcg/d",
"       </td>",
"       <td>",
"        Asthma",
"       </td>",
"       <td>",
"        CS (74)",
"       </td>",
"       <td>",
"        No difference in BMD between asthmatics using inhaled GC and control asthmatics (34 mo average duration of use)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     P: prospective study; GC: glucocorticoids; BMD: bone mineral density; CS: retrospective cross sectional survey.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Biskobing DM. COPD and osteoporosis. Chest 2002; 121:609. Copyright &copy; 2002 American College of Chest Physicians.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_63_29693=[""].join("\n");
var outline_f28_63_29693=null;
var title_f28_63_29694="Desens 16step";
var content_f28_63_29694=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F65192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F65192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Example of 16-step desensitization protocol for cefepime (2000 mg dose, 20 mL per solution)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Solution",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Total volume",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Concentration",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution 1",
"       </td>",
"       <td colspan=\"2\">",
"        20 mL",
"       </td>",
"       <td colspan=\"2\">",
"        0.1 mg/mL",
"       </td>",
"       <td colspan=\"2\">",
"        2 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution 2",
"       </td>",
"       <td colspan=\"2\">",
"        20 mL",
"       </td>",
"       <td colspan=\"2\">",
"        1 mg/mL",
"       </td>",
"       <td colspan=\"2\">",
"        20 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution 3",
"       </td>",
"       <td colspan=\"2\">",
"        20 mL",
"       </td>",
"       <td colspan=\"2\">",
"        10 mg/mL",
"       </td>",
"       <td colspan=\"2\">",
"        200 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution 4",
"       </td>",
"       <td colspan=\"2\">",
"        20 mL",
"       </td>",
"       <td colspan=\"2\">",
"        96.053 mg/mL",
"       </td>",
"       <td colspan=\"2\">",
"        2000 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Step",
"       </td>",
"       <td class=\"subtitle1\">",
"        Solution",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rate (mL/hour)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Time (minute)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Volume infused per step (mL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose administered with this step (mg)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cumulative dose (mg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"       <td>",
"        0.013",
"       </td>",
"       <td>",
"        0.013",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        0.025",
"       </td>",
"       <td>",
"        0.038",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        0.50",
"       </td>",
"       <td>",
"        0.050",
"       </td>",
"       <td>",
"        0.088",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        0.100",
"       </td>",
"       <td>",
"        0.188",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        0.250",
"       </td>",
"       <td>",
"        0.438",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        0.50",
"       </td>",
"       <td>",
"        0.500",
"       </td>",
"       <td>",
"        0.938",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        1.000",
"       </td>",
"       <td>",
"        1.938",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        2.00",
"       </td>",
"       <td>",
"        2.000",
"       </td>",
"       <td>",
"        3.938",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        0.50",
"       </td>",
"       <td>",
"        5.000",
"       </td>",
"       <td>",
"        8.938",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        10.000",
"       </td>",
"       <td>",
"        18.938",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        2.00",
"       </td>",
"       <td>",
"        20.000",
"       </td>",
"       <td>",
"        38.938",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        4.00",
"       </td>",
"       <td>",
"        40.000",
"       </td>",
"       <td>",
"        78.938",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        96.053",
"       </td>",
"       <td>",
"        174.991",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        2.50",
"       </td>",
"       <td>",
"        240.133",
"       </td>",
"       <td>",
"        415.123",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        5.00",
"       </td>",
"       <td>",
"        480.266",
"       </td>",
"       <td>",
"        895.389",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        17.25",
"       </td>",
"       <td>",
"        11.50",
"       </td>",
"       <td>",
"        1104.611",
"       </td>",
"       <td>",
"        2000.000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Each step is administered over 15 minutes. At conclusion of protocol, observe patient for 30 minutes, then give full therapeutic dose by the desired route.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        Total time = 242.25 minutes (4 hours 2 minutes).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Desensitization protocol instructions:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"7\">",
"        1. Confirm written consent is in medical record.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"7\">",
"        2. Please ensure preceding dose of beta-blockers was held, unless otherwise advised by supervising clinician.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"7\">",
"        3. Obtain IV access, and vital signs (temperature, HR, BP, RR, oxygen saturation, peak flow).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"7\">",
"        4. Have at bedside: Epinephrine 0.3 mg (for adult) for IM injection, oxygen, normal saline, peak flow meter, and BP cuff, albulterol, injectable preparation of diphenhydramine , and methylprednisolone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"7\">",
"        5. A nurse must closely observe the patient throughout the protocol (one-to-one).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Administration:",
"        </strong>",
"        Hang each solution successively. Each step is administered over 15 minutes, per protocol. There is no reason to wait between bags. Vital signs should be taken and recorded every 15 minutes, and every 30 minutes during the last step.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Monitoring and charting during desensitization:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"7\">",
"        Please clearly document any reaction, including:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"7\">",
"        a. Patient's symptoms, vital signs, and physical findings;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"7\">",
"        b. Exactly when the reaction occurred (ie, what step, how many minutes into that step);",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"7\">",
"        c. Treatment administered, how and when the reaction resolved, and when the protocol was restarted.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Treatment of allergic reactions:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"7\">",
"        1.",
"        <strong>",
"         For mild reactions:",
"        </strong>",
"        In case of isolated itching, flushing, hives, mild chest tightness, nausea, abdominal pain, or back pain, with normal vital signs, stop the infusion and treat with IV diphenhydramine. Observe patient until the reaction subsides, and then resume the protocol by repeating the step at which the reaction occurred.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"7\">",
"        2.",
"        <strong>",
"         For severe reactions:",
"        </strong>",
"        In case of hypotension, throat swelling, wheezing/respiratory distress, or decreased oxygen saturation, stop the infusion and treat with epinephrine 0.3 mg IM x 1, diphenhydramine and methylprednisolone IV, oxygen, inhaled albuterol for bronchospasm, and IV fluids (normal saline). Place patient in a recumbent position if hypotensive. Consider glucagon 1 to 2 mg IV bolus if patient has taken beta-blockers, followed by infusion at 1 to 5 mg/hour.",
"        <strong>",
"         Immediately alert the housestaff and supervising clinician.",
"        </strong>",
"        When the patient is stable, the protocol will be resumed as instructed by the supervising clinician.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"7\">",
"        <strong>",
"         Contact the supervising&nbsp;clinician for ANY severe or prolonged reaction, or any questions regarding the protocol, reactions, and appropriate management.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Legere HJ 3rd, Palis RI, Bouza TR, et al. A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity. J Cyst Fibros 2009; 8:418. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"     <br>",
"      Instructions courtesy of Mariana Castells, MD, PhD.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_63_29694=[""].join("\n");
var outline_f28_63_29694=null;
var title_f28_63_29695="Nocturnal nasal NPPV";
var content_f28_63_29695=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nocturnal nasal NPPV",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 242px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient is being fitted for a transparent custom acrylic nasal interface for nocturnal nasal NPPV.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John R Bach, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_63_29695=[""].join("\n");
var outline_f28_63_29695=null;
